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  Electrochemical	  methods	  for	  the	  detection	  of	  catecholamines	  in	  vivo	  
and	  in	  vitro	  
(Invited	  review,	  submitted	  in	  part	  to	  the	  Journal	  of	  Analytical	  Methods)	  
1.1	  Introduction	  to	  neurochemical	  measurements	  by	  electrochemistry	  
Dopamine,	   norepinephrine,	   and	   epinephrine	  make	   up	   a	   class	   of	   neurotransmitters	   called	  
catecholamines.1	  	  By	  definition,	  these	  are	  organic	  structures	  that	  consist	  of	  a	  benzene	  ring	  with	  
two	  hydroxyl	   groups	   at	   the	  3-­‐	   and	  4-­‐positions,	   as	  well	   as	   an	   amine	   group	   side	   chain.2,3	   Their	  
synthesis	   pathway	   is	   interconnected	   such	   that	   epinephrine	   is	   derived	   from	   norepinephrine,	  
which	   itself	   is	  made	   from	   a	   dopamine.1	   	   Together,	   this	   class	   of	   neurotransmitters	   have	   been	  
linked	   to	   the	   proper	   regulation	   of	   various	   biological	   functions	   such	   as	   the	   fight-­‐or-­‐flight	  
response,	   control	   of	   respiration,	   cardiovascular	   regulation,	   and	   the	   sleep-­‐wake	   cycle.	   These	  
neurotransmitter	   systems	   also	   mediate	   cognitive	   processes	   involved	   in	   attention,	   reward	  
recognition,	  and	  memory,	  such	  that	  dysfunction	  in	  these	  systems	  give	  rise	  to	  attention	  deficit	  
hyperactivity	   disorder,	   addiction,	   schizophrenia,	   and	   posttraumatic	   stress	   disorder.1,4,5	  	  
Therefore,	   it	   has	   become	   imperative	   in	   both	   clinical	   and	   laboratory	   settings	   to	   be	   able	   to	  
accurately	  detect	  and	  monitor	  catecholamine	  levels	  as	  they	  can	  serve	  as	  diagnostic	  tools	  for	  a	  
variety	  of	  medical	  conditions.	  
Historically,	   detection	   of	   catecholamines	   has	   been	   an	   analytical	   challenge	   due	   to	   several	  
factors.	   As	   the	   physiological	   concentrations	   of	   these	   neurotransmitters	   are	   quite	   low	   in	   the	  
brain,	   very	   sensitive	   techniques	  are	   required	   to	  make	  accurate	  and	  precise	  measurements.2,6	  
Additionally,	   measurement	   from	   biological	   samples	   such	   as	   brain	   tissue	   or	   blood	   requires	  





reproducibility.	  Catecholamine	  compounds	  are	  also	  unstable	  in	  neutral	  and	  basic	  environments;	  
therefore,	   sample	   preparation	   conditions	   need	   to	   be	   optimized	   to	   prevent	   oxidation	   or	  
decomposition	   of	   analytes	   during	   the	   process	   of	   quantification.2,7	   Two	   well	   established	  
methods	  of	  catecholamine	  detection	  and	  quantification	  that	  meet	  the	  abovementioned	  criteria	  
and	   challenges	   are:	   1)	   fast-­‐scan	   cyclic	   voltammetry	   (FSCV)	   and	   2)	   microdialysis	   sampling	  
coupled	   with	   separation	   by	   high	   performance	   liquid	   chromatography	   (HPLC)	   or	   capillary	  
electrophoresis	   (CE)	   with	   electrochemical	   detection.	   The	   purpose	   of	   this	   mini-­‐review	   is	   to	  
explore	  the	  recent	  advances	  made	  in	  the	  field	  of	  catecholamine	  detection	   in	  vitro	  and	   in	  vivo,	  
with	   specific	   attention	   given	   to	   the	   techniques	   of	   FSCV	   and	   separation	  methods	   coupled	   to	  
electrochemical	  detection.	  
1.2	  Fast	  Scan	  Cyclic	  Voltammetry	  (FSCV)	  
FSCV	   is	   an	   electrochemical	   technique	   that	   detects	   analytes,	   such	   as	   catecholamines,	   by	  
utilizing	  their	   inherent	  electroactivity.8,9,10	  Although	  carbon-­‐fiber	  microelectrodes	  are	  sensitive	  
enough	   to	   detect	   non-­‐stimulated	   burst	   firing	   (‘phasic’	   release),	   typically	   measuring	  
catecholamines	  from	  either	  slices	  or	  in	  vivo	  requires	  a	  bipolar	  stimulating	  electrode	  for	  eliciting	  
release	   of	   neurotransmitters	   via	   electrical	   stimulation.11,12	   A	   carbon-­‐fiber	   microelectrode	   is	  
used	   for	   the	   detection	   of	   analytes	   based	   on	   their	   characteristic	   oxidation	   and	   reduction	  
potentials	  in	  reference	  to	  a	  Ag/AgCl	  electrode.	  The	  carbon-­‐fiber	  microelectrode	  is	  inserted	  into	  
the	  brain	  region	  of	  interest	  and	  a	  potential	  is	  applied	  as	  a	  waveform	  optimized	  for	  the	  detection	  
of	  one	  particular	  analyte.	  For	  example,	   to	  detect	  dopamine,	  a	   triangular	  waveform	   is	  applied	  
that	  is	  first	  held	  at	  a	  potential	  of	  -­‐0.4	  V,	  ramped	  up	  to	  +1.2	  V,	  then	  brought	  back	  down	  to	  -­‐0.4	  V	  





the	  region	  in	  which	  measurements	  are	  being	  made,	  as	  well	  as	  the	  potential	  at	  which	  it	  oxidizes,	  
so	  no	  additional	  separation	  component	  is	  required.	  Additionally,	  the	  spatial	  resolution	  afforded	  
by	  the	  size	  of	  the	  carbon-­‐fiber	  (typically	  about	  7	  µm	  in	  diameter	  and	  150	  µm	  in	  length)	  and	  the	  
millisecond	   temporal	   resolution	   enables	   functional	   analysis	   of	   both	   neurotransmitter	   release	  
and	  uptake	  dynamics	  in	  vivo	  and	  in	  oxygenated	  brain	  slices	  (in	  vitro).	  
One	  drawback	  of	  slice	  and	  anesthetized	  in	  vivo	  FSCV	  is	  that	  it	  can	  only	  measure	  differences	  
in	  analyte	  levels,	  making	  it	  difficult	  to	  estimate	  absolute	  extracellular	  concentrations.	  Although	  
FSCV	  cannot	  measure	  basal	  dopamine	  levels,	  in	  vivo	  FSCV	  can	  detect	  and	  measure	  spontaneous	  
dopamine	   transients	   that	   arise	   from	  brief	   but	   intense	  phasic	   firing	  of	   dopamine	  neurons.13,14	  
Additionally,	   FSCV	   is	   limited	   to	   detection	   of	   analytes	   that	   are	   easily	   oxidizable/reducible	   and	  
requires	   that	   these	   redox	   potentials	   are	   within	   the	   range	   supported	   by	   carbon-­‐fiber	  
microelectrodes.	  Finally,	  FSCV	  measurements	  can	  only	  be	  made	  from	  “living”	  tissue	  within	  a	  6	  -­‐	  
8	   hour	   time	   frame,	   making	   it	   difficult	   to	   compare	   concentrations	   of	   neurotransmitters	   in	  
different	  regions	  or	  to	  perform	  any	  type	  of	  longitudinal	  study.	  	  Many	  researchers,	  therefore,	  are	  
working	  towards	  making	  improvements	  to	  overcome	  these	  challenges.	  	  
1.2.1 Method	  Improvements	  
Over	   the	   past	   few	   years,	   several	   refinements	   have	   been	   made	   to	   improve	   detection	   of	  
biological	  analytes,	  more	  specifically	  neurotransmitters,	  at	  the	  carbon	  fiber	  microelectrode	  that	  
is	  used	  in	  FSCV.	  Detection	  of	  neurotransmitters	  is	  dependent	  on	  the	  surface	  properties	  of	  the	  
carbon	   fiber.15	   Thus,	  one	  of	   the	   simplest	  modifications	   that	   can	  be	  made	   to	   the	   carbon-­‐fiber	  
microelectrodes	  is	  to	  alter	  their	  surface	  chemistry.	  The	  Venton	  group	  has	  been	  leading	  the	  way	  





sensitivity	  and	  detection	  of	  dopamine	  at	  these	  electrodes.	  For	  example,	  Jacobs	  et	  al.	  used	  a	  dip-­‐
coating	  method	   to	  modify	   the	   electrode,	   which	  meets	   their	   ideal	   criteria	   of	   a	   CNT-­‐modified	  
electrode	  that	  can	  be	  easily	  and	  reproducibly	  made	  at	  low	  cost.16	  Three	  types	  of	  functionalized	  
single-­‐walled	   carbon	   nanotubes	   (SWCNTs)	   were	   evaluated	   for	   their	   ability	   to	   measure	  
dopamine,	  serotonin,	  and	  ascorbic	  acid	  by	  FSCV.	  Although	  the	  dip-­‐coating	  method	  sufficiently	  
covered	   the	   electrodes,	   high	   variability	   in	   the	   coverage	  was	   reported.	   Even	   so,	   Jacobs	   et	   al.	  
successfully	  demonstrated	  two-­‐	  to	  six-­‐fold	  increased	  oxidation	  currents	  for	  both	  dopamine	  and	  
serotonin	   using	   carboxylic	   acid	   and	   amide	   functionalized	   SWCNTs,	   but	   only	   carboxylic	   acid	  
functionalized	   SWCNTs	   showed	  a	   significant	  4.5	   times	   increase	   in	   sensitivity	   to	   ascorbic	   acid.	  
The	  detection	  of	  the	  neurotransmitters	  was	  not	  improved	  by	  functionalization	  of	  electrodes	  by	  
octadecylamine	   modified	   SWCNTs.	   Additionally,	   improved	   selectivity	   was	   observed	   when	  
detecting	  positively	  charged	  analytes	  versus	  negatively	  charged	  analytes	  based	  on	  the	  charge	  of	  
the	  functional	  group	  on	  the	  nanotubes	  used.	  Jacobs	  et	  al.	  concluded	  that	  there	  was	  room	  for	  
improvement	  when	  attaching	  SWCNTs	  to	  the	  surface	  of	  a	  carbon	  fiber	  electrode,	  in	  particular	  
regarding	   reproducibility	   using	   this	   method	   to	   modify	   an	   electrode.	   Overall,	   the	   Venton	   lab	  
demonstrated	  a	  simple	  method	  to	  modify	  the	  electrode	  surface	  by	  dip-­‐coating,	  which	  affords	  
the	  freedom	  to	  pick	  and	  choose	  different	  functional	  groups	  for	  surface	  alteration	  based	  on	  the	  
analyte	  of	  interest.	  
In	  a	   follow	  up	  study,	   the	  Venton	  group	  modified	  the	  coating	  protocol	   to	  generate	  a	  more	  
uniform	   self-­‐assembled	   forest	   of	   SWCNTs	   on	   the	   surface	   of	   disk	   electrodes,	   but	   this	   time	  
exclusively	   using	   the	   carboxylic	   acid	   functionalized	   SWCNTs.17	   These	   electrodes	   demonstrate	  





evidence	   of	   a	   nine-­‐fold	   improvement	   in	   temporal	   resolution	   without	   loss	   in	   sensitivity.	  
Compared	   to	   bare	   electrodes,	   they	   demonstrated	   36-­‐fold	   higher	   oxidation	   currents	   when	  
detecting	   dopamine.	   Compared	   to	   the	   abovementioned	   dip-­‐coating	   method,	   the	   sensitivity	  
towards	  dopamine	  was	  34-­‐fold	  higher.	  The	  SWCNT-­‐modified	  electrodes	  were	  evaluated	  using	  
an	  expanded	  analyte	  set	  including	  the	  catecholamines	  epinephrine	  and	  norepinephrine,	  which	  
exhibited	  the	  same	  trends	  of	  higher	  oxidation	  currents.	  The	  authors	  conclude	  that	  this	  method	  
of	   depositing	   a	   dense	   forest	   of	   SWCNTs	   on	   carbon	   fiber	   electrodes	   shows	   a	   significant	  
improvement	  of	  the	  electrode	  surface	  for	  the	  detection	  of	  catecholamines.	  
Aside	  from	  the	  surface,	  modification	  of	  catecholamine	  detection	  at	  the	  electrode	  can	  also	  
be	   achieved	   by	   altering	   other	   parameters,	   such	   as	   the	   applied	   potential.	   An	   increase	   in	  
sensitivity	   towards	   dopamine	   detection	   has	   also	   been	   demonstrated	   by	   Roberts	   et	   al.	   by	  
applying	   an	  additional	  waveform	   to	  pretreat	   the	  electrode	  before	   the	  detection	  waveform	   is	  
used.18	  In	  this	  work,	  cycling	  for	  an	  additional	  5	  minutes	  using	  an	  extended	  triangle	  waveform,	  
from	   -­‐0.5	   V	   to	   +1.8	   V,	   prior	   to	   voltammetric	   detection	  was	   shown	   to	   increase	   carbonyl	   and	  
hydroxyl	  groups	  on	  the	  surface	  of	  the	  electrode.	  The	  result	  was	  an	  improvement	  in	  sensitivity,	  
as	   demonstrated	   by	   a	   six-­‐fold	   increase	   in	   the	   slope	   of	   the	   graph	   plotting	   increasing	  
concentrations	  of	  dopamine	  detected	  versus	  peak	  anodic	  current.	  The	  Wightman	  group	  used	  a	  
similar	   approach,	   this	   time	   extending	   the	   applied	   potential	   window	   of	   the	   detection	  
waveform.19	   In	   this	   work,	   carbon	   fiber	  microelectrodes	   and	   pyrolyzed	   photoresist	   film	   (PPF)	  
carbon	  electrodes	  were	  used	   in	  conjunction	  with	  extended	  waveforms	  to	   improve	  adsorption	  
of	   analytes	   on	   the	   surface	   of	   carbon	   electrodes.	   The	   resultant	   oxidative	   etching	   of	   the	  





analytes	   and	   complex	   environments	   that	   would	   heretofore	   irreversibly	   foul	   electrodes.	  
Although	   not	   as	   common,	   the	   contribution	   of	   scan	   rate	   on	   sensitivity	   and	   selectivity	   of	  
catecholamine	   detection	   has	   also	   been	   evaluated.	   Most	   researchers	   who	   use	   FSCV	   use	   a	  
“standard”	  scan	  rate	  of	  about	  400	  V/s,	  Keithley	  et	  al.	  evaluated	  the	  effect	  of	  ramping	  the	  scan	  
rate	   of	   the	   standard	   applied	  waveform	   to	   2400	  V/s.20	   The	   faster	   scan	   rate	   led	   to	   a	   four-­‐fold	  
increase	   in	   detected	   oxidation	   current	   of	   dopamine,	  without	   the	   increase	   in	   time	   associated	  
with	   extended	  waveforms	   that	   have	   been	   applied	   by	   others	   to	   improve	   detection	   current.19	  
When	  an	  extended	  voltage	  window	  with	  a	  positive	  limit	  of	  +1.3	  V	  was	  used	  in	  conjunction	  with	  
this	  faster	  scan	  rate,	  the	  shape	  of	  the	  waveform	  was	  adjusted	  as	  well,	  such	  that	  the	  shape	  of	  
the	  waveform	  resembled	  a	  sawhorse.	  The	  sawhorse	  waveform	  demonstrated	   improved	   limits	  
of	  detection	  in	  vitro,	  from	  5.3	  nM	  to	  0.96	  nM.	  In	  other	  studies,	  increasing	  the	  frequency	  of	  the	  
waveform	  from	  10	  Hz	  to	  60	  Hz	   improved	  the	  temporal	  resolution	  of	  FSCV.21	  At	  standard	  scan	  
rate	   of	   400	   V/s,	   this	   allowed	   for	   an	   improvement	   in	   temporal	   resolution	   so	   that	   it	   was	  
equivalent	   to	   constant	   potential	   amperometry,	   showing	   maximal	   response	   67	   ms	   after	  
stimulus,	   compared	   to	   the	   200	   ms	   delay	   observed	   at	   10	   Hz.	   Although	   this	   increase	   in	   the	  
frequency	  resulted	  in	  lower	  observed	  oxidation	  currents	  than	  when	  the	  waveform	  is	  applied	  at	  
10	  Hz,	  the	  measured	  concentration	  of	  dopamine	  was	  equivalent.	  Despite	  lower	  signal	  current,	  
the	  signal-­‐to-­‐noise	  ratio	  was	  maintained	  by	  increasing	  the	  scan	  rate	  to	  2400	  V/s.	  
Most	   of	   the	   research	   for	   the	   FSCV	  method	  development	   has	   focused	  on	  parameters	   and	  
physical	   alterations	   to	   the	   working	   electrode.	   However,	   it	   is	   equally	   appropriate	   to	   give	  
attention	  to	  the	  challenges	  associated	  with	  the	  reference	  electrode.	  To	  that	  end,	  Hashemi	  et	  al.	  





without	  producing	  a	  shift	  in	  potential.22	  Despite	  using	  sintered	  Ag/AgCl	  electrodes,	  which	  have	  
thicker	  chloride	  plating	  than	  reference	  electrodes	  made	  in	  house,	  in	  vivo	  measurements	  made	  
as	  early	  as	  4	  days	  after	  implantation	  typically	  show	  a	  +0.2	  to	  +0.3	  V	  shift	  in	  analyte	  peaks.	  Since	  
voltages	  are	  used	  to	  identify	  the	  analyte,	  it	  is	  critical	  to	  address	  the	  shift	  in	  analyte	  potential.	  By	  
fabricating	  the	  reference	  electrode	  with	  a	  Nafion-­‐coating,	  these	  modified	  reference	  electrodes	  
were	  stable	  for	  up	  to	  28	  days	  for	  in	  vivo	  FSCV	  measurements.	  
1.2.2 Electrode	  Design	  
An	  area	  that	  has	  attracted	  increasing	  interest	  is	  developing	  FSCV-­‐compatible	  microelectrode	  
array	  that	  allow	  simultaneous	  detection	  of	  neurotransmitters	  within	  a	  specific	  brain	  region.	  A	  
prototype	  of	  this	  microelectrode	  array	  has	  demonstrated	  dopamine	  detection	  at	  four	  different	  
channels,	   which	   could	   be	   controlled	   by	   individual	   waveforms,	   suggesting	   the	   potential	   for	  
detection	  of	  multiple	  neurotransmitters	  simultaneously	  in	  the	  future.23,24	  In	  more	  recent	  work	  
from	   the	  McCarty	  group,	   a	   similar	   fabrication	  method	  was	  used	   to	   create	  an	  electrode	  array	  
that	  detects	  background	  and	  slowly	  changing	  extracellular	  dopamine	  levels.25	  In	  this	  microarray	  
design,	   a	   square	   potential	   waveform	   applied	   to	   the	   two	   outer	   electrodes	   allowed	   for	   rapid	  
adsorption	   and	   desorption	   of	   dopamine/dopamine-­‐ortho-­‐quinone.	   This	   small	   change	   in	  
dopamine	  concentration	  could	  be	  measured	  by	  the	  middle	  electrode,	  where	  a	  triangular	  FSCV	  
waveform	  was	  applied,	  enabling	  the	  possibility	  of	  future	  detection	  of	  tonic	  dopamine	  release	  in	  
vivo.	  
A	  limitation	  of	  monitoring	  neurochemicals	  in	  their	  native	  environment	  with	  electrochemical	  
methods	  is	  the	  inability	  to	  monitor	  longitudinal	  changes	  for	  greater	  than	  a	  12-­‐24	  hour	  period.	  





biocompatible	  and	  stable	  when	  implanted	  for	  long	  periods	  of	  time.	  In	  light	  of	  that	  requirement,	  
Phillips	   and	   coworkers	   have	   developed	   silica	   encased	   carbon	   fiber	   microsensors	   that	  
demonstrated	   excellent	   viability	   in	   vivo	   for	   up	   to	   4	  months	   after	   implantation.26	   This	   design	  
modification	  of	  using	  silica	  versus	  glass	  as	  the	  outer	  casing	  enables	  repeated	  measurement	  of	  
neurotransmitters	  in	  the	  same	  subject	  over	  time.	  An	  advantage	  of	  silica	  cased	  electrodes	  that	  
can	  be	   implanted	   for	   long	  periods	  of	   time	   is	   that	   they	  will	  provide	  a	  better	  understanding	  of	  
dynamic	  changes	  over	  the	  course	  of	  disease	  progression	  and	  other	  progressive,	  time	  sensitive	  
models.	  	  
1.2.3 Pushing	  Boundaries	  
Optimization	  of	   various	   parameters	   and	   technological	   advances	   of	   FSCV	  over	  many	   years	  
has	  made	  it	  a	  well-­‐established	  technique	  for	  detection	  of	  neurotransmitters	  in	  the	  rodent	  brain,	  
both	  in	  slices	  and	  in	  freely	  moving	  animals.	  In	  addition	  to	  new	  avenues	  being	  pursued	  in	  rodent	  
studies,	   researchers	   have	   also	   been	   approaching	   new	   fronts	   in	   models	   used	   for	   studying	  
catecholamines/monoamines,	   such	  as	  PC12	  Cells,	  Drosophila,	   and	  human	  blood	  platelets.27-­‐30	  
Recent	  advancements	  and	  innovations	  have	  also	  been	  made	  in	  the	  pursuit	  of	  utilizing	  FSCV	  to	  
better	  understand	  neurochemical	  dynamics	  in	  the	  human	  brain.	  There	  are	  numerous	  challenges	  
when	   adapting	   a	   method	   from	   animal	   models	   to	   utilization	   in	   human	   studies.	   One	   of	   the	  
biggest	  challenges	  is	  developing	  a	  microelectrode	  that	  will	  be	  approved	  by	  the	  Food	  and	  Drug	  
Administration.	   Applying	   FSCV	   in	   human	   studies,	   Kishida	   et	   al.	   used	   modified	   carbon	   fiber	  
microelectrodes	   for	   detection	   of	   dopamine.31	   These	   FSCV	   electrodes	   were	   modeled	   after	  
electrophysiology	  electrodes	  used	  during	  deep	  brain	  stimulation	  and	  therefore	  were	  expected	  





neurosurgery	   equipment,	   and	   capable	   of	   detecting	   physiological	   dopamine.	   This	   work	   is	   the	  
first	  to	  demonstrate	  sub-­‐second	  detection	  of	  dopamine	  in	  the	  striatum	  of	  an	  awake	  human.	  
In	  order	  to	  further	  develop	  FSCV	  for	  application	  in	  human	  patients,	  there	  is	  a	  desire	  to	  have	  
the	   experimental	   scientist	   and	   the	   instrumentation	   out	   of	   the	   surgery	   room	   to	   give	   the	  
physicians	  and	  surgical	  team	  enough	  room	  to	  interact	  without	  the	  confines	  of	  instrumentation.	  
Thus,	  the	  Garris	  group,	  in	  collaboration	  with	  researchers	  at	  the	  Mayo	  Clinic,	  has	  developed	  the	  
Wireless	  Instantaneous	  Neurotransmitter	  Concentration	  Sensing	  System	  (WINCS),	  which	  shows	  
great	  promise,	  not	  only	   for	   further	   facilitating	  animal	   research	  sans	   the	  constraints	  of	  wiring,	  
but	   also	   for	   future	   intraoperative	   use	   in	  monitoring	   neurotransmitter	   release	   in	   conjunction	  
with	   deep-­‐brain	   stimulating	   electrodes.32	   They	   have	   gone	   on	   to	   integrate	   the	   WINCS	   with	  
carbon	   nanofiber	   multielectrode	   arrays	   to	   improve	   spatial	   resolution	   of	   neurotransmitter	  
detection	  when	   employing	   this	   system.33	   	  Nearly	   all	   the	   proof-­‐of-­‐concept	  work	  with	   humans	  
started	  with	  using	  WINCS	  to	  evaluate	  dopamine	  since	  dopamine	  is	  the	  most	  well-­‐characterized	  
neurotransmitter	   in	   the	   field	   of	   electrochemical	   detection.	  However,	   an	   ultimate	   goal	  within	  
the	  electrochemical	  community	  is	  to	  optimize	  the	  parameters	  of	  any	  new	  technique	  so	  that	  it	  
can	   eventually	   be	   applied	   to	   other	   neurotransmitters	   as	   well.	   In	   particular,	   their	   work	   has	  
focused	   on	   measuring	   the	   neuromodulator	   adenosine	   using	   FSCV,	   which	   was	   originally	  
pioneered	  by	  the	  Venton	  lab.	  Lee	  et	  al.	  have	  taken	  advantage	  of	  the	  electroactive	  properties	  of	  
adenosine	   to	   demonstrate	   the	   feasibility	   of	   measuring	   both	   dopamine	   and	   adenosine	   using	  
WINCS	  in	  proof-­‐of-­‐concept	  experiments	  with	  animal	  models.34	  	  
Historically,	   FSCV	   has	   been	   used	   exclusively	   to	   measure	   dopamine.	   However,	   there	   is	   a	  





Norepinephrine	  is	  structurally	  related	  to	  dopamine,	  but	  until	  recently,	  little	  has	  been	  done	  with	  
using	  FSCV	  to	  probe	  norepinephrine	  dynamics.	  The	  Wightman	  lab	  demonstrated	  that	  FSCV	  can	  
be	  used	  to	  measure	  norepinephrine	  in	  the	  bed	  nucleus	  of	  the	  strial	  terminalis	  (BNST).35	  These	  
findings	  have	  since	  then	  been	  extended	  to	  demonstrate	  that	  norepinephrine	  can	  be	  detected	  in	  
the	   BNST	   while	   dopamine	   is	   concurrently	   detected	   in	   the	   nucleus	   accumbens.36	   Although	  
beyond	   the	   scope	   of	   this	   review,	   other	   researchers	   have	   also	   applied	   the	   technique	   of	   FSCV	  
recently	   towards	   the	  quantitation	  and	  pharmacological	   study	  of	  other	  neurotransmitters	   and	  
neuromodulators	  such	  as	  serotonin,	  adenosine,	  and	  hydrogen	  peroxide	  as	  well.30,37-­‐39	  	  
1.3	  Microdialysis	  Sampling	  Coupled	  to	  Separation	  with	  Electrochemical	  Detection	  
Other	  modes	  of	  electrochemical	  detection	  can	  also	  be	  useful	  in	  quantifying	  catecholamines,	  
such	  as	  for	  detection	  following	  separation	  of	  microdialysis	  samples.	  Microdialysis	   is	  an	   in	  vivo	  
technique	  that	  uses	  a	  probe	   implanted	   in	  the	  brain	  region	  of	   interest	  to	  collect	  samples	  from	  
freely	  moving	   animals.40	   Although	   both	   the	   size	   of	   the	   probe	   (for	   example	   about	   240	   µm	   in	  
diameter	   and	   2	   mm	   in	   length	   typical	   for	   mouse	   brain	   measurements)	   and	   the	   temporal	  
resolution	   (on	   the	   order	   of	   minutes)	   of	   this	   technique	   are	   worse	   than	   FSCV,	   the	   ability	   to	  
determine	  basal	  extracellular	  levels	  of	  multiple	  neurotransmitters	  in	  a	  single	  sample,	  as	  well	  as	  
the	   ability	   to	   perform	   multi-­‐day	   experiments	   make	   this	   a	   comparable	   and	   complementary	  
technique.	   The	   microdialysis	   probe	   is	   inserted	   following	   stereotaxic	   surgery	   using	   a	   guide	  
cannula	  to	  target	  the	  specific	  brain	  region	  of	  interest.	  Perfusion	  of	  physiological	  buffer	  devoid	  
of	  the	  analyte	  of	  interest	  through	  the	  inlet	  of	  the	  probe	  generates	  a	  concentration	  gradient	  at	  
the	  semipermeable	  membrane	  of	   the	   tip.	  Small	  molecules	  under	   the	  molecular-­‐weight	  cutoff	  





sufficient	   equilibration	   time,	   are	   collected	   through	   the	   outlet.	   Dialysate	   samples	   can	   be	  
collected	   off-­‐line	   and	   frozen	   until	   further	   analysis	   or	   on-­‐line,	   in	   which	   case	   the	   dialysate	   is	  
directly	   fed	   into	   the	   separation	   and	   detection	   set-­‐up.	   	   Regardless	   of	   which	  method	   is	   used,	  
separation	  of	  the	  complex	  mixture	  into	  multiple	  analytes	  is	  typically	  accomplished	  using	  either	  
HPLC	   or	   CE	   coupled	   to	   a	   detector.2,41,42	   	   For	   the	   scope	   of	   this	   review,	   only	   methods	   using	  
electrochemical	  detectors	  will	  be	  discussed.	  	  
1.3.1	  HPLC	  Separation	  
For	   HPLC	   separation,	   the	   primary	   components	   required	   for	   separation	   and	   detection	   of	  
catecholamines	  are	  a	  solvent	  reservoir,	  pump(s),	  an	  injector,	  column,	  electrochemical	  detector,	  
and	  a	   computer	   to	   collect	   and	  analyze	   the	  data.41	  Optimization	  of	   the	  mobile	  phase,	   type	  of	  
column,	   type	   of	   detector,	   and	   applied	   potential	   allows	   for	   the	   targeted	   study	   of	   specific	  
neurotransmitters.	   Once	   the	   dialysate	   is	   injected	   on	   to	   the	   HPLC,	   it	   is	   carried	   through	   the	  
column	  by	  the	  mobile	  phase	  where	  it	  interacts	  with	  the	  stationary	  phase	  of	  the	  column.	  Due	  to	  
the	  physical	  properties	  of	  each	  of	  these	  components,	  the	  analytes	  are	  separated	  based	  on	  their	  
interaction	  with	  the	  column,	  resulting	  in	  varying	  retention	  times	  for	  different	  analytes.	  Analyte	  
peak	  area	  is	  determined	  by	  integration	  and	  quantified	  against	  known	  standards.	  Separation	  by	  
CE	  requires	  a	  high	  voltage	  power	  supply,	  the	  capillary,	  source	  and	  destination	  buffer	  reservoirs,	  
a	  detector,	  and	  data	  collection	  and	  analysis	  system.42	  CE	  relies	  on	  the	  different	  electrophoretic	  
mobilities	   of	   each	   analytes	   to	   separate	   them	   as	   they	   travel	   through	   the	   capillary	   from	   the	  
anode	  to	  the	  cathode.	  Upon	  detection,	  peaks	  are	  depicted	  on	  an	  electropherogram	  based	  on	  





In	  recent	  years,	  advances	  to	  the	  method	  of	  HPLC	  analysis	  of	  catecholamines	  has	  stemmed	  
from	  improvements	  to	  the	  column	  itself.	  By	  altering	  the	  density	  of	  the	  C18	  moieties,	  the	  Atlantis	  
T3	  column	  retains	  polar	  compounds	  better,	  a	   feat	  that	  was	  difficult	   to	  accomplish	   in	  the	  past	  
with	   the	   conventionally	  used	  hydrophobic	   stationary	  phase.2,43,44	  Alternatively,	  using	   columns	  
with	   porous	   silica	   rods	   such	   as	   the	  C18	  monolithic	   column	   results	   in	   better	   separation	  of	   the	  
catecholamines	   norepinephrine	   and	   epinephrine.2,45	   Advancements	   in	   column	   technologies	  
have	   led	   to	   improved	   sample	   through-­‐put	   and	   sensitivity	   using	   traditional,	   commercially	  
available	   electrochemical	   detectors	  when	   it	   comes	   to	  HPLC	   analysis.	   Although	   improvements	  
for	   catecholamine	   analysis	   are	   found	   through	   improved	   separation,	   advancements	   in	   the	  
detection	  of	  other	  neurotransmitters	  have	  also	  been	  made	  in	  recent	  years.	  As	  those	  studies	  are	  
beyond	  the	  scope	  of	  this	  review,	  they	  have	  not	  been	  included	  in	  this	  discussion.	  
1.3.2	  Electrophoresis	  Separation	  
True	   progress	   is	   being	   made	   when	   it	   comes	   to	   utilizing	   electrophoretic	   separation	   of	  
microdialysis	  samples,	  especially	  in	  the	  pursuit	  of	  lab-­‐on-­‐a-­‐chip	  designs.	  The	  pioneering	  work	  of	  
the	   Martin	   group	   in	   2008	   produced	   the	   first	   report	   of	   a	   microchip	   system	   that	   combined	  
microdialysis	  sampling	  with	  microchip	  electrophoresis	  coupled	  to	  electrochemical	  detection.46	  	  
Biological	  measurements	  were	  demonstrated	  via	  detection	  of	  stimulated	  dopamine	  from	  PC	  12	  
cells.	   Sampling	   dopamine	   standards	   through	   the	   same	   process	   allowed	   for	   quantification	   of	  
dopamine,	   as	   well	   as	   identification	   by	   matching	   migration	   times.	   Others	   have	   gone	   on	   to	  
explore	  novel	  materials	  for	  fabrication	  in	  an	  effort	  to	  produce	  lower	  cost,	  portable,	  yet	  effective	  
microchips	   for	   catecholamine	   detection.47,48	   Novel	   methodologies	   have	   also	   been	   applied	   to	  





electrodes	  have	  been	  devised	  to	  allow	  for	  the	  variation	  of	  the	  electrode	  if	  required.49	  They	  also	  
demonstrated	  the	  ability	  of	  using	  carbon-­‐fiber	  and	  glassy	  carbon	  electrodes	  in	  conjunction	  with	  
their	  epoxy-­‐encapsulated	  microchip	  systems	   for	   the	  separation	  and	  detection	  of	  a	  mixture	  of	  
catecholamines.	  
Developing	  the	  first	  step	  in	  catecholamine	  separation	  and	  detection,	  the	  Kennedy	  group	  has	  
been	   working	   towards	   improving	   the	   temporal	   resolution	   of	   microdialysis	   sampling	   so	   that	  
analysis	  can	  be	  done	  on	  the	  order	  of	  seconds	  to	  more	  closely	  match	  the	  dynamic	  behavior	  of	  
neurotransmitter	   systems.	  With	   that	   goal,	   their	  work	   generates	   discrete	   sample	   plugs	   of	   the	  
dialysate	  stream	  to	  decouple	  temporal	  resolution	  from	  factors	  such	  as	  flow	  rate	  and	  tubing	  size.	  
50	  Using	  immiscible	  oil,	  2	  nL	  dialysate	  plugs	  are	  generated	  and	  collected	  into	  a	  capillary,	  which	  
are	  then	  fed	  into	  a	  microfluidic	  chip	  for	  analysis.	  This	  methodology	  was	  shown	  to	  bring	  down	  
temporal	   resolution	   (0.1-­‐2	   seconds);	   additionally,	   the	   storage,	   stability,	   and	   analysis	   of	   these	  
samples	   were	   also	   assessed	   and	   reported.51	   Although	   this	   technique	   employs	   CE	   coupled	   to	  
laser-­‐induced	   fluorescence,	   not	   electrochemical	   detection,	   we	   believe	   the	   improvement	   in	  
microdialysis	   sampling	   is	   noteworthy,	   and	   may	   in	   the	   future	   be	   translated	   into	   the	   field	   of	  
electrochemical	  detection	  of	  catecholamines.	  Further	  exploring	  nano	  level	  methodologies,	  Wu	  
et	  al.	  have	  devised	  a	  novel	  nanocapillary	  electrophoretic	  electrochemical	   (Nano-­‐CEEC)	  chip	  to	  
achieve	  zeptomole	   limits	  of	  detection	  of	  neurotransmitters	  with	  a	  total	  sampling-­‐to-­‐detection	  
time	  of	  15	  min.53	  
Most	  remarkably,	  the	  study	  of	  catecholamines	  by	  electrochemical	  methods	  has	  advanced	  to	  
combine	   the	   techniques	   of	   FSCV	   and	   CE	   to	  make	  measurements	   in	   a	   single	  Drosophila	   larva	  





researchers	   to	   combine	   the	   benefits	   of	   each	   to	   make	   breakthrough	   discoveries	   in	  
unconventional	  biological	  models,	  such	  as	  the	  Drosophila	  larva.	  	  
1.4	  Conclusions	  
Although	   well	   established	   for	   neurotransmitter	   detection,	   FSCV	   and	   HPLC/CE	   separation	  
paired	  with	  electrochemical	  detection	  are	  constantly	  being	  optimized	  to	  utilize	  their	  capability	  
of	  quantification	  and	  detection	  to	  its	  fullest	  potential.	  In	  this	  review	  we	  have	  presented	  some	  of	  
the	   recent	   noteworthy	   advances	   made	   in	   catecholamine	   detection	   using	   electrochemical	  
detection	  methods.	  As	  methodology	  is	  key	  for	  any	  technique,	  improvements	  in	  methods	  have	  
also	   been	   highlighted.	   Improvements	   in	   sensitivity	   and	   limits	   of	   detection	  mentioned	   herein	  
allow	   for	   the	   extension	   of	   these	   techniques	   to	   in	   vivo	   systems	   beyond	   traditional	   rodent	  
models.	   Strides	   made	   in	   applying	   FSCV	   to	   human	   studies	   pave	   the	   way	   for	   translating	  
laboratory	   research	   results	   to	   clinical	   therapeutics	   by	  providing	   a	   standardized	  platform	  with	  
which	  drugs	  can	  be	  evaluated.	  Overall,	   the	  advancements	  presented	  herein	  demonstrate	  that	  
despite	  being	  well-­‐established	   technique,	   researchers	  across	   the	   field	  are	   successfully	   finding	  












Chapter	  2:	  Manganese	  and	  Dopamine	  
	  
2.1	  Neuronal	  Communication	  
Communication	  in	  the	  brain	  occurs	  through	  a	  combination	  of	  electrical	  and	  chemical	  signals.	  
Although	   that	   is	   a	   simple	   and	   straightforward	   description,	   the	   complexity	   of	   neuronal	  
communication	  stems	  from	  each	  of	  the	  individual	  aspects	  of	  this	  process.	  When	  one	  unravels	  all	  
the	   different	   combinations	   associated	   with	   signal	   transduction,	   factoring	   in	   which	   types	   of	  
neurons	  are	  involved,	  which	  part	  of	  the	  brain	  the	  signal	  originates	  from,	  what	  kind	  of	  message	  is	  
being	  passed	  on,	  where	   the	  message	   is	  being	   received,	  which	   chemicals	  are	   released,	   etc.,	   the	  
number	   of	   total	   outcomes	   is	   breathtaking.	   Indeed,	   for	   an	   organ	   that	   is	   the	   control	   center	   for	  
every	   function	   in	   our	   body,	   an	   intricate	   and	   precisely	   regulated	   network	   of	   communication	   is	  
befitting.	  	  
Neurons	  can	  be	  found	  in	  one	  of	  several	  thousand	  varieties,	  each	  with	  their	  own	  structure	  and	  
function.1	   Conventionally,	   neurons	   are	   represented	   in	   the	   form	   depicted	   in	   Figure	   2.1,	   which	  
highlights	  the	  components	  common	  to	  most,	   if	  not	  all,	  neurons.	  Comparable	  to	  other	  cells,	   the	  
central	   structure	  of	  a	  neuron	   is	   the	  cell	  body	   (soma),	  which	  contains	   the	  nucleus	  and	  all	  other	  
major	   organelles.	   Stemming	   from	   the	   soma	   are	   the	   dendrites,	   which	   are	   branched	   structures	  
responsible	  for	  receiving	  signals	  from	  other	  neurons.	  These	  signals	  are	  sent	  via	  the	  axon,	  which	  is	  
found	  as	  a	  single	  projection	  extending	  from	  the	  cell	  body,	  terminating	  at	  the	  axon	  terminal,	  which	  
may	  or	  may	  not	  be	  branched.	  Distinction	  amongst	  neurons	  occurs	  based	  on	  several	  factors,	  such	  
as	  the	  level	  of	  branching	  of	  dendrites,	  the	  location	  of	  the	  axon	  with	  respect	  to	  the	  location	  of	  the	  





present.	  Regardless	  of	  type	  of	  neuron,	  neuronal	  communication	  occurs	  via	  the	  same	  mechanism	  















The	  propagation	  of	  an	  action	  potential	   is	  central	   to	   the	  success	  of	  communication	  between	  
neurons.	  Neurons	  have	  a	  negative	  resting	  potential,	  around	  -­‐70	  mV,	  compared	  to	  their	  external	  
environment	   due	   to	   the	   uneven	   pumping	   of	   positive	   and	   negatively	   charged	   ions	   present	   on	  
either	   side	   of	   the	   neuronal	   membrane.1,4	   An	   external	   stimulus	   has	   the	   ability	   to	   change	   that	  
potential	   to	  a	   less	  negative	  one,	  which	   is	   called	  “depolarization”	  of	   the	  membrane	  potential.	   If	  
this	  depolarization	  is	  significant	  enough	  and	  passes	  a	  certain	  threshold,	  then	  an	  action	  potential	  is	  
generated	   (Figure	   2.2).	   This	   manifests	   as	   a	   complete,	   all-­‐or-­‐none	   depolarization	   and	  
repolarization	   of	   the	   neuron.	   This	   action	   potential	   migrates	   down	   the	   axon,	   facilitated	   by	   the	  
myelin	  sheath	   that	  encompasses	   the	  axon,	  until	   it	   reaches	   the	  axon	  terminal.	  The	  activation	  of	  
the	   neuron	   by	   this	   electrical	   signal	   causes	   the	   terminal	   to	   release	   stored	   chemicals.	   These	  
chemicals	   further	   propagate	   neuronal	   communication	   by	   traveling	   across	   the	   synapse	   to	   the	  
dendrites	  of	  the	  target	  neuron.	  The	  synapse	  is	  a	  junction	  created	  from	  the	  connection	  made	  by	  
the	  axon	  terminal	  (termed	  the	  presynaptic	  terminal)	  of	  one	  neuron	  and	  the	  dendritic	  terminal	  of	  
a	  different	  neuron	  (called	  the	  postsynaptic	  terminal).	  The	  two	  terminals	  do	  not	  physically	  touch;	  
hence	  chemicals	  are	  used	  to	  transmit	  information.	  The	  two	  ends	  of	  the	  synapse	  are	  held	  tightly	  
together	  by	  a	  variety	  of	  proteins	  and	  astrocytes	  to	  generate	  this	  ~	  20	  -­‐	  40	  nm	  space.1	  Once	  the	  
chemical	   transmitters	   act	   on	   the	   receptors	   of	   the	   postsynaptic	   neuron,	   downstream	   signaling	  
then	   carries	   out	   the	   intended	   function	   of	   the	   communicated	   signal,	   either	   at	   the	   postsynaptic	  






















The	  chemicals	  that	  transmit	  signals	  across	  the	  synaptic	  cleft	  are	  neurotransmitters.	  Correlated	  
with	   different	   aspects	   of	   biological	   functioning	   (Table	   2.1),	   neurotransmitters	   are	   chemical	  
messengers	   that	   are	   synthesized	   and	   stored	   in	   the	   neuron.	   The	   most	   well	   characterized	  
neurotransmitter	   in	   the	   mammalian	   brain	   is	   the	   catecholamine	   dopamine	   (3,4-­‐
dihydroxyphenethylamine).	   Dopamine	   neurons	   are	   found	   in	   the	   midbrain	   and	   project	   out	   to	  
various	  regions	  of	  the	  forebrain	  through	  several	  different	  pathways	  (Figure	  2.3).1,4	  Dopaminergic	  
neurons	   of	   the	  mesolimbic	   pathway	   have	   cell	   bodies	   in	   the	   ventral	   tegmental	   area	  with	   axon	  
terminals	   in	   the	   nucleus	   accumbens,	   while	   the	   mesocortical	   pathway	   also	   originates	   at	   the	  
ventral	   tegmental	   area	   but	   terminates	   at	   the	   cortex.1,4	   Finally	   the	   mesostriatal	   (also	   called	  
nigrostriatal)	  pathway	  projects	  from	  the	  substantia	  nigra	  to	  the	  caudate	  putamen.1,4	  	  
Dopamine	   is	   synthesized	   in	   the	   neuron	   (Figure	   2.4)	   by	   a	   multi-­‐step	   pathway	   starting	   with	  
tyrosine,	  subsequently	  forming	  3,4-­‐dihydroxy-­‐L-­‐phenylalanine	  (L-­‐DOPA)	  by	  tyrosine	  hydroxylase,	  
which	   is	   converted	   to	   dopamine	   by	   aromatic	   amino	   acid	   decarboxylase	   (AADC;	   Figure	   2.5).1,4	  	  
Once	  synthesized,	  dopamine	   is	  packaged	   into	  vesicles	  via	   the	  vesicular	  monoamine	   transporter	  
(VMAT),	  where	  it	  is	  stable	  at	  an	  acidic	  pH.1	  The	  sequestered	  dopamine	  is	  localized	  near	  the	  nerve	  
terminal	  and	  upon	  sufficient	  action	  potential,	  an	  influx	  of	  calcium	  ions	  triggers	  activation	  of	  the	  
vesicles,	  causing	   them	  to	   fuse	  with	   the	  terminal	  membrane	  and	  release	   their	  contents	   into	   the	  
synaptic	  space.	  Once	  released	  dopamine	  interacts	  with	  its	  receptors	  on	  the	  pre-­‐	  or	  postsynaptic	  
neuron.	  There	  are	  five	  dopamine	  receptors,	  D1	  –	  D5,	  that	  are	  grouped	  into	  two	  families.	  The	  D1	  
and	  D5	  receptors	  make	  up	   the	  D1	   family,	  while	   the	  D2,	  D3,	  and	  D4	  receptors	  comprise	   the	  D2	  





that	  when	  dopamine	  binds	   to	  one	  of	   them,	   they	   initiate	  a	   response	   in	  a	   specific	  G	  protein.	  D1	  
family	   receptors	   are	   coupled	   to	   GS	   proteins,	   which	   stimulate	   adenylyl	   cyclase	   activity	   and	  
increases	   concentration	   of	   the	   second	  messenger	   cyclic	   adenosine	   monophosphate	   (cAMP).1,4	  
Conversely,	   D2	   receptors	   are	   coupled	   to	   Gi/Go	   proteins,	   which	   inhibit	   adenyly	   cyclase	   and	  
therefore,	   cAMP	   production.	   D2	   and	   D3	   receptors	   also	   function	   as	   inhibitory	   autoreceptors,	  
meaning	  they	  are	  also	  found	  on	  the	  presynaptic	  neuron	  from	  where	  they	  regulate	  extracellular	  
dopamine	  levels	  by	  feedback	  inhibition	  signaling.1,4	  Dopamine	  in	  the	  synaptic	  space	  will	  not	  only	  
interact	  with	   its	   receptors,	   but	   dopamine	   can	   also	   be	  metabolized	   by	   one	   of	   several	   different	  
pathways	  (Figure	  2.6).1,4	  If	  acted	  on	  by	  the	  enzyme	  monoamine	  oxidase,	  dopamine	  is	  converted	  
to	   dihydroxyphenyl-­‐acetic	   acid	   (DOPAC).	   Through	   a	   different	   pathway,	   catechol-­‐o-­‐
methyltransferase	   can	   form	  3-­‐methoxytyramine	   (3-­‐MT).	   Either	  of	   these	  products	   (DOPAC	  or	  3-­‐
MT)	  can	  subsequently	  interact	  with	  the	  opposite	  enzyme;	  both	  pathways	  lead	  to	  the	  formation	  of	  
homovanillic	  acid	  (HVA).	  	  Any	  remaining	  dopamine	  that	  has	  not	  diffused	  away	  from	  the	  synaptic	  
cleft	  is	  taken	  back	  up	  into	  the	  cytoplasm	  of	  the	  presynaptic	  neuron	  by	  the	  dopamine	  transporter	  
(DAT),	  a	  transmembrane	  protein,	  to	  be	  recycled.	  
	  
Neurotransmitter	   	   	   Primary	  Function	  
Acetylcholine	   muscle	  control,	  memory	  formation,	  sensory	  response	  
Dopamine	   reward,	  motor	  behavior,	  learning	  
Norepinephrine	   fight-­‐or-­‐flight	  response	  
GABA	   central	  nervous	  system	  inhibition	  
Glutamate	   long	  term	  potentiation,	  memory	  
Serotonin	   mood	  regulation,	  sleep,	  muscle	  control	  
	  






Figure	  2.3:	  Dopamine	  Pathways.	  Sagittal	  rodent	  brain	  slice	  adapted	  from	  Paxinos	  et	  al.	  showing	  














































The	  importance	  of	  the	  dopamine	  neurotransmitter	  stems	  from	  the	  multitude	  of	  functions	   it	  
regulates	  in	  the	  human	  body.	  The	  dopaminergic	  system	  plays	  a	  critical	  role	  in	  motor	  movement,	  
learning,	  reward,	  pleasure,	  cognition,	  and	  motivation	  behavior,	  just	  to	  name	  a	  few.1,4	  Dysfunction	  
in	   the	   dopamine	   system	   leads	   to	   a	   variety	   of	   disorders,	   the	   best	   known	   of	   which	   is	   the	  
neurodegenerative	   movement	   disorder	   of	   Parkinson’s	   disease.1,4	   In	   addition	   to	   deficits	   in	  
movement,	   both	   slowness	   and	   impaired	   initiation,	   patients	   of	   this	   disease	   exhibit	   depression,	  
apathy,	  and	  cognitive	  decline.	  As	  a	  progressive	  disorder,	  most	  symptoms	  of	  Parkinson’s	  disease	  
don’t	  manifest	  until	   at	   least	   70%	  of	   striatal	   dopamine	  projection	  neurons	  have	  degenerated.1,4	  
Other	   movement	   disorders	   connected	   to	   neuronal	   dysfunction	   in	   the	   striatum	   include	  
Huntington’s	   disease	   and	   dystonia.1,4	   Non-­‐movement	   diseases	   that	   have	   been	   linked	   to	  
dopamine	  system	  malfunction	  include	  schizophrenia,	  attention	  deficit	  hyperactivity	  disorder,	  and	  
addiction.1,4	  Most	  critical	  to	  the	  work	  presented	  herein,	  the	  symptomatology	  of	  the	  neurological	  
disorder	  manganism	  also	  strongly	  implicates	  striatal	  dopamine	  in	  its	  etiology.55,56	  
2.3	  Manganism	  
First	   reported	   in	   1837,	  manganism	   is	   a	  movement	   disorder	   characterized	  by	  motor	   deficits	  
and	   a	   progression	   of	   symptoms	   very	   similar	   to	   Parkinson’s	   disease,	   such	   as	   speech	   deficits,	  
muscular	   rigidity,	   “intention	   tremors,”	   bradykinesia,	   and	   gait	   changes.55,57,58	   Although	   many	  
symptoms	  of	  manganism	  appear	  to	  be	  similar	  to	  those	  found	  in	  Parkinson’s	  patients,	   it	   is	  still	  a	  
point	   of	   contention	   as	   to	   whether	   the	   two	   are	   related.	   By	   one	   hypothesis,	   “Mn	   poisoning”	   is	  
believed	  to	  be	  a	  precursor	  to	  the	  onset	  of	  Parkinson’s	  in	  later	  years.59	  This	  is	  suggested	  because	  
aside	   from	   the	   similarity	   in	   symptoms,	  both	  appear	   to	  act	  on	   the	   same	  brain	   region,	   the	  basal	  





Mn	  developed	  Parkinson’s	  disease	  an	  average	  of	  17	  years	  earlier	  than	  controls,	  suggest	  that	  Mn	  
exposure	  may	  increase	  the	  risk	  of	  Parkinson’s	  development.61	  However,	  the	  lack	  of	  a	  substantial	  
number	  of	  such	  clinical	  studies	  still	   leaves	  room	  for	  questions	  when	  accepting	  the	  link	  between	  
the	   two	   neurological	   disorders.	   Alternatively,	   the	   opposing	   hypothesis	   rejecting	   a	   correlation	  
between	   the	   two	   disorders	   cites	   as	   its	  main	   piece	   of	   evidence	   that	   the	   two	   appear	   to	   act	   on	  
different	   pathways	   and	   regions	   in	   the	  brain.	  While	   it	   is	   true	   that	   the	  basal	   ganglia,	   a	   group	  of	  
brain	   regions	   that	   includes	   the	   caudate	   putamen	   (CPu),	   nucleus	   accumbens	   (NAc),	   the	   globus	  
pallidus,	   the	   subthalamic	   nucleus,	   and	   the	   substantia	   nigra	   pars	   reticulate	   and	   compacta,	   is	  
implicated	   in	   both,	   Mn	   accumulates	   primarily	   in	   the	   globus	   pallidus,	   CPu,	   and	   NAc	   whereas	  
Parkinson’s	   is	   associated	   with	   an	   80%	   degeneration	   of	   the	   nigrostriatal	   pathway,	   primarily	   of	  
dopamine	   neurons	   in	   the	   substantia	   nigra	   pars	   compacta19	   and	   CPu.4,62	   Interestingly,	   such	  
significant	   degeneration	   of	   dopamine	   neurons	   has	   not	   yet	   been	   correlated	   with	   the	   onset	   of	  
manganism.	   Moreover,	   subtle	   differences	   in	   the	   symptoms	   also	   exist	   between	   these	   two	  
neurological	  diseases,	  for	  example	  between	  the	  “intention	  tremors”	  of	  manganism	  patients	  that	  
occur	  when	  movement	  is	  attempted	  and	  the	  “resting	  tremors”	  of	  Parkinson’s	  patients	  that	  occur	  
without	  any	  intended	  movement	  at	  all13.	  In	  spite	  of	  this	  debate,	  the	  preferential	  accumulation	  of	  
Mn	  in	  dopamine	  rich	  regions,	  as	  well	  as	  the	  cognitive	  and	  movement	  symptoms	  associated	  with	  
the	   disorder,	   point	   to	   the	   dysregulation	   of	   the	   dopamine	   system	   as	   the	   primary	   candidate	   to	  
explain	  how	  Mn	  disrupts	   the	  brain	   in	  patients	  afflicted	  with	  manganism.56,63	  When	  relaying	  the	  
relevance	   of	   studying	   the	   relationship	   between	  manganism	   and	   dopamine	   to	   better	   strategize	  
approaches	   for	   treatment,	   it	   is	   imperative	   to	   understand	   that	   although	   disorders	   such	   as	  





exposure	  to	  manganese	  makes	  more	  people	  susceptible	  to	  developing	  this	  disease	  as	  compared	  
to	  Parkinson’s,	  which	  requires	  genetic	  predisposition	  and	  vulnerability	  to	  some	  degree.	  
2.4	  Manganese	  
As	  manganese	   is	   an	   essential	   trace	   element,	   it	   is	   necessary	   for	   the	   human	   body	   for	  many	  
functions	  such	  as	  immunological	  response,	  reproduction,	  and	  bone	  growth.55,58,64,65	  Manganese	  is	  
found	   in	  a	  variety	  of	   foods,	   such	  as	  grain,	   rice,	  nuts,	  and	   tea,	  as	  well	  as	   in	  parenteral	  nutrition	  
solutions	  for	  neonates,	  therefore	  meeting	  the	  low	  dose	  daily	  requirements	  by	  diet	  is	  not	  difficult	  
to	   accomplish.65	   As	   a	   metal,	   the	   most	   well	   known	   use	   of	   manganese	   is	   in	   iron	   and	   steel	  
production.66	   It	  also	  serves	  an	  important	  function	  in	  alkaline	  batteries	  as	  the	  electron	  accepting	  
cathode.67	   Additionally,	   it	   can	   be	   found	   in	   pesticides,	   as	  well	   as	   in	   gasoline	   in	   the	   form	  of	   the	  
antiknock	  agent	  methylcyclopentadienyl	  manganese	   tricarbonyl.55	  The	  onset	  of	  manganism	  has	  
been	  suggested	  to	  be	  due	  to	  long	  term	  exposure	  to	  the	  metal,	  which	  can	  accumulate	  in	  the	  body	  
and	  brain	  through	  one	  of	  several	  different	  routes.	  
2.5	  Sources	  of	  Manganese	  Overexposure	  
Occupational	  exposure	  appears	  to	  be	  the	  leading	  cause	  of	  excess	  manganese	  inhalation,	  with	  
occupations	  in	  welding,	  mining,	  and	  battery	  assembly	  being	  the	  worst	  offenders.66-­‐69	  Recently,	  a	  
study	  also	  showed	   that	  environmental	  exposure	   to	  children	   living	   in	  an	  area	  with	  high	   rates	  of	  
electronic	   waste	   recycling	   resulted	   in	   significantly	   elevated	   blood	   manganese	   levels.70	  
Environmental	  factors	  such	  as	   industrial	  pollution	  and	  residency	  in	  contaminated	  areas	  has	  also	  
been	   reported	   to	   increase	   manganese	   exposure.71	   Once	   inhaled	   or	   ingested,	   the	   method	   by	  
which	   ingested	   manganese	   passes	   through	   the	   blood	   brain	   barrier	   is	   not	   fully	   understood;	  





metal	   transporter	  1	   (DMT-­‐1).72-­‐75	  DMT-­‐1	   is	   a	  non-­‐exclusive	   transporter	  as	   it	   can	  also	  bind	   iron,	  
and	   interestingly,	   iron	  deficiency	  has	  been	   linked	   to	  manganism	  vulnerability.76,77	  An	  additional	  
connection	   between	   manganese	   and	   iron	   stems	   from	   the	   preferential	   accumulation	   of	  
manganese	  in	  the	  basal	  ganglia,	  as	  that	  region	  is	  already	  rich	  in	  both	  metals	  and	  therefore	  more	  
likely	  to	  accumulate	  them.78	  Even	  if	  all	  modes	  of	  environmental	  exposure	  can	  be	  avoided,	  studies	  
have	   reported	   that	  medical	   conditions	   such	   as	   liver	   or	   kidney	   failure	   that	   impair	   clearance	   of	  
metals	   from	  the	  body	  can	  result	   in	  accumulation	  of	  dietary	  manganese	  and	  eventually	  result	   in	  
the	  same	  type	  of	  basal	  ganglia	  accumulation	  and	  neurological	  symptoms.79-­‐81	  	  For	  similar	  reasons,	  
conditions	  such	  as	  alcoholism,	  which	  can	  impair	  the	  liver’s	  ability	  to	  properly	  function	  and	  clear	  
toxins	   from	   the	   body,	   have	   been	   suggested	   to	   be	   risk	   factors	   for	   the	   development	   of	  
manganism.82	  	  	  
2.6	  Research	  Model	  and	  Objectives	  
For	  the	  purposes	  of	  this	  work,	  a	  sub-­‐acute	  manganese	  treatment	  protocol	  was	  adapted	  from	  
Dodd	  et	  al.	   that	   results	   in	   significant	  manganese	  accumulation	   in	   the	  basal	   ganglia	  of	  mice	   via	  
subcutaneous	   injections.60	   The	   overall	   aim	   of	   this	   work	   was	   to	   determine	   how	   basal	   ganglia	  
manganese	  accumulation	  impacts	  striatal	  dopamine	  dynamics	  over	  a	  period	  of	  21	  days.	  Based	  on	  
this	  treatment	  method,	  C57Bl/6	  mice	  were	  administered	  three	  0.1	  mL	  subcutaneous	  injections	  of	  
50	  mg/kg	  MnCl2	  over	  the	  course	  of	  7	  days,	  with	  no	  treatment	  for	  two	  days	  between	  each	  dose.	  	  A	  
control	   group	  was	   given	   the	   same	   volume	  of	   saline	   on	   treatment	   days.	   All	   neurochemical	   and	  
behavioral	  data	  from	  the	  saline	  group	  at	  each	  time	  point	  were	  collapsed	  to	  form	  a	  single	  control	  
group,	   as	   these	   results	  were	  not	  different	   across	   time	  points.	  After	   the	   third	  dose,	   analyses	  of	  





and	   three	   weeks	   later	   (day	   21),	   to	   assess	   the	   short	   and	   long	   term	   effects	   of	   manganese	  
accumulation.	  The	  three	  objectives	  of	  this	  research	  were	  to	  answer	  the	  following	  questions:	  
Research	   Objective	   I:	   Does	   excess	   accumulation	   of	   manganese	   result	   in	   changes	   to	   striatal	  
dopamine	  release,	  uptake,	  or	  extracellular	   levels?	  Additionally,	  can	  time-­‐dependent	  changes	  be	  
observed	  by	   this	  protocol	   to	   correlate	   to	   the	   time-­‐dependent	  development	  and	  progression	  of	  
manganism?	  
Research	  Objective	  II:	  Are	  the	  attenuated	  dopamine	  release	  levels	  observed	  in	  Objective	  1	  due	  to	  
impaired	  functionality	  or	  lower	  concentration	  of	  dopamine	  reserve	  pool	  vesicles?	  
	  Research	   Objective	   III:	   Do	   lower	   levels	   of	   dopamine	   in	   the	   striatum	   result	   in	   behavioral	  


















Chapter	  3:	  Dopamine	  Monitoring	  By	  Fast	  Scan	  Cyclic	  Voltammetry	  (FSCV)	  
	  
Two	   out	   of	   the	   three	   research	   objectives	   for	   this	   thesis	   work	   were	   achieved	   using	   the	  
technique	   of	   fast	   scan	   cyclic	   voltammetry	   (FSCV)	   therefore	   more	   in	   depth	   background	   and	  
methodology	   are	   provided	   here.	   Methodology	   of	   other	   techniques	   is	   provided	   within	   the	  
relevant	  chapters.	  For	  a	  step	  by	  step	  instructional	  video	  and	  corresponding	  literature,	  see	  our	  
publication:	  
Maina,	  F.,*	  Khalid,	  M.,*	  Apawu,	  A.,*	  and	  Mathews,	  T.A.,	  “Presynaptic	  Dopamine	  Dynamics	  in	  
Striatal	  Brain	  Slices	  with	  Fast-­‐Scan	  Cyclic	  Voltammetry”	  J	  Vis	  Exp,	  59,	  pii:	  3464.	  	  
doi:	  10.3791/3464	  (2012).	  *indicates	  co-­‐first	  authors.83	  
	  
3.1	  Fast	  Scan	  Cyclic	  Voltammetry	  Background	  
FSCV	   is	  one	  of	   the	  primary	  methods	  used	  today	  to	  study	  dopamine	  neurotransmission.	   In	  
contrast	  to	  neuroanalytical	  techniques	  like	  microdialysis,	  FSCV	  provides	  the	  advantage	  of	  better	  
temporal	   and	   spatial	   resolution,	   selectivity	  without	   an	   additional	   separation	   component,	   and	  
the	  capability	  of	  analyzing	  neuronal	  functionality	  in	  real	  time.	  	  
Electrochemical	   methods	   such	   as	   voltammetry	   rely	   on	   the	   charge-­‐transfer	   process	   at	   an	  
electrode	   surface	   to	   characterize	   the	   sampling	   environment.84	  More	   specifically,	   this	  method	  
quantitates	   the	   concentration	   of	   oxidizable	   species	   based	   on	   the	   current	   generated	   by	   their	  
redox	   reaction.	   Although	   Jaroslav	   Heyrovsky	   developed	   the	   Nobel	   Prize	   winning	   method	   of	  
using	  applied	  voltage	  to	  both	  identify	  and	  quantify	  organic	  molecules,	  it	  was	  Ralph	  Adams	  who	  
applied	   it	   for	   the	   purpose	   of	   measuring	   neurotransmitters	   in	   the	   rodent	   brain.86	   By	   using	  
biocompatible	   carbon-­‐based	   electrodes	   for	   FSCV	   induces	   less	   tissue	   damage	   than	   other	  





can	  monitor	   simply	   by	   varying	   the	   parameters	   of	   the	   applied	   potential	   and	   the	   brain	   region	  
from	  which	  measurements	  are	  made.	  
For	   the	   detection	   of	   dopamine,	   a	   sweeping	   triangular	   waveform	   is	   used	   that	   spans	   the	  
potentials	  at	  which	  dopamine	  is	  known	  to	  oxidize	  and	  its	  oxidation	  product	  is	  known	  to	  reduce.	  
At	   scan	   rates	   upward	  of	   400	  V/s,	   this	   8	   -­‐	   9	  ms	  waveform	   can	  be	   repeated	   approximately	   10	  
times	   every	   second,	   allowing	   for	   temporal	   resolution	   capable	   of	   making	   dynamic	  
measurements	   of	   the	   neurotransmission	   process.84	   During	   this	   two-­‐electron	   process	   (Figure	  
3.1),	  a	  current	  is	  generated,	  the	  integral	  of	  which	  over	  time	  equals	  charge	  (Q).	  Using	  Faraday’s	  
law	  (Equation	  3.1),	  that	  charge	  can	  be	  related	  back	  to	  the	  moles	  of	  dopamine	  undergoing	  the	  
redox	   process,	   thereby	   giving	   a	   concentration	   of	   dopamine	   found	   in	   the	   vicinity	   of	   the	  




Figure	  3.1:	  Oxidation-­‐reduction	  reaction	  of	  dopamine.	  
Q	  =	  nFN	  
	  
Equation	  1:	  Faraday’s	  law	  
Q:	  total	  charge	  (Coulombs)	  
n:	  number	  of	  moles	  of	  electrons	  transferred	  per	  molecule	  
F:	  Faraday’s	  constant	  (9.649	  x	  104	  Coulombs/mole)	  






Carbon-­‐fiber	  microelectrodes	  are	  most	  commonly	  used	  for	  detection	  of	  catecholamines	   in	  
the	  brain.	  In	  the	  cylindrical	  form,	  such	  as	  the	  ones	  used	  in	  this	  work,	  the	  typical	  working	  surface	  
of	  the	  electrode	  spans	  about	  50	  –	  200	  µm	  in	  length,	  with	  a	  diameter	  of	  7	  µm.	  These	  dimensions	  
contribute	   to	   the	   excellent	   spatial	   resolution	   provided	   by	   this	   technique	   to	   measure	   from	  
discrete	   anatomical	   regions,	   as	   well	   as	   the	   minimal	   tissue	   damage	   that	   is	   induced.	  
Unfortunately,	  the	  size	  of	  these	  electrodes,	  though	  smaller	  than	  microdialysis	  probes,	  is	  still	  not	  
small	  enough	  to	  sample	  directly	  from	  the	  synaptic	  cleft	  (Figure	  3.2).	  Therefore,	  it	  is	  important	  to	  
understand	  that	  measurements	   from	  FSCV	  are	  also	  being	  made	   in	   the	  extracellular	  space.	  An	  
advantage	   that	   the	   carbon	   microfiber	   electrodes	   have	   is	   their	   ability	   to	   rapidly	   respond	   to	  
changes	   in	   extracellular	   environment	   and	   relate	   them	   back	   to	   release	   and	   uptake	   events	   of	  
dopamine.	  Additionally,	   using	  pharmacological	   agents,	   functionality	  of	   autoreceptors	   and	   the	  
dopamine	  transporter	  can	  also	  be	  assessed.8,9,84	  Unfortunately,	  post-­‐synaptic	  receptor	  activity	  








Figure	   3.2:	   Size	   comparison	   of	   carbon-­‐fiber	   microelectrode	   and	   microdialysis	   probe.	   For	  
measurements	   in	  a	  mouse	  brain,	  diameter	  of	  carbon-­‐fiber	  electrode	  (7	  μm,	  top)	  as	  compared	  













Development	  of	  FSCV	  over	  the	  course	  of	  several	  decades	  has	  optimized	  it	  for	  use	  in	  both	  in	  
vitro	   (slice)	   and	   in	   vivo	  experiments.	  While	  monitoring	  of	  neurotransmission	   in	   freely	  moving	  
animals	  enables	  researchers	  to	  correlate	  brain	  activity	  with	  behavioral	  experiments,	  there	  are	  
several	   advantages	   to	   performing	   FSCV	   in	   slices	   as	  well.	   First,	   working	  with	   slices	   allows	   for	  
multiple	  experiments	  and	  pharmacological	  experiments	  to	  be	  performed	  on	  the	  same	  animal,	  
within	   the	   same	   day	   without	   having	   to	   account	   for	   clearance	   times	   in	   between	   drugs	   as	  
typically	   multiple	   slices	   for	   a	   particular	   brain	   region	   can	   be	   generated.	   Second,	   local	  
manipulations	  to	  a	  particular	  brain	  region	  assess	  their	  effects	  on	  dopamine	  neurotransmission	  
without	   contributing	   effects	   from	  other	   brain	   regions/neuronal	   projections.	   Third,	   conditions	  
pertaining	  to	  stimulation,	  temperature,	  and	  pH	  are	  under	  the	  control	  of	  the	  researcher.	  Finally,	  
multiple	  brain	   regions	   can	  be	   tested	  within	   the	   same	   slice	   since	   there	   is	   not	   trailing	  damage	  
from	  placement	  of	   the	  electrode.	  For	  these	  reasons,	  our	  analysis	  of	   the	  dopaminergic	  system	  
using	  FSCV	  was	  done	  using	  slice	  experiments.	  
3.2	  Electrode	  Fabrication	  and	  Calibration	  
For	  all	  experiments,	  cylindrical	  carbon-­‐fiber	  microelectrodes	  were	  used	  that	  were	  fabricated	  
in-­‐house.	   In	   this	   process,	   vacuum	   suction	   aspiration	   is	   first	   used	   to	   thread	   a	   carbon	   fiber	  
(diameter	  7	  μm;	  Goodfellow	  Oakdale,	  PA)	  through	  a	  borosilicate	  glass	  capillary	  (length	  10	  cm,	  
o.d.	  1.2	  mm,	  i.d.	  0.68	  mm;	  A-­‐M	  systems,	  Carlsborg,	  WA).	  The	  capillary	  is	  melted	  in	  half	  at	  the	  
center	  to	  create	  two	  electrodes,	  each	  with	  a	  tapered	  end	  of	  approximately	  4.4	  mm	  and	  a	  tight	  
seal	   around	   the	   fiber	   using	   an	   electrode	   puller	   (Narishige,	   Tokyo,	   Japan;	   setting	   -­‐	   90.7	  main	  
magnet,	  23.2	  sub-­‐magnet,	  and	  53.4	  heater).	  A	  microscope	  (Olympus,	  Tokyo,	  Japan)	  is	  then	  used	  





filled	   with	   a	   150	   mM	   KCl	   solution	   and	   a	   lead	   wire	   is	   then	   inserted	   (Squires	   Electronics,	  
Cornelius,	  OR)	  to	  help	  connect	  the	  electrode	  to	  the	  headstage	  of	  the	  potentiostat.	  
Each	   electrode	   is	   calibrated	   before	   use	   to	   determine	   sensitivity,	   as	  well	   as	   afterwards	   to	  
obtain	   a	   calibration	   factor	   for	  data	   analysis.	   Calibration	   is	   done	  using	   a	   flow	   t-­‐cell	   that	  has	  3	  
ports.	   A	   Ag/AgCl	   reference	   electrode	   is	   also	   inserted	   through	   one	   side	   via	   a	   self-­‐made	   hole.	  
Tubing	   is	  used	   to	  connect	   the	   inlet	   to	  a	   syringe	  pump	  set	   to	  a	   flow	  rate	  of	  2	  mL/min	   for	   the	  
modified-­‐	  artificial	  cerebrospinal	  fluid	  (aCSF;	  see	  Section	  3.3).	  A	  second	  port	  is	  connected	  to	  a	  
10	  cc	  syringe	  that	   is	   filled	  with	  the	  calibration	  dopamine	  solution.	  The	  third	  port	  at	  the	  top	   is	  
where	  the	  electrode	  is	  lowered	  into	  during	  calibration.	  Dopamine	  standard	  of	  3	  μM	  is	  made	  up	  
in	  modified	   aCSF	   (see	   Section	   3.3)	   at	   the	   time	   of	   calibration	   and	   filled	   into	   the	   syringe.	   The	  
dopamine	  signal	  is	  recorded	  at	  least	  three	  times,	  and	  the	  current	  is	  averaged.	  To	  obtain	  a	  pre-­‐
calibration	   factor,	   the	   average	   is	   divided	   by	   3	   (to	   account	   for	   the	   concentration	   of	   standard	  
being	  3	  μM).	  Only	  electrodes	  above	  a	  specific	  threshold	  calibration	  factor	  (10	  nA/μM)	  are	  used	  
for	   experiments.	   After	   each	   experiment,	   the	   process	   is	   repeated,	   and	   that	   post-­‐calibration	  
factor	  is	  used	  for	  data	  analysis.	  
The	  reference	  electrode,	  which	  can	  be	  used	  multiple	  times	  before	  requiring	  replacement,	  is	  
also	  fabricated	  in-­‐house.	  For	  that	  process,	  a	  250	  μm	  silver	  wire	  (A-­‐M	  Systems,	  Carlsborg,	  WA)	  is	  
chloridized	  in	  1	  M	  HCl	  for	  5	  -­‐	  10	  minutes	  to	  form	  a	  layer	  of	  AgCl	  on	  the	  surface.	  
To	  elicit	  dopamine	  release,	  a	  commercially	  available	  bipolar	  tungsten	  stimulating	  electrode	  







	  3.3	  FSCV	  Solutions	  
For	  all	  experiments,	   the	  following	  three	  versions	  of	  artificial	  cerebrospinal	   fluid	   (aCSF)	  are	  
required,	  all	  three	  made	  in	  ultrapure	  (18	  MΩ	  cm)	  water:	  
1. Modified	   aCSF	   for	   electrode	   calibrations.	   Can	   be	   made	   in	   advance	   and	   kept	  
unrefrigerated	   for	   up	   to	   one	   week.	   Concentrations	   of	   components	   are	   as	   follows	   (in	  
mM):	  2.5	  KCl,	  126	  NaCl,	  1.2	  NaH2PO4,	  2.4	  CaCl2,	  1.2	  MgCl2,	  and	  25	  NaHCO3	  (pH	  7.4).	  
2. Sucrose	  aCSF	  for	  slicing	  (see	  Section	  3.4).	  Once	  prepared,	  requires	  at	  least	  20	  minutes	  of	  
oxygenation	  and	  can	  be	  stored	  in	  the	  refrigerator	  at	  4	  °C	  for	  up	  to	  1	  week.86	  	  Consists	  of	  
(in	  mM):	  180	  sucrose,	  30	  NaCl,	  4.5	  KCl,	  1.0	  MgCl2,	  26	  NaHCO3,	  1.2	  NaH2PO4,	  and	  10	  D-­‐
glucose	  (pH	  7.4).	  
3. Recording	  aCSF	  for	  data	  acquisition	  (see	  Section	  3.5).This	  aCSF	  must	  be	  prepared	  daily	  
before	   experiments	   and	   kept	   oxygenated	   by	   bubbling	   with	   95%	   O2/5%	   CO2	   at	   room	  
temperature.	  Contained	  (in	  mM):	  126	  NaCl,	  2.5	  KCl,	  2.4	  CaCl2,	  1.2	  MgCl2,	  25	  NaHCO3,	  1.2	  
NaH2PO4,	  11	  D-­‐glucose,	  and	  0.4	  ascorbic	  acid	  (pH	  7.4).	  
3.4	  Brain	  Slices	  
Once	   solutions	   are	   made,	   the	   mouse	   is	   sacrificed	   by	   CO2	   asphyxiation	   in	   a	   small	   gas	  
chamber,	  followed	  by	  decapitation	  using	  scissors.	  The	  brain	  is	  rapidly	  removed	  and	  sliced	  using	  
a	  Vibratome	  (St.	  Louis,	  MO).	  Coronal	  slices	  of	  400	  μm	  thickness	  are	  cut	  until	  the	  brain	  region	  of	  
interest	  is	  identified.	  For	  all	  experiments,	  striatal	  brain	  slices	  were	  obtained	  to	  utilize	  the	  brain	  
region	   of	   the	   caudate	   putamen	   (CPu).	   Slices	   are	   then	   allowed	   to	   acclimate	   in	   oxygenated	  






3.5 Data	  Acquisition	  
After	   incubation,	   the	   brain	   slice	   is	   moved	   to	   a	   custom	   made	   recording	   chamber	  
continuously	  perfusing	  with	  oxygenating	  aCSF	  and	  set	  to	  32oC.	  The	  carbon-­‐fiber	  and	  stimulating	  
electrodes	  are	  lowered	  onto	  the	  slice	  as	  shown	  in	  Figure	  3.3A	  while	  the	  reference	  electrode	  is	  
connected	  to	  the	  headstage	  via	  an	  alligator	  clip	  and	  is	  making	  contact	  with	  the	  aCSF	  bathing	  the	  
slice.	  The	  stimulating	  electrode	  should	  rest	  on	  top	  of	  the	  slice	  while	  the	  carbon-­‐fiber	  electrode	  
is	   inserted	  about	  75	  μm	  deep	   into	   the	  slice,	  100	   -­‐	  200	  μm	  away	   from	  the	  bipolar	   stimulating	  
electrodes.	  Electrical	  stimulation	  parameters	  are	  set	   in	  TarHeel	  CV	  software	   (ESA	  Biosciences,	  
Inc.,	  Chelmsford,	  MA)	  to	  apply	  a	  single	  pulse	  stimulation	  (monophasic,	  350	  μA,	  60	  Hz,	  and	  4	  ms	  
pulse	   width)	   to	   evoke	   dopamine	   release.87	   The	   slice	   is	   stimulated	   every	   5	   minutes	   while	   a	  
potential	  is	  applied	  at	  the	  carbon	  fiber	  electrode	  in	  the	  shape	  of	  a	  triangular	  waveform	  (Figure	  
3.3B).	   Initially,	   the	   potential	   is	   held	   at	   -­‐0.4	   V	   vs.	   Ag/AgCl	   reference	   electrode	   to	   facilitate	  
adsorption	  of	  dopamine	  onto	   the	  electrode.	   The	  potential	   is	   then	   ramped	  up	   to	  +1.2	  V	   then	  
brought	  back	  down	  to	  -­‐0.4	  V	  at	  a	  scan	  rate	  of	  400	  V/s.	  This	  process	  generates	  a	  stable	  charging	  
current	   that	   is	   digitally	   subtracted	   out	   from	   the	   data	   files	   so	   only	   current	   from	   dopamine	  
oxidation	  is	  recorded.	  During	  the	  upward	  scan,	  at	  approximately	  +0.6	  V,	  dopamine	  is	  oxidized	  
to	   dopamine-­‐ortho-­‐quinone	   (Figure	   3.3C).	   On	   the	   downward	   scan,	   at	   approximately	   -­‐0.2	   V,	  
dopamine-­‐ortho-­‐quinone	   is	   reduced	   back	   to	   dopamine.	   If	   a	   dopamine	   signal	   is	   obtained,	  
collection	   is	   continued	   at	   that	   location	   of	   the	   electrode	   every	   5	  minutes	   until	   at	   least	   three	  
stable	  values	  are	  obtained.	  A	  signal	  is	  considered	  stable	  if	  three	  consecutive	  readings	  are	  within	  








Figure	   3.3:	   Schematic	   of	   FSCV	   data	   acquisition.	   A)	   Coronal	   brain	   slice	   displayed	   to	   portray	  
placement	  of	  carbon-­‐fiber	  microelectrode	  and	  stimulating	  electrode	  in	  brain	  region	  of	  interest,	  
the	   caudate	   putamen.	   B)	  Waveform	   applied	   to	   working	   electrode	   for	   dopamine	   detection.	  
Starting	  from	  -­‐400	  mV,	  potential	  is	  ramped	  up	  to	  +1200	  mV	  and	  then	  brought	  back	  down	  to	  -­‐
400	  mV	  vs.	  Ag/AgCl	  at	  a	  scan	  rate	  of	  400	  V/s.	  This	  waveform	  lasts	  for	  approximately	  8	  ms	  and	  is	  
repeated	  every	  100	  ms.	  C)	  Visual	  representation	  of	  redox	  reaction	  occurring	  at	  the	  electrode’s	  
surface	  oxidizing	  dopamine	  to	  dopamine-­‐ortho-­‐quinone	  before	  reducing	  it	  back	  to	  dopamine	  in	  









the	   process	   is	   repeated.	   Only	   after	   obtaining	   stable	   signal	   are	   any	   pharmacological	   agents	  
perfused	  over	  the	  slice	  (using	  a	  pump	  set	  at	  a	  flow	  rate	  of	  1	  mL/min).	  	  
3.6 Data	  Analysis	  
	  
FSCV	   data	   is	   presented	   in	   one	   of	   three	   ways.	   Primarily,	   a	   cyclic	   voltammogram	   can	   be	  
generated	   which	   shows	   the	   applied	   potential	   against	   the	   current	   generated	   by	   the	   redox	  
process	   (Figure	  3.4).	  The	   locations	  of	   the	  peaks,	  corresponding	  to	  the	  potentials	  at	  which	  the	  
neurotransmitter	   oxidizes	   and	   reduces,	   serve	   as	   a	  way	   to	   identify	  which	   neurotransmitter	   is	  
being	   detected.	   In	   the	   case	   of	   dopamine,	   the	   peaks	   are	   found	   at	   +0.6	   V	   and	   -­‐0.2	   V.	  
Alternatively,	   the	   generated	   current	   can	   be	   plotted	   against	   time	   to	   examine	   the	   release	   and	  
uptake	  properties	  of	  the	  neurotransmitter	  of	  interest	  (Figure	  3.5).	  The	  ascending	  phase	  on	  the	  
left	  represents	  predominantly	  the	  release	  of	  the	  neurotransmitter;	  the	  maximum	  peak	  height	  is	  
converted	   to	   a	   concentration	  by	  using	   the	  post	   calibration	   factor	   and	   LVIT	   analysis	   software.	  
The	  descending	  phase	  on	   the	   right	   is	   associated	  with	   the	  uptake	  of	  dopamine,	  which	   can	  be	  
analyzed	   to	  determine	  how	   fast	   the	   transporter	   is	   taking	  dopamine	  back	  up	   into	   the	  neuron	  
(Vmax,	   µM/sec).	   A	   false	   color	   plot	   can	   also	   be	   generated,	  which	   combines	   the	   parameters	   of	  
time	  (x),	  applied	  voltage	  (y),	  and	  current	  (z)	  in	  one	  plot	  (Figure	  3.6).	  The	  characteristic	  oxidation	  
and	  reduction	  current	  peaks	  of	  dopamine	  can	  be	  seen	  by	  the	  green	  and	  blue	  regions	  at	  +0.6	  mV	  











Figure	  3.4:	  Representative	  cyclic	  voltammogram	  of	  dopamine.	  
	  
	  










Figure	  3.6:	  Color	  plot	  depicting	  dopamine	  oxidation	  and	  reduction	  peaks	   in	   false	  color.	  Red	  












Current	  versus	  time	  traces	  obtained	  from	  experiments	  are	  analyzed	  using	  Labview	  software	  
(National	   Instruments,	  Austin,	   TX).	  Based	  on	  Michaelis-­‐Menten	  kinetics	   (Equation	  3.2),	   traces	  
are	   fit	  by	  nonlinear	   regression	   to	  obtain	  values	   for	   three	  parameters.8,9	   The	  concentration	  of	  
dopamine	  released	  per	  pulse	  ([DA],	  nM)	  is	  correlated	  to	  the	  height	  of	  the	  trace.	  The	  Vmax	  value	  
(µM/s)	   estimates	   the	   rate	   at	   which	   dopamine	   is	   taken	   back	   up	   into	   the	   transporter	   and	   is	  
visually	  expressed	  by	  the	  decay	  of	  the	  current	  trace	  on	  its	  right	  side.	  The	  affinity	  of	  dopamine	  
for	  the	  dopamine	  transporter	  is	  related	  to	  the	  Km	  value	  and	  for	  the	  purposes	  of	  our	  analysis,	  is	  
fixed	  at	  0.16	  µM.	  The	  other	  two	  parameters	  are	  varied	  for	  the	  purposes	  of	  obtaining	  a	  fit	  with	  




















Chapter	  4:	  Altered	  Striatal	  Dopamine	  Release	  Following	  a	  Sub-­‐acute	  Exposure	  to	  
Manganese	  
Adapted	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  Release	  Following	  a	  
Sub-­‐acute	  Exposure	  to	  Manganese,”	  J.	  Neurosci.	  Methods,	  202(2),	  182-­‐191	  (2011)88	  
(Copyright	  License	  Number:	  3143730589208)	  
	  
4.1	  Introduction	  
Manganese	   (Mn)	   is	   a	   key	   component	   for	   cellular	   function,	   immunological	   response,	  
adenosine	  triphosphate	  (ATP)	  regulation,	  digestion,	  and	  reproduction.55,64	  Mn	   is	  also	  required	  
for	  metalloenzymes	  such	  as	  superoxide	  dismutase	  and	  glutamine	  synthetase.65	  Normal	  levels	  of	  
Mn	  intake	  by	  dietary	  consumption	  are	  around	  2-­‐5	  mg	  per	  day	  and	  regulating	  homeostatic	  levels	  
of	  Mn	   is	   crucial	   for	   sustained	   functioning	  of	   the	  body	   in	   several	  aspects.65	  Mn	  deficiency	  has	  
been	   linked	   to	   fertility	   problems,	   birth	   defects,	   stunted	   growth,	   and	   impaired	   formation	   of	  
bones.65	  On	  the	  other	  end	  of	   the	  spectrum,	  overexposure	  to	  Mn	  can	   lead	  to	  accumulation	   in	  
the	   brain	   and	   subsequent	   neurotoxicity.	   High	   exposure	   can	   occur	   through	   occupations	   in	  
welding,	  mining,	  and	  battery	  assembly,	  amongst	  others.66-­‐69	  Elevated	  Mn	  levels	  can	  also	  result	  
from	  medical	  conditions	  such	  as	   liver	  or	   renal	   failure	  or	   iron	  deficiency,	  both	  of	  which	   inhibit	  
the	   clearance	   of	  Mn	   from	   the	   body.76,77,79-­‐81	  Manganism,	   the	   resultant	   neurological	   disorder	  
caused	   by	   overexposure	   to	   Mn,	   leads	   to	   a	   progression	   of	   symptoms	   that	   mimic	   those	   of	  
Parkinson’s	  disease.	   In	   the	  early	   stages	  of	  manganism,	  general	   symptoms	  such	  as	  headaches,	  
hypersomnia,	   psychosis,	   irritability,	   anorexia,	   and	   apathy	   begin	   to	   appear.89	   As	   the	   disease	  





manifest.89-­‐91	   The	   final	   symptoms	   to	   emerge	   are	   primarily	   motor	   deficits,	   such	   as	   muscular	  
rigidity,	  “intention	  tremors,”	  dystonia,	  bradykinesia,	  and	  gait	  changes.55,62	  
Clinical	  magnetic	   resonance	   imaging	   has	   demonstrated	   that	   preferential	   accumulation	   of	  
Mn	  occurs	   in	   the	  dopamine	   (DA)	   rich	   regions	  of	   the	  basal	   ganglia.92	  Although	   the	  method	  by	  
which	  Mn	   passes	   through	   the	   blood	   brain	   barrier	   is	   not	   fully	   understood,	   calcium	   channels,	  
transferrin,	  the	  divalent	  metal	  transporter	  1	  (DMT-­‐1),	  and	  N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	  have	  
been	  suggested	  to	  regulate	  blood	  brain	  barrier	  transport	  of	  Mn.72-­‐75	  	  
Despite	  the	  similarities	  between	  the	  symptoms	  of	  manganism	  and	  Parkinson’s	  disease	  and	  
the	   evidence	   implicating	   Mn	   overexposure	   in	   the	   onset	   of	   Parkinson’s	   disease,	   these	   two	  
neurological	  disorders	  appear	   to	  act	  on	  different	  pathways	  and	  regions	   in	   the	  brain.61	  Within	  
the	  basal	  ganglia,	  excess	  Mn	  accumulation	  associated	  with	  manganism	  occurs	  primarily	   in	  the	  
globus	   pallidus,	   caudate	   putamen	   (CPu),	   and	   nucleus	   accumbens	   (NAc).62,93,94	   In	   contrast,	  
Parkinson’s	  disease	  etiology	  is	  primarily	  associated	  with	  a	  greater	  than	  80%	  loss	  of	  nigrostriatal	  
dopamine	  neurons	  in	  the	  CPu,	  which	  originate	  in	  the	  substantia	  nigra	  pars	  compacta,	  as	  well	  as	  
the	  appearance	  of	  Lewy	  bodies.95	  This	  significant	  degeneration	  of	  DA	  neurons	  in	  the	  substantia	  
nigra	   pars	   compacta	   is	   not	   observed	   with	   the	   onset	   of	   manganism.94,96,97	   Furthermore,	  
manganism	   patients	   show	   no	   difference	   in	   radiolabeled	   fluorodopa	   uptake	   (as	  measured	   by	  
positron	   emission	   tomography,	   PET),	   while	   Parkinson’s	   patients	   show	   reduced	   uptake.62,98	  
Paired	  with	  the	  clinical	  differences	  seen	  in	  symptoms	  between	  the	  two	  disorders,	  such	  as	  the	  
“resting	   tremors”	  of	  Parkinson’s	  patients	  versus	   the	  “intention	   tremors”	  of	  manganism’s,	   this	  
information	  suggests	  that	  manganism	  is	  distinct	  from	  Parkinson’s.	  62	  As	  a	  result,	  there	  is	  a	  need	  





relying	  on	  the	  findings	  of	  Parkinson’s	  studies	  as	  an	  indirect	  means	  to	  understand	  the	  alterations	  
occurring	  in	  the	  DA	  system	  upon	  Mn	  exposure.	  
Previous	   studies	   performed	   on	   non-­‐human	   primates	   and	   rats	   have	   indicated	   several	  
impairments	   of	   the	   DA	   system	   as	   a	   result	   of	   Mn	   administration.99-­‐104	   Decreases	   in	  
amphetamine-­‐induced	   DA	   release	   have	   been	   observed	   in	   non-­‐human	   primates	   (via	   PET),	  
emphasizing	   that	  excessive	  accumulation	  of	  Mn	   impairs	  DA	   release.99,100	  However,	   reports	  of	  
alterations	   in	   other	   presynaptic	   components	   of	   DA	   dynamics	   have	   been	   inconsistent.	   For	  
example,	  some	  studies	  show	  an	  increase	  in	  DA	  transporter	  expression/binding	  upon	  excess	  Mn	  
exposure,	  while	  others	  show	  a	  decrease	  or	  no	  change.99,101,105,106	  Additionally,	  the	  influence	  of	  
Mn	   toxicity	   on	   the	   DA	   D2	   autoreceptor	   shows	   variable	   effects,	   ranging	   from	   decreased	   to	  
increased	   expression	   to	   no	   effect	   at	   all.99,107,108	   The	   inconclusive	   evidence	   obtained	   thus	   far	  
begs	  for	  a	  more	  in	  depth	  analysis	  of	  the	  effect	  of	  Mn	  exposure	  on	  the	  presynaptic	  DA	  system.	  	  	  
In	  this	  study,	  we	  used	  several	  complementary	  analytical	  techniques	  to	  probe	  the	  effect	  of	  a	  
sub-­‐acute	  manganese	   (II)	   chloride	   (MnCl2)	   exposure	   on	  DA	   dynamics	   in	   C57Bl/6	  mice	   over	   a	  
period	   of	   three	   weeks.	   The	   integration	   of	   three	   different	   techniques	   allows	   for	   a	   novel	  
methodological	  approach	  to	  correlate	  Mn	  tissue	  levels	  with	  the	  functionality	  of	  the	  DA	  system.	  
Tissue	   content	   analysis	   quantified	   intracellular	   Mn	   and	   DA	   levels	   present	   in	   the	   brain	   after	  
treatment	   was	   halted.	   Using	   in	   vivo	   microdialysis,	   the	   consequences	   of	   Mn	   treatment	   on	  
striatal	   extracellular	   DA	   levels,	   as	  well	   as	   levels	   of	   its	  metabolites,	   3,4-­‐dihydroxyphenylacetic	  
acid	   (DOPAC)	   and	   homovanillic	   acid	   (HVA),	   were	   assessed.	   Additionally,	   fast	   scan	   cyclic	  
voltammetry	   (FSCV)	   was	   used	   to	   characterize	   DA	   dynamics,	   specifically	   DA	   clearance,	  





our	  results	  demonstrate	  no	  serious	  deleterious	  effects	  from	  sub-­‐acute	  administration	  of	  MnCl2	  
on	   DA	   tissue	   content	   levels,	   the	   microdialysis	   and	   voltammetry	   results	   highlight	   subtle	   but	  
significant	  alterations	  on	  the	  DA	  release	  mechanism.	  	  
4.2	  Materials	  and	  Methods	  
4.2.1	  Animals	  
C57Bl/6	   mice	   were	   obtained	   from	   Jackson	   Laboratories	   and	   bred	   in-­‐house	   for	   all	  
experiments.	   Mice	   were	   group	   housed	   (3-­‐4	   animals	   per	   cage)	   at	   Wayne	   State	   University’s	  
animal	  care	  facilities.	  A	  12	  h	  light/dark	  cycle	  was	  used	  with	  food	  and	  water	  available	  ad	  libitum.	  
Tissue	   content	   and	   microdialysis	   studies	   were	   performed	   on	   males	   only,	   weighing	   23-­‐25	   g.	  
Voltammetry	  experiments	  were	  conducted	  on	  both	  male	  and	  female	  mice	  weighing	  23-­‐33	  g.	  All	  
protocols	  and	  animal	  care	  followed	  guidelines	  set	  by	  the	  National	  Institutes	  of	  Health	  Office	  of	  
Animal	   Care	   and	  Use	   and	  were	   approved	  by	   the	  Wayne	   State	  University	   Institutional	  Animal	  
Care	  and	  Use	  Committee.	  	  
4.2.2	  Manganese	  Treatment	  
Mice	  were	  injected	  subcutaneously	  with	  manganese	  (II)	  chloride	  tetrahydrate	  (MnCl2.4H2O)	  
in	   a	   sub-­‐acute	   treatment	   based	   on	   a	   published	   protocol	   shown	   to	   significantly	   increase	  Mn	  
concentrations	  in	  the	  basal	  ganglia.60	  Briefly,	  animals	  were	  randomly	  assigned	  to	  two	  treatment	  
groups	  and	  injected	  with	  either	  0.1	  mL	  of	  Mn	  (50	  mg/kg,	   in	  saline)	  or	  saline	  (0.9%	  NaCl).	  This	  
treatment	  was	  repeated	  every	  third	  day	  for	  a	  week,	  for	  a	  total	  of	  3	  treatments	  on	  days	  1,	  4,	  and	  
7.	   After	   the	   last	   injection,	   neurochemical	   analyses	   by	   three	   different	   techniques	   were	  
conducted	  at	  three	  time	  points,	  1,	  7,	  and	  21	  days	  later,	  to	  assess	  both	  the	  short	  and	  long	  term	  





4.2.3	  Tissue	  Content	  Analysis	  for	  Neurotransmitter	  and	  Metal	  Detection	  
Brain	  tissue	  samples	  were	  analyzed	  for	  metal	  accumulation,	  DA,	  and	  its	  metabolite	  DOPAC.	  
Briefly,	  mice	  were	   sacrificed	  by	   cervical	   dislocation	   and	  brains	  were	   removed,	   dissected,	   and	  
weighed.	   To	   determine	  which	   acid	   provided	   optimal	   recovery	   for	  both	   DA	   and	  Mn	   from	   the	  
CPu,	  samples	  were	  homogenized	  in	  400	  µL	  of	  either	  0.1	  M	  HNO3	  or	  0.1	  M	  HClO4.	  Overall,	  HNO3	  
provided	  the	  best	  recovery	  (Table	  1)	  and	  it	  was	  used	  to	  prepare	  all	  subsequent	  tissue	  samples.	  
For	  all	  experiments,	  tissue	  homogenates	  were	  centrifuged	  for	  15	  min	  at	  12,000	  g	  at	  4	  °C	  in	  400	  
µL	  of	  0.1	  M	  HNO3.	  Metal	  levels	  for	  Mn,	  Cu,	  and	  Fe	  were	  assayed	  using	  graphite	  furnace	  atomic	  
absorption	  spectrometery	  (GFAAS).	  DA	  and	  DOPAC	  were	  detected	  in	  the	  supernatant	  using	  high	  
performance	  liquid	  chromatography	  (HPLC)	  coupled	  to	  an	  electrochemical	  detector.	  	  
All	  tissue	  samples	  were	  analyzed	  for	  Mn,	  Cu,	  or	  Fe	  using	  GFAAS	  as	  previously	  described.	  109-­‐
111	  After	  tissue	  samples	  were	  homogenized	  and	  centrifuged,	  they	  were	  diluted	  with	  0.2%	  HNO3	  
and	  5	  µg/mL	  Mg(NO3)2	  was	  added	  as	  a	  matrix	  modifier.	  Each	  sample	  (20	  µl)	  was	  injected	  onto	  a	  
pyrocoated	  graphite	  atomizer	   tube	  with	  an	   integrated	   L’vov	  platform	  within	  a	  GFAAS	   system	  
(Perkin	   Elmer,	   Uberlingen,	   Germany)	   equipped	   with	   an	   electrothermal	   atomizer	   and	   an	  
autosampler.	   The	   detection	   of	   each	   metal	   was	   achieved	   using	   an	   element	   specific	   hollow	  
cathode	   lamp.	  The	   lamp	  was	  operated	  at	  20	  mA,	  with	  a	  wavelength	  of	  279.5	  nm	  (Mn),	  324.8	  
nm	  (Cu),	  or	  248.3	  nm	  (Fe).	  The	  slit	  width	  was	  0.2	  nm	  for	  both	  Mn	  and	  Fe	  and	  0.7	  nm	  for	  Cu.	  The	  
GFAAS	   parameters	   were	   optimized	   to	   obtain	   the	   highest	   absorbance	   value	   and	   maximum	  
pyrolysis	  temperature	  possible	  without	  loss	  of	  analyte.	  Metal	  peak	  areas	  were	  integrated	  using	  






To	   assay	   tissue	   samples	   for	   the	   neurotransmitter	   DA	   and	   its	   metabolite	   DOPAC,	   tissue	  
samples	   were	   homogenized	   and	   centrifuged	   as	   described	   above.	   DA	   and	   DOPAC	   from	   each	  
sample	   supernatant	   (20	  𝜇L)	   were	   separated	   and	   detected	   in	   a	   single	   chromatogram	   using	   a	  
Shimadzu	  LC-­‐20AD	  HPLC	  (Shimadzu,	  Columbia,	  MD)	  with	  electrochemical	  detection	  (ESA	  5011	  
cell;	   +220	  mV	   relative	   to	   a	   Pd	   reference	   electrode).	   The	   isocratic	   separation	   of	   analytes	  was	  
achieved	  using	  a	  Luna	  C18	  (100	  x	  3	  mm)	  column	  with	  3	  µm	  particles	  (Phenomenex,	  Torrance,	  CA)	  
with	  the	  same	  mobile	  phase	  used	  for	  microdialysis	  sample	  separation	  (see	  section	  2.5)	  at	  a	  flow	  
rate	   of	   0.55	   mL/min.112	   Neurotransmitter	   peak	   areas	   were	   integrated	   using	   Shimadzu	   LC	  
Solutions	  software	  and	  quantified	  against	  known	  standards.	  
4.2.4	  Microdialysis	  Surgery	  
Male	   C57Bl/6	   mice	   (5-­‐8	   weeks	   old)	   were	   anesthetized	   with	   Avertin	   (20	   mL/kg)	   by	  
intraperitoneal	   injection.113	   Once	   anesthetized,	   eyes	   were	   protected	   with	   sterile	   ophthalmic	  
ointment	   and	   the	   skin	   over	   the	   skull	  was	   shaved	   and	   sterilized	  with	  Betadine	   and	   alcohol.	   A	  
small	   incision	  was	  made	  above	   the	   skull,	  which	  was	   cleaned	  and	  dehydrated	  with	  10%	  H2O2.	  
Mice	   were	   placed	   on	   a	   stereotaxic	   frame	   for	   implantation	   of	   a	   guide	   cannula	  
(CMA/Microdialysis,	   Chelmsford,	  MA)	   targeted	   to	   the	   dorsal	   striatum	   (coordinates	   in	  mm:	   A	  
+0.8,	  L	  -­‐1.3,	  V	  -­‐2.5	  from	  Bregma),	  based	  on	  the	  Paxinos	  mouse	  atlas.54	  The	  guide	  cannula	  was	  
secured	   in	   place	   using	   fast	   drying	   dental	   cement	   (Teets,	   Diamond	   Springs,	   CA).	   Following	  
dialysis	   experiments,	  mice	  were	   euthanized	   by	   carbon	   dioxide	   asphyxiation	   and	   brains	   were	  








Approximately	   6	   hours	   after	   surgery,	   the	   dummy	   cannula	   was	   removed	   and	   the	  
microdialysis	  probe	   (CMA/7,	  2	  mm	   length,	  240	  μm	  diameter,	  Cuprophane,	  6	  kDa	  MW	  cutoff;	  
CMA/Microdialysis,	   Chelmsford,	   MA)	   was	   inserted	   and	   perfused	   overnight	   with	   artificial	  
cerebrospinal	  fluid	  (aCSF;	  in	  mM:	  145	  NaCl,	  3.5	  KCl,	  2.0	  Na2HPO4,	  1.2	  MgCl2,	  1.0	  CaCl2,	  pH	  7.4)	  
at	   a	   flow	   rate	   of	   1.1	  µL/min.	   After	   the	   dialysis	   probe	  was	   inserted,	   the	   dialysate	   outlet	  was	  
inserted	   into	   a	  microcentrifuge	   tube	   on	   ice	   and	   an	   overnight	   sample	   (collection	   period	   ~	   12	  
hours)	   was	   collected.	   The	   next	   morning,	   this	   sample	   was	   analyzed	   by	   GFAAS	   to	   determine	  
extracellular	  Mn	  levels	  in	  saline-­‐	  and	  Mn-­‐treated	  mice.	  Concurrently,	  at	  least	  three	  metabolite	  
baseline	   samples	  were	   collected	   at	   20-­‐minute	   intervals	   to	  measure	   extracellular	   DOPAC	   and	  
HVA	   levels.	   Next,	   at	   least	   3	   baseline	   samples	   were	   collected	   to	   measure	   extracellular	  
concentrations	  of	  DA.	  After	  the	  collection	  of	  baseline	  samples,	  the	  saline-­‐	  and	  Mn-­‐treated	  mice	  
were	  divided	  into	  two	  groups	  for	  two	  different	  types	  of	  experiments:	  (1)	  zero	  net	  flux	  analysis	  
or	  (2)	  stimulation	  of	  DA	  release	  with	  120	  mM	  KCl	  aCSF.	  	  	  	  
The	  quantitative	  microdialysis	  method	  of	  zero	  net	   flux	  was	  performed	  to	  determine	  basal	  
extracellular	  DA	  levels	  in	  saline	  and	  Mn-­‐treated	  mice.	  A	  programmable	  gradient	  infusion	  pump	  
(CMA/402)	   was	   used	   to	   perfuse	   5,	   10,	   and	   20	   nM	   DA	   (prepared	   in	   aCSF)	   through	   the	  
microdialysis	   probe	   to	   the	   striatum	   for	   90	   minutes	   each.114-­‐117	   Typically,	   when	   using	   this	  
method,	  the	  amount	  of	  analyte	  being	  perfused	  into	  the	  microdialysis	  probe	  is	  not	  measured,	  as	  
it	   is	  assumed	  that	  DAin	  equals	  the	  targeted	  concentration	  chosen	  for	  perfusion.	  Prior	  to	  the	   in	  
vivo	   experiments,	   an	   in	   vitro	   calibration	   was	   performed	   to	   more	   accurately	   determine	   the	  





and	  20	  nM	  DA	  via	  the	  same	  set	  up,	  only	  in	  the	  absence	  of	  the	  animal.	  Since	  DA	  is	  easily	  oxidized	  
to	  its	  ortho-­‐quinone,	  the	  DA	  stock	  standard	  solution	  (1	  mM)	  was	  prepared	  in	  0.1	  M	  perchloric	  
acid,	  10	  μg/mL	  ascorbic	  acid,	  and	  10%	  methanol,	  and	  aliquots	  (250	  μL)	  were	  stored	  at	  -­‐80◦C.	  118	  
Zero	   net	   flux	   solutions	   were	   made	   fresh	   daily	   by	   successive	   dilution	   of	   the	   stock	   standard	  
solution	  in	  aCSF	  containing	  200	  μM	  ascorbic	  acid.	  	  
Microdialysis	  samples	  (20	  μL)	  were	  manually	  injected	  onto	  a	  Luna	  100	  x	  3	  mm,	  C18,	  2.6	  µm	  
column	   (Phenomenex,	   Torrance,	   CA)	   for	   separation	   of	   DA	   and	   its	   metabolites	   (DOPAC	   and	  
HVA),	   followed	   by	   electrochemical	   detection	   using	   an	   ESA	   5041	   cell	   (ESA	   Coulochem	   III,	  
Chelmsford,	  MA)	  with	  an	  applied	  potential	  of	  +220	  mV	  relative	   to	  a	  palladium	  (Pd)	   reference	  
electrode	  (Szapacs	  et	  al.,	  2004).	  A	  guard	  cell	  (ESA	  5020)	  was	  placed	  in	  line	  before	  the	  injection	  
loop	  and	  set	  at	  a	  potential	  of	  +350	  mV.	  The	   isocratic	  separation	  was	  achieved	  using	  a	  mobile	  
phase	  that	  consisted	  of	  75	  mM	  of	  NaH2PO4,	  3.0	  mM	  1-­‐octanesulfonic	  acid,	  0.125	  mM	  EDTA,	  9.0	  
%	  acetonitrile,	  and	  0.2-­‐0.5	  %	  triethylamine	  (pH	  ~	  3.0).	  A	  flow	  rate	  of	  0.4	  mL/min	  was	  used	  to	  
detect	   the	   neurotransmitters	   in	   a	   single	   chromatogram	   within	   20	   minutes.	   DA	   and	   its	  
metabolite	   peak	   areas	  were	   integrated	   using	   Shimadzu	   LC	   Solutions	   software	   and	   quantified	  
against	  known	  standards.	  
In	  a	  second	  cohort	  of	  mice,	  isotonic	  aCSF	  containing	  120	  mM	  KCl	  (in	  mM:	  120	  KCl,	  30.5	  NaCl,	  
2.0	  Na2HPO4,	  1.2	  MgCl2,	  1.0	  mM	  CaCl2,	  pH	  7.4)	  was	  perfused	  through	  the	  probe	  for	  20	  minutes	  
following	   baseline	   sample	   collections.	   117,119	   Immediately	   after	   the	   20	   minutes	   of	   high	   K+	  
stimulation,	   the	   perfusate	  was	   switched	   back	   to	   standard	   aCSF.	   This	   influx	   of	   K+	   depolarizes	  
neurons,	  inducing	  exocytosis	  and	  subsequently	  increasing	  extracellular	  DA	  levels.	  The	  effect	  of	  





These	  samples	  were	  analyzed	  by	  HPLC	  and	  electrochemical	  detection	  as	  described	  for	  zero	  net	  
flux	  experiments	  above.	  Additionally,	  the	  area	  under	  the	  curve	  (AUC)	  for	  high	  K+	  DA	  release	  was	  
calculated	  from	  80	  to	  140	  minutes	  (Figure	  4.3,	  inset)	  for	  all	  animal	  groups.	  	  
4.2.6	  Fast	  Scan	  Cyclic	  Voltammetry	  
For	   in	   vitro	   fast	   scan	   cyclic	   voltammetry	   (FSCV),	   mice	   were	   sacrificed	   by	   decapitation	  
following	  CO2	  asphyxiation.	  The	  brain	  was	  immediately	  removed	  and	  placed	  in	  pre-­‐oxygenated	  
(95%	  O2/5%	  CO2)	  high	  sucrose	  aCSF	  (in	  mM:	  180	  sucrose,	  30	  NaCl,	  26	  NaHCO3,	  10	  D-­‐glucose,	  4.5	  
KCl,	  1.0	  MgCl2.6H2O,	  1.2	  NaH2PO4,	  pH	  7.4)	  on	  ice	  for	  5-­‐10	  minutes.	  86	  Coronal	  400	  µm	  thick	  slices	  
that	   encompassed	   the	   striatal	   brain	   region	   (which	   includes	   the	  CPu	  and	  NAc)	  were	  prepared	  
using	   a	   vibrating	   tissue	   slicer	   (Vibratome®,	   St.	   Louis,	  MO).	   Slices	  were	   kept	   in	   a	   continuously	  
oxygenated	  reservoir	  of	  aCSF	  (in	  mM:	  126	  NaCl,	  25	  NaHCO3,	  11	  glucose,	  2.5	  KCl,	  2.4	  CaCl,	  1.2	  
NaH2PO4,	  1.2	  MgCl2,	  0.4	  ascorbate,	  pH	  7.4)	  for	  at	  least	  one	  hour	  before	  use.	  	  At	  the	  time	  of	  the	  
experiment,	   a	   brain	   slice	   was	   transferred	   to	   a	   custom-­‐made	   submersion	   chamber	   (Custom	  
Scientific,	  Denver,	  CO)	  that	  was	  continuously	  perfused	  with	  aCSF	  and	  kept	  at	  32oC.	  	  	  
For	   all	   experiments,	   a	   two-­‐electrode	   system	  was	   employed	   in	  which	   a	  Ag/AgCl	   reference	  
electrode	  was	  paired	  with	  a	  carbon-­‐fiber	  working	  microelectrode,	   inserted	  ~	  75	  µm	  deep	  into	  
the	  slice.	  Carbon-­‐fiber	  microelectrodes	  were	  made	  by	  first	  aspirating	  carbon	  fiber	  (diameter	  =	  7	  
μm,	   Goodfellow,	   Oakdale,	   PA)	   through	   a	   glass	   capillary	   (A-­‐M	   Systems,	   Carlsborg,	   WA).	   The	  
capillary	  was	  subsequently	  heated	  using	  a	  micropipette	  puller	  (Narishige,	  Tokyo,	  Japan)	  to	  form	  
two	   electrodes,	   each	  with	   a	   tight	   seal	   at	   the	   glass-­‐fiber	   junction.	   The	   exposed	   length	   of	   the	  
carbon	  fiber	  was	  cut	  to	  approximately	  50-­‐200	  μm.	  Each	  electrode	  was	  then	  filled	  with	  150	  mM	  





Using	  a	  ChemClamp	  potentiostat	  (Dagan	  Corporation,	  Minneapolis,	  MN),	  potential	  was	  applied	  
at	  the	  carbon-­‐fiber	  microelectrode	  in	  the	  shape	  of	  a	  triangular	  waveform,	  initially	  held	  at	  -­‐0.4	  V.	  
That	  potential	  was	  ramped	  up	  to	  +1.2	  V,	  then	  back	  down	  to	  -­‐0.4	  V	  at	  a	  scan	  rate	  of	  400	  V/s.	  This	  
waveform	   was	   repeated	   every	   100	   ms.	   To	   evoke	   DA	   release	   in	   slice,	   a	   bipolar	   stimulating	  
tungsten	   electrode	   was	   placed	   approximately	   100-­‐200	   µm	   away	   from	   the	   carbon-­‐fiber	  
microelectrode,	  controlled	  by	  TH	  software	  (ESA	  Inc.,	  Chelmsford,	  MA).	  An	  electrical	  stimulation	  
was	   applied	   to	   the	   slice	   by	   a	   single	   pulse	   (monophasic,	   350	   µA,	   60	   Hz,	   4	  ms	  width)	   every	   5	  
minutes.	  
DA	  release	  and	  uptake	  measurements	  were	  made	  after	  slices	  were	  allowed	  to	  equilibrate	  in	  
the	  submersion	  chamber	  for	  at	  least	  30	  minutes.	  For	  receptor	  characterization,	  dose-­‐response	  
curves	   were	   generated	   using	   pre-­‐drug	   values	   for	   each	   animal	   as	   their	   own	   controls.	   DA	  
dynamics	   were	   analyzed	   only	   after	   subtracting	   out	   the	   background	   current.	   Electrode	  
calibration	  was	   performed	  post-­‐experiment	   using	   a	   flow	   injection	   system.	   The	   electrode	  was	  
calibrated	  with	  a	  3	  µM	  DA	  solution	  in	  aCSF	  to	  obtain	  a	  calibration	  factor,	  which	  was	  later	  used	  
to	   convert	   the	   current	   to	   a	   concentration.	   A	  Michaelis-­‐Menten	   based	   set	   of	   equations	  were	  
used	   to	   fit	   the	   current	   versus	   time	   profile	   of	   each	   release	   event	   to	   quantify	   the	   maximum	  
concentration	   of	   DA	   released	   per	   pulse	   ([DA]p),	   as	   well	   as	   the	   rate	   of	   uptake	   by	   the	   DA	  
transporter	  (µM/s;	  Vmax).8,87,120,121	  
Data	  obtained	  from	  FSCV	  experiments	  can	  be	  presented	  in	  one	  of	  three	  ways,	  as	  depicted	  
by	  representative	  plots	  in	  Figure	  4.5.	  The	  top	  traces	  in	  Figure	  4.5A	  are	  current	  versus	  time	  plots.	  
The	   rise	   phase	   of	   the	   peak	   is	   predominately	   indicative	   of	   electrically-­‐evoked	   DA	   release	  





aforementioned	  calibration	  factor.	  The	  descending	  phase	  of	  the	  peak	  (decay	  of	  peak	  returning	  
to	   baseline)	   represents	   DA	   uptake	   rates	   (μM/s).	   The	   insets	   show	   the	   respective	   cyclic	  
voltammograms,	  which	  plot	  the	  measured	  current	  (y-­‐axis)	  against	  the	  potential	  (x-­‐axis)	  applied	  
to	  the	  electrode.	  The	  voltammograms	  are	  used	  to	  confirm	  the	  detection	  of	  DA	  by	  the	  location	  
of	  the	  oxidation	  peak	  of	  DA	  at	  +0.6	  V	  and	  reduction	  peak	  of	  dopamine-­‐ortho-­‐quinone	  at	  -­‐0.2	  V.	  
Below	  the	  two-­‐dimensional	  plots	  is	  an	  all	  inclusive	  three-­‐dimensional	  color	  plot	  which	  combines	  
time	   (x-­‐axis),	  applied	  voltage	   to	   the	  working	  electrode	   (y-­‐axis),	  and	  generated	  current	   (z-­‐axis;	  
color	  scale).	  The	  characteristic	  oxidation	  current	  of	  DA	   is	   revealed	  as	  a	  bright	  green	  mark	   (an	  
increase	   in	   current	   that	   corresponds	   to	   the	   amount	   of	   dopamine	   being	   oxidized)	   at	  
approximately	  +0.6	  V	  on	  the	  y-­‐axis.	  	  
4.2.7	  Chemicals	  
Components	   of	   the	   mobile	   phase	   and	   neurotransmitter	   standards	   were	   either	   of	   HPLC	  
grade	  or	   the	  highest	  quality	  obtained	   from	  Sigma-­‐Aldrich	   (St.	   Louis,	  MO)	  and	  Fisher	  Scientific	  
(Pittsburgh,	   PA).	   Concentrated	   HNO3,	   HClO4,	   boric	   acid,	   triethylamine,	   and	   citric	   acid	   were	  
purchased	  from	  EMD	  (Gibbstown,	  NJ).	  All	   standards	   for	  calibration	  curves	  used	   in	  GFAAS	  and	  
HPLC	  analysis	  were	  prepared	  fresh	  daily.	  	  
4.2.8	  Statistical	  Analysis	  
Data	  was	  analyzed	  using	  GraphPad	  Prism	  software	   (GraphPad,	  La	   Jolla,	  CA).	  All	  values	  are	  
expressed	  as	  means	  ±	   standard	  error	  of	  mean	   (SEM)	  with	  a	  difference	  of	  P<	  0.05	  considered	  
statistically	  significant.	   	  Comparisons	  of	   two	  means	  were	  analyzed	  by	  Student’s	   t-­‐tests.	  When	  





performed.	  	  Two-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐test	  was	  used	  when	  testing	  for	  interaction	  
of	  multiple	  variables.	  
4.3	  Results	  
4.3.1	  Tissue	  Content	  Protocol	  and	  Analysis	  
The	   levels	  of	  striatal	  Mn,	  Fe,	  and	  Cu	  were	  analyzed	  by	  GFAAS	  first	   to	  assess	  the	  extent	  to	  
which	   the	  acid	  used	   for	   tissue	   treatment	   influences	  metal	   recovery.	   Levels	  of	  DA	  and	  DOPAC	  
were	  concurrently	  determined	   from	  acid-­‐digested	   tissue	  by	  HPLC.	  The	   striatum	  was	   similarily	  
homogenized	  in	  two	  different	  acids,	  0.1	  M	  HNO3	  or	  0.1	  M	  HClO4	  (Table	  4.1).	  Striatal	  Mn	  levels	  
were	  unaffected	  by	  the	  choice	  of	  acid	  used	  for	  homogenization	  (P	  =	  0.1203),	  as	  were	  levels	  of	  
DA	  (P	  =	  0.4809)	  and	  DOPAC	  (P	  =	  0.0542).	  Striatal	  Cu	  (P	  <	  0.0001)	  and	  Fe	  (P	  <	  0.0001)	  levels	  were	  
significantly	   reduced	  when	   the	   tissue	  was	   treated	  with	  HClO4	  as	   compared	   to	  HNO3.	   For	   this	  
reason,	  HNO3	  was	  selected	  for	  all	  subsequent	  tissue	  content	  experiments.	  
Typically,	  metal	  levels	  in	  brain	  tissue	  are	  measured	  following	  sample	  digestion	  with	  a	  strong	  
acid	  at	  60	  °C.	  However,	  high	  heat	  can	  degrade	  biological	  molecules,	  such	  as	  neurotransmitters,	  
necessitating	   the	   use	   of	   cold	   acid	   solutions.111	   To	   determine	   if	   lower	   temperatures	   and	   acid	  
content	  would	  be	  suitable	  for	  the	  recovery	  of	  trace	  metals,	  the	  striatum	  was	  divided	  in	  half	  and	  
the	  sides	  were	  either	  homogenized	  in	  0.1	  M	  HNO3	  at	  room	  temperature	  or	  digested	  overnight	  
at	   60	   °C	   in	   pure	   HNO3.	   No	   difference	   was	   observed	   in	   the	   Mn	   levels	   extracted	   from	  
homogenized	  tissues	  (0.92	  ±	  0.03	  ng/mg	  wet	  weight;	  n	  =	  6)	  compared	  to	  the	  overnight	  digested	  
samples	  (0.96	  ±	  0.04	  ng/mg	  wet	  weight;	  n	  =	  6;	  P	  =	  0.38;	  Table	  4.1).	  Since	  similar	  Mn	  levels,	  as	  





preparations,	   the	   cold	   acid	   homogenizing	   assay	   was	   chosen	   for	   all	   measurements	   so	   that	  
parallel	  neurotransmitter	  analyses	  could	  also	  be	  performed.	  
Employing	  the	  optimized	  tissue	  content	  protocol	  discussed	  above,	  Mn	  levels	  in	  the	  striatum	  
were	   measured	   using	   GFAAS	   at	   three	   time	   points	   (day	   1,	   7,	   and	   21)	   after	   repeated	   Mn	  
treatment	   (Figure	   4.1).	   Analysis	   by	   one-­‐way	   ANOVA	   indicated	   a	   significant	   difference	   in	  Mn	  
tissue	  content	  in	  Mn-­‐treated	  mice	  compared	  to	  saline	  controls	  (F3,33	  =	  112.9,	  P	  <	  0.001,	  n	  =	  7;	  
Figure	   4.1A).	  On	   day	   1	   a	   260%	   increase	   in	  Mn	   levels	  was	   observed	   in	  mice	   treated	  with	  Mn	  
compared	  to	  saline	  controls	  (P	  <	  0.001);	  this	  increase	  is	  similar	  to	  that	  reported	  by	  Dodd	  et	  al.	  60	  
at	  the	  same	  time	  point.	  Mn	  accumulation	  persisted	  for	  up	  to	  21	  days	  after	  treatment,	  revealing	  
a	  150%	  (P	  <	  0.001)	  and	  30%	  (P	  <	  0.05)	  increase	  on	  days	  7	  and	  21,	  respectively.	  The	  same	  tissue	  
homogenate	   was	   used	   to	   concurrently	   detect	   DA	   tissue	   levels,	   which	   primarily	   reflects	   the	  
content	  of	   intraneuronal	   stores.	  No	  difference	   in	   intracellular	   striatal	  DA	   levels	  was	  observed	  
between	  Mn	  and	  saline	  treated	  mice	  at	  any	  of	  the	  time	  points	  of	  analysis	  (F3,36	  =	  0.60,	  P	  =	  0.62,	  






Table	   4.1:	   Analysis	   of	   trace	   metals,	   DA,	   and	   the	   DA	  metabolite	   DOPAC	   in	   dorsal	   striatum	  
tissue	  homogenized	  with	  HNO3	  or	  HClO4.	  Within	  the	  HNO3	  group,	  homogenization	  is	  compared	  
to	  overnight	  digestion	  of	  tissue	  as	  a	  preparation	  method.	  All	  data	  reported	  as	  average	  (n	  =	  5	  -­‐	  6)	  
of	  wet	   tissue	  weight	   (ng/mg)	   ±	   SEM.	  DA	   and	  DOPAC	   levels	   cannot	   be	   detected	   by	   overnight	  
digestion	   and	   are	   therefore	   reported	   as	   ‘not	   determined’	   (ND).	   (a)	   P	   <	   0.001	   compared	   to	  










Figure	  4.1:	  Striatal	  tissue	  A)	  Mn	  and	  B)	  DA	  levels	  in	  saline-­‐	  and	  Mn-­‐treated	  mice.	  Dashed	  line	  
indicates	  the	  normalized	  values	  for	  saline-­‐treated	  mice	  (set	  as	  100%).	  Results	  are	  means	  (n	  =	  7-­‐
8)	  expressed	  as	  percentage	  of	  saline-­‐treated	  mice.	  *P	  <	  0.05,	  ***P	  <	  0.001	  compared	  to	  control	  













In	  vivo	  microdialysis	  was	  used	  to	  determine	  whether	  the	  accumulation	  of	  Mn	  observed	   in	  
striatal	   tissue	   influences	   the	   concentration	   of	   DA	   in	   the	   extracellular	   space	   of	   freely	  moving	  
animals.	   Striatal	   extracellular	   DA	   levels	   (analyzed	   without	   correction	   for	   probe	   recovery)	  
showed	  a	  significant	  difference	  between	  treatment	  groups	  (F3,15	  =	  14.13,	  P	  =	  0.0003;	  Figure	  4.2).	  	  
Extracellular	   DA	   concentrations	   averaged	   from	   three	   baseline	   samples	   were	   not	   different	  
between	   saline-­‐treated	   mice	   (3.1	   ±	   0.1	   nM;	   n	   =	   10)	   and	   Mn-­‐treated	   mice	   when	   DA	   was	  
measured	  1	  (3.3	  ±	  0.1	  nM;	  n	  =	  6)	  or	  21	  (3.1	  ±	  0.3	  nM,	  n	  =	  8)	  days	  after	  Mn	  treatment.	  However,	  
striatal	  DA	  levels	  were	  significantly	  decreased	  7	  days	  after	  Mn	  treatment	  (2.1	  ±	  0.1	  nM;	  n	  =	  8;	  P	  
<	  0.01).	  	  	  
	  
Figure	  4.2:	  Baseline	  dialysis	  levels	  of	  DA	  and	  its	  metabolites	  DOPAC	  and	  HVA	  in	  the	  striatum	  
of	   saline-­‐treated	   versus	   Mn-­‐treated	   mice.	   Results	   are	   reported	   as	   mean	   (n	   =	   5	   -­‐	   10)	  






Since	  a	  decrease	  in	  extracellular	  DA	  levels	  was	  observed	  only	  at	  the	  day	  7	  time	  point,	  we	  set	  
out	  to	  determine	  if	  this	  DA	  decrease	  is	  actually	  persistent	  across	  all	  time	  points	  but	  is	  perhaps	  
masked	  by	  other	  presynaptic	  events.	  Others	  have	  established	  that	  the	  method	  of	  zero	  net	  flux	  
can	   expose	   alterations	   in	   extracellular	   DA	   levels	   that	   are	   masked	   by	   transporter-­‐mediated	  
changes	   in	   in	   vivo	  probe	   recovery.122,123	   Therefore,	   zero	   net	   flux	  was	   utilized	   to	   evaluate	  DA	  
levels	   at	   the	   day	   1	   and	   21	   time	   points,	   in	   addition	   to	   confirming	   the	   changes	   observed	   in	  
extracellular	   levels	  at	  day	  7.	  Basal	  DA	   levels	   in	   saline-­‐treated	  mice,	  determined	  with	  zero	  net	  
flux	   analysis,	  were	   similar	   at	   all	   time	   points	   and	   therefore	   the	   data	  were	   collapsed	   into	   one	  
representative	  group	  labeled	  saline	  controls.	  The	  average	  extracellular	  DA	  levels	  (corrected	  for	  
probe	  recovery)	  for	  this	  combined	  saline	  control	  group	  were	  10.1	  ±	  1.1	  nM	  (n	  =	  8).	  Using	  zero	  
net	   flux,	   a	   significant	   main	   effect	   of	   Mn	   treatment	   on	   extracellular	   DA	   in	   the	   striatum	   was	  
revealed	  (F3,25	  =	  7.871,	  P	  =	  0.009,	  Figure	  4.3).	  In	  mice	  treated	  with	  Mn,	  striatal	  DA	  levels	  were	  
6.9	  ±	  1.2	  nM	  (n	  =	  6)	  and	  9.7	  ±	  1.6	  nM	  (n	  =	  6)	  1	  and	  21	  days	  after	  Mn	  treatment,	  respectively,	  
which	  are	  not	  different	  from	  those	  observed	  in	  the	  saline	  control	  group.	  However,	  similar	  to	  the	  
results	   using	   conventional	   microdialysis,	   Mn-­‐treated	   mice	   showed	   a	   significant	   reduction	   in	  
extracellular	   DA	   levels	   to	   3.0	   ±	   0.4	   nM	   (n	   =	   6;	  P	  <	   0.05)	   7	   days	   after	   cessation	   of	   sub-­‐acute	  
treatment.	  	  
In	  zero	  net	  flux	  experiments,	  the	  extraction	  fraction	  (Ed),	  determined	  from	  the	  slope	  of	  the	  
regression	   lines,	   gives	   an	   approximation	   of	   the	   probe	   recovery.116	   The	   average	   Ed	   for	   saline	  
controls	  (0.41	  ±	  0.05	  nM)	  was	  not	  found	  to	  be	  significantly	  different	  (one-­‐way	  ANOVA)	  from	  the	  
extraction	  fraction	  at	  day	  1	  (0.31	  ±	  0.03	  nM;	  P	  <	  0.01),	  day	  7	  (0.38	  ±	  0.02	  nM),	  or	  day	  21	  (0.34	  ±	  





Together,	  conventional	  and	  quantitative	  microdialysis	  results	  indicate	  that	  extracellular	  DA	  
concentrations	  in	  the	  dorsal	  CPu	  are	  more	  susceptible	  to	  the	  effects	  of	  Mn	  accumulation	  at	  the	  
intermediate	  time	  point	  of	  analysis	  (day	  7)	  post-­‐Mn	  exposure.	  In	  contrast,	  the	  relative	  recovery	  
rate	   of	   DA	  was	   altered	   on	   days	   1	   and	   21	   (but	   not	   on	   day	   7),	   suggesting	  Mn	   treatment	   has	  
different	  time-­‐dependent	  biological	  effects	  on	  DA	  neurotransmission.	  	  
Extracellular	   levels	   of	   the	   DA	   metabolites	   DOPAC	   and	   HVA	   were	   also	   evaluated	   to	  
determine	   if	  Mn	   overexposure	   results	   in	   alterations	   in	  DA	  metabolism	   (Figure	   4.2).	  One-­‐way	  
ANOVA	  demonstrated	  that	  DOPAC	  levels	  were	  significantly	  different	  due	  to	  Mn	  treatment	  (F3,	  19	  
=	  8.24;	  P	  =	  0.002).	  On	  day	  7,	  extracellular	  DOPAC	  in	  saline-­‐treated	  mice	  was	  800	  ±	  100	  nM	  (n	  =	  
5),	  but	  only	  300	  ±	  100	  nM	  (n	  =	  5)	   in	  Mn-­‐treated	  mice.	  Similarly,	  striatal	  HVA	   levels	  showed	  a	  
significant	  decrease	  after	  treatment	  (F3,	   18	  =	  7.00;	  P	  =	  0.004).	  Dialysate	  samples	  analyzed	  from	  
saline-­‐	  and	  Mn-­‐treated	  mice	  at	  the	  day	  7	  time	  point	  had	  mean	  HVA	  levels	  of	  700	  ±	  80	  nM	  (n	  =	  
6)	  and	  400	  ±	  40	  nM	  (n	  =	  4),	  respectively.	  No	  differences	  in	  DOPAC	  or	  HVA	  levels	  were	  seen	  at	  
any	   other	   time	   points.	   Thus,	   changes	   in	   extracellular	   levels	   of	   DA	   metabolites	   were	   only	  









Figure	  4.3:	  Extracellular	  DA	  levels	  determined	  by	  zero	  net	  flux	  microdialysis	  (n	  =	  5).	  A)	  Striatal	  
DA	  levels	  (Cext),	  corrected	  for	  in	  vivo	  probe	  recovery,	  are	  represented	  by	  the	  x-­‐intercepts	  of	  the	  
plotted	  linear	  regression	  lines.	  B)	  Summary	  of	  extracellular	  DA	  levels	  corrected	  for	  in	  vivo	  probe	  











To	  investigate	  whether	  Mn	  treatment	  affects	  stimulated	  DA	  release,	  extracellular	  DA	  levels	  
were	   assessed	   by	   in	   vivo	  microdialysis	   following	   reverse	   dialysis	   with	   high-­‐K+	   aCSF.	   	   Twenty	  
minute	  perfusion	  of	  high-­‐K+	  aCSF	  (120	  mM	  KCl)	  maximally	  elevated	  extracellular	  DA	  levels	  (46	  ±	  
5	  nM)	  to	  ~15-­‐fold	  above	  the	  baseline	   levels	   (3.1	  ±	  0.1	  nM;	  n	  =	  10)	  observed	   in	  saline-­‐treated	  
mice.	  Conversely,	  Mn	  treatment	  attenuated	  stimulated	  DA	  release	  at	  all	  time	  points.	  DA	  levels	  
in	  Mn-­‐treated	  mice	  were	  only	  increased	  to	  approximately	  22	  ±	  2	  (n	  =	  6),	  24	  ±	  4	  (n	  =	  8),	  and	  29	  ±	  
5	  (n	  =	  8)	  nM	  at	  1,	  7,	  and	  21	  days	  after	  Mn	  treatment,	  respectively	  (Figure	  4.4).	  Two-­‐way	  ANOVA	  
showed	  a	  significant	  main	  effect	  of	  treatment	  (F1,	  126	  =	  13.19,	  P	  <	  0.001)	  and	  time	  (F8,	  126	  =	  83.57,	  
P	  <	  0.001)	  as	  well	  as	  a	  significant	  interaction	  (F8,	  126	  =	  13.02,	  P	  <	  0.001),	  indicating	  Mn	  treatment	  
significantly	  altered	  high-­‐K+	  evoked	  increases	  in	  extracellular	  DA	  at	  all	  time	  points.	  	  
	  
Figure	   4.4:	   Extracellular	   DA	   levels	   determined	   by	   in	   vivo	   microdialysis.	   Time	   vs.	   DA	  
concentration	  plots	  of	  high	  K+	  stimulated	  DA	  release.	  Black	  bar	  indicates	  20	  min	  time	  fraction	  in	  
which	  120	  mM	  KCl	  aCSF	  was	  applied.	  Results	  are	  means	  (n	  =	  6	  -­‐	  10)	  of	  DA	  concentration	  (nM)	  ±	  
SEM.	  Inset	  compares	  area	  under	  curve	  upon	  high	  K+	  stimulation	  in	  saline-­‐	  (control)	  versus	  Mn-­‐





4.3.3	  Fast	  Scan	  Cyclic	  Voltammetry	  	  
Due	   to	   the	   slow	   temporal	   resolution	   of	   microdialysis	   (20	   minute	   sample	   intervals),	   this	  
technique	  mainly	  detects	  net	  changes	   in	  the	  extracellular	   levels	  of	  DA	  and	   its	  metabolites.	  To	  
assess	  various	  aspects	  of	  neuronal	  DA	  dynamics	  on	  a	  sub-­‐second	  time	  scale,	  FSCV	  was	  utilized.	  
FSCV	  enables	  the	  investigation	  of	  dopamine	  system	  functionality	  by	  quantifying	  DA	  release	  and	  
uptake.	  Electrically-­‐evoked	  DA	  release	  was	  measured	  in	  the	  CPu	  of	  saline	  and	  Mn-­‐treated	  mice	  
1,	  7,	  and	  21	  days	  after	   treatment.	  Additionally,	   the	  rate	  at	  which	  the	  DA	  transporter	   recycles	  
extracellular	  DA	  back	   into	   the	  presynaptic	   neuron	  was	   compared	  between	   the	   control	   group	  
and	  Mn-­‐treated	  group	  at	  all	   three	  time	  points	  using	  a	  calculated	  Vmax	  value.	  Since	  DA	  release	  
and	  uptake	  were	  comparable	  across	  all	  treatment	  time	  points	  for	  the	  saline-­‐treated	  mice,	  these	  
data	  were	  collapsed	  into	  a	  single	  control	  group.	  This	  control	  group	  (n	  =	  6)	  had	  an	  average	  DA	  
release	  of	  approximately	  1.7	  ±	  0.04	  μM	  and	  an	  average	  uptake	  rate	  of	  4.1	  ±	  0.2	  μM/s.	  Analysis	  
with	  one-­‐way	  ANOVA	  determined	  electrically-­‐evoked	  DA	   release	  was	   significantly	  different	   in	  
Mn-­‐treated	  mice	  compared	   to	  controls	  on	  day	  21	   (F3,23	   =	  4.486;	  P	  <	  0.05;	  Figure	  4.5B),	  when	  
stimulated	  release	  was	  recorded	  to	  be	  0.6	  ±	  0.04	  μM	  (n	  =	  6),	  exhibiting	  approximately	  a	  66%	  
attenuation	  in	  signal.	  Neither	  day	  1	  levels	  of	  released	  dopamine	  (1.9	  ±	  0.3	  μM;	  n	  =	  6)	  nor	  day	  7	  
levels	  (1.6	  ±	  0.4	  μM;	  n	  =	  6)	  showed	  any	  significant	  change	  from	  the	  control	  group.	  Additionally,	  
the	  rate	  of	  DA	  uptake	  in	  the	  dorsal	  CPu	  was	  not	  altered	  in	  Mn-­‐treated	  mice	  at	  any	  time	  point	  
(average	  approximately	  4.5	  ±	  0.09	  μM/s;	  F3,23	  =	  2.413;	  P	  =	  0.0968;	  Figure	  4.5C).	  Since	  all	  FSCV	  
experiments	   examine	   dopamine	   release	   and	   uptake,	   when	   all	   animals	   were	   combined	   for	  








Figure	   4.5:	   Electrically	   evoked	  DA	   release	   and	  uptake	   from	   the	  dorsal	   CPu	   as	  measured	  by	  
FSCV.	  A)	  Representative	  concentration	  vs.	  time	  and	  false	  color	  plot	  of	  saline-­‐	  and	  Mn-­‐treated	  
mice	  on	  day	  21.	  Central	  figures	  show	  color	  plots	  integrating	  time,	  applied	  potential,	  and	  current	  
as	  false	  color	  3D	  plots.	  Red	  triangle	  represents	  time	  point	  of	  electrical	  stimulation	  (5	  s).	  Current	  
vs.	   time	   traces	   (converted	   to	   concentration	   vs.	   time	   using	   post-­‐experiment	   electrode	  
calibration)	   shown	   above,	   with	   inset	   showing	   characteristic	   DA	   current	   vs.	   voltage	  
voltammograms.	  Summary	  of	  B)	  electrically	  evoked	  DA	  release	  and	  C)	  DA	  uptake	  rates	   in	   the	  
CPu	  of	  saline-­‐	  (control)	  and	  Mn-­‐treated	  mice.	  Data	  are	  mean	  (n	  =	  6/group)	  ±	  SEM	  expressed	  as	  









Figure	  4.6:	  Scatter	  plot	  demonstrated	  reproducible	  trends	  in	  DA	  release	  and	  uptake	  in	  greater	  
sampling	   population.	   A)	   FSCV	   measured	   DA	   release	   (n	   =	   31	   -­‐	   72/group)	   demonstrating	  
reproducible	   trend	   of	   day	   21	   attenuation	   in	   release	   (inset),	   as	   well	   as	   precision	   of	  
measurements.	  B)	  DA	  uptake	  rates	  are	  not	  different	  when	  samples	  are	  recorded	  from	  a	  larger	  











To	  test	   if	  alterations	   in	  the	  functionality	  of	  DA	  D2	  autoreceptors	  caused	  the	  differences	   in	  
DA	  levels	  detected	  following	  Mn	  treatment,	  the	  effect	  of	  the	  D2	  receptor	  agonist	  quinpirole	  on	  
electrically-­‐evoked	  DA	  release	  was	  measured	  in	  slices	  from	  saline-­‐	  and	  Mn-­‐treated	  mice.124-­‐126	  
Dose-­‐response	   curves	   were	   generated	   by	   perfusing	   increasing	   concentrations	   of	   quinpirole	  
(0.001	  to	  10	  µM)	  over	   the	  brain	  slice	  at	  30-­‐minute	   intervals	   (Figure	  4.7).	   125	  For	  all	   treatment	  
groups,	  quinpirole	  decreased	  electrically-­‐stimulated	  DA	  release	  (F7,	  66	  =	  119.5;	  P	  <	  0.0001).	  The	  
concentration	   at	   which	   the	   pre-­‐drug	   value	   of	   DA	   release	   was	   reduced	   by	   50%	   from	   the	  
maximum	  response	  (IC50)	  was	  determined	  for	  each	  of	  the	  treatment	  groups.	  The	  IC50	  for	  saline-­‐
treated	  mice	  was	  71	  ±	  12	  nM	  (n	  =	  10)	  and	  60	  ±	  12	  nM	  (average)	  for	  Mn-­‐treated	  mice,	  indicating	  
that	   our	   protocol	   for	   Mn	   treatment	   does	   not	   affect	   the	   functionality	   of	   release-­‐regulating	  










Figure	  4.7:	  Quinpirole	  dose-­‐response	   curves	   in	   the	  CPu.	  Dose-­‐response	   curves	   generated	  by	  
plotting	  the	   log	  concentration	  of	  quinpirole	  (M)	  vs.	  the	  maximal	  release	  of	  DA	  per	  pulse,	  as	  a	  
percent	   of	   baseline	   response	   (defined	   as	   100%).	   Dose-­‐response	   curve	   of	   quinpirole	   on	  
stimulated	  release	  in	  saline-­‐treated	  controls	  versus	  Mn-­‐treated	  mice	  shown	  for	  A)	  day	  1,	  B)	  day	  









4.4	  Discussion	  	  
Herein,	  we	  demonstrated	  that	  a	  sub-­‐acute	  MnCl2	  exposure	  elevates	  striatal	  tissue	  Mn	  levels	  
for	  at	  least	  21	  days	  after	  cessation	  of	  treatment	  compared	  to	  saline-­‐treated	  mice.	  Despite	  being	  
unable	  to	  detect	  changes	  in	  intraneuronal	  DA	  levels,	  both	  in	  vivo	  microdialysis	  and	  in	  vitro	  FSCV	  
reveal	   Mn-­‐induced	   baseline	   and	   stimulated	   release	   changes	   in	   extracellular	   DA,	   as	   well	   as	  
differences	  in	  extracellular	  levels	  of	  the	  DA	  metabolites	  DOPAC	  and	  HVA.	  Contrary	  to	  literature	  
reports,	   these	  alterations	   in	   release	  were	  not	   coupled	  with	  any	  compensatory	   changes	   in	  DA	  
uptake	  or	  D2	  autoreceptor	  functionality.	  101,105,106,107,108	  
Multiple	  administration	  methods	  (e.g.	   intraperitoneal,	  subcutaneous,	   inhalation,	  and	  oral),	  
Mn	  salts	  (e.g.	  MnCl2,	  MnSO4,	  and	  Mn(OAc)3),	  and	  doses	  (e.g.	  25-­‐100	  mg/kg,	  >300	  mg/kg,	  single-­‐	  
or	  multiple-­‐dose	  regimes)	  have	  been	  used	  to	  study	  the	  subsequent	  neurological	  effects	  of	  Mn	  
exposure.55,59,127	  The	  primary	  consideration	  in	  choosing	  an	  exposure	  protocol	  is	  whether	  or	  not	  
the	  exogenous	  application	  of	  Mn	  results	  in	  a	  significant	  accumulation	  at	  the	  region	  of	  interest.	  
In	  a	  review	  by	  Burton	  et	  al.,	  55	  it	  is	  suggested	  that	  cumulative	  doses	  any	  lower	  than	  300	  mg/kg	  
do	  not	  significantly	  alter	  DA	  levels	  in	  the	  striatum	  of	  non-­‐human	  primates.	  However	  in	  rodents,	  
Dodd	  et	  al.	  60	  have	  shown	  that	  an	  intermittent,	  subcutaneous	  dose	  of	  50	  mg/kg	  MnCl2	  causes	  
significant	  accumulation	  of	  Mn	  in	  the	  basal	  ganglia.	  Therefore,	  to	  better	  understand	  the	  impact	  
of	  a	  sub-­‐acute	  Mn	  exposure	  on	  DA	  dynamics,	  we	  adopted	  the	  protocol	  developed	  by	  Dodd	  et	  
al.	  60	  	  
The	  development	  of	  a	  parallel	  detection	  method	  for	  Mn	  and	  DA	  in	  the	  striatum	  enabled	  a	  
direct	   correlation	   between	  Mn	   accumulation	   and	   DA	   levels	   in	   the	   same	   tissue	   sample.	   This	  





though	   persistent	   accumulation	   of	   Mn	   is	   observed	   in	   the	   striatum	   for	   up	   to	   21	   days	   after	  
subcutaneous	  MnCl2	  exposure	  (Figure	  4.1).	  This	  increase	  in	  Mn	  is	  in	  accordance	  with	  what	  was	  
observed	   by	   Dodd	   et	   al.,60	   who	   also	   reported	   a	   significant	   effect	   on	   locomotor	   activity	   but	  
conducted	  no	  analysis	  of	  the	  DA	  system.	  Our	  tissue	  content	  results	   indicate	  that	  there	  are	  no	  
alterations	  in	  intracellular	  DA	  concentrations.	  However,	  there	  may	  still	  be	  underlying	  changes	  in	  
DA	  dynamics	  that	  are	  masked	  by	  the	  inability	  of	  tissue	  content	  analysis	  to	  distinguish	  between	  
intra-­‐	  and	  extracellular	  DA	  levels.	  
In	   vivo	  microdialysis	  was	   used	   to	   determine	  whether	   sub-­‐acute	  Mn	   treatment	   selectively	  
altered	   extracellular	   DA,	   DOPAC,	   or	   HVA	   levels	   in	   the	   striatum	   at	   three	   discrete	   time	   points	  
after	  Mn	   exposure.	   Extraneuronal	   DA,	   DOPAC,	   and	   HVA	   levels,	   without	   correction	   for	   probe	  
recovery,	   showed	   no	   differences	   immediately	   (24	   hours)	   or	   21	   days	   post-­‐Mn	   treatment	   but	  
were	  significantly	   reduced	  7	  days	  after	   sub-­‐acute	  exposure	  compared	   to	  control	  mice	   (Figure	  
4.2).	  These	  results	  suggest	  that	  alterations	  in	  presynaptic	  DA	  dynamics	  are	  delayed,	  despite	  the	  
immediate	  increase	  in	  striatal	  Mn	  levels	  observed	  by	  tissue	  content	  analysis.	  Furthermore,	  our	  
results	  suggest	  that	  a	  sub-­‐acute	  Mn	  exposure	  does	  not	  deplete	  intracellular	  DA,	  as	  total	  tissue	  
DA	   levels	   in	   the	   striatum	  were	  unchanged	  despite	   reductions	   in	  extracellular	  DA	   levels.	   Since	  
the	   tissue	   content	   of	  DA	   is	  mainly	   reflective	   of	   intraneuronal	   stores,	   this	   treatment	   protocol	  
does	  not	  appear	  to	  be	  neurotoxic.	  However,	  the	  dialysate	  results	  from	  this	  study	  suggest	  that	  
the	   presynaptic	   DA	   system	   is	   vulnerable	   to	   the	   effects	   of	   excessive	   Mn	   accumulation.	  
Compared	  to	  previous	  studies	  that	  have	  examined	  the	  acute	  or	  long-­‐term	  consequence	  of	  Mn	  
on	   presynaptic	   dopamine	   dynamics,	   our	   study	   investigated	   more	   intermediate	   time	   points	  





while	  no	  difference	  was	  observed	   in	  extracellular	  DA	   levels	   in	  either	   the	  CPu	  or	  NAc	  70	  days	  
following	  prolonged	  (20	  consecutive	  days)	  postnatal	  Mn-­‐treatment.101,103,104	  Although	  our	  study	  
did	   not	   detect	   any	   immediate	   changes	   in	   extracellular	   DA	   levels	   as	   in	   the	   Serra	   and	   Vidal	  
studies,	  which	  may	  be	  the	  result	  of	  differences	  in	  Mn	  concentration	  or	  duration	  of	  Mn	  infusion,	  
our	   results	   suggest	   that	   sub-­‐acute	   Mn	   exposure	   in	   adults	   has	   the	   ability	   to	   influence	  
presynaptic	  DA	  dynamics;	  however,	  these	  impairments	  are	  apparent	  for	  only	  a	  restricted	  period	  
of	  time.	  	  	  
To	  investigate	  whether	  Mn	  exposure	  results	  in	  other	  compensatory	  changes	  at	  presynaptic	  
DA	  terminals,	  high	  K+	  was	  perfused	  (via	  reverse	  dialysis)	  into	  the	  striatum	  to	  measure	  DA	  efflux.	  
Our	  results	  show	  that	  Mn-­‐treated	  mice	  at	  all	  time	  points	  had	  an	  attenuated	  response	  to	  high	  K+	  
infusion	  compared	  to	  controls.	  These	  results	  are	  consistent	  with	  the	  reduction	  in	  K+	  evoked	  DA	  
release	  observed	  by	  Vidal	  et	  al.	  upon	  an	  intrastriatal	  infusion	  of	  Mn.	  104	  Furthermore,	  long-­‐term	  
consequences	  of	  Mn-­‐treatment	  have	  been	  seen	   in	   the	   form	  of	  a	  blunted	  striatal	   response	   to	  
cocaine	   induced	   DA	   efflux.	   101	   Additionally,	   Guilarte	   et	   al.	   99,100	   have	   shown	   a	   decrease	   in	  
amphetamine-­‐induced	   DA	   release	   upon	   Mn	   accumulation	   in	   non-­‐human	   primates.	   Taken	  
together,	   these	   results	   suggest	   that	   Mn	   profoundly	   influences	   the	   ability	   of	   exogenous	  
compounds	   to	   evoke	   presynaptic	   DA	   release.	   In	   further	   support	   of	   this	   conclusion,	   when	  
electrically-­‐evoked	  DA	  release	  was	  monitored	  using	  FSCV,	  a	  blunted	  DA	  response	  was	  observed	  
in	  Mn-­‐treated	  mice	  that	  paralleled	  the	  alterations	  observed	  with	  in	  vivo	  microdialysis.	  Although	  
the	   neurochemical	   techniques	   (microdialysis	   versus	   FSCV)	   and	   sample	   preparation	   methods	  
(intact	  brain	  versus	  slice	  preparation)	  used	  to	  probe	  DA	  dynamics	  are	  different,	  together	  they	  





efflux.	   One	   thing	   to	   note	   is	   that	   FSCV	   only	   shows	   impairments	   21	   days	   after	  Mn-­‐treatment	  
whereas	  alterations	  in	  microdialysis	  results	  are	  seen	  at	  all	  time	  points.	  This	  difference	  may	  be	  
attributed	   to	   the	   stimulation	  parameters	  used	   for	  each	  of	   these	   techniques.	   	   Specifically,	   the	  
microdialysis	  high	  K+	  stimulation	  of	  20	  mins	  is	  six	  orders	  of	  magnitude	  greater	  in	  duration	  than	  
the	  4	  ms	  electrical-­‐stimulation	  applied	  to	  the	  slice	  when	  using	  FSCV.	  As	  a	  result,	  a	  stimulation	  
longer	   in	   duration	   may	   be	   able	   to	   overcome	   any	   release-­‐regulating	   impairments	   that	   are	  
elucidated	  by	  shorter	  stimulation	  methods.	  	  
To	  better	  understand	  whether	  subtle	  but	  biologically	  significant	  alterations	  in	  extracellular	  
DA	  occur	  at	  any	  other	  time	  points	  in	  Mn-­‐treated	  mice,	  the	  microdialysis	  technique	  of	  zero	  net	  
flux	  was	  used.	  Zero	  net	  flux	  microdialysis	  permits	  estimation	  of	  basal	  extracellular	  DA	  levels	  by	  
infusing	   in	   various	   concentrations	  of	  DA	   to	  quantify	   the	  extracellular	  DA	   concentration	   (Cext).	  
Cext	   is	   defined	   as	   the	   point	   where	   there	   is	   no	   net	   diffusion	   of	   DA	   between	   the	   extracellular	  
space	   and	   the	  microdialysis	  membrane	   (the	   x-­‐intercept).129,130	   This	  method	   also	   provides	   an	  
approximation	  of	   in	  vivo	  extraction	  fraction	  (Ed)	  from	  the	  slope	  of	  the	  zero	  net	  flux	  regression	  
line.	   123,131	  The	  present	   results	  obtained	  by	  zero	  net	   flux	   in	   the	  CPu	  agree	  with	   those	  without	  
correction	   for	   extraction	   fraction,	   as	   a	   significant	   decrease	   in	   extracellular	   DA	   concentration	  
was	  observed	  only	  7	  days	  after	  Mn-­‐treatment	  in	  both	  cases.	  Notably,	  zero	  net	  flux	  results	  did	  
not	  show	  a	  significant	  difference	  in	  Ed	  at	  any	  of	  the	  time	  points	  after	  Mn	  treatment	  (Figure	  4.3).	  
Since	  previous	  studies	  by	  Justice	  and	  co-­‐workers	  have	  shown	  that	  pharmacologic	   inhibition	  of	  
DA	   transporter-­‐mediated	  uptake	  alters	  Ed,	   this	   finding	  suggests	  Mn	  treatment	  may	  not	  affect	  
DA	  transport.114,115,123,128-­‐130	  However,	  zero	  net	  flux	  studies	  in	  monoamine	  transporter	  knockout	  





difference	   in	   striatal	   Ed.	   117,132	   Thus,	   there	   is	   considerable	   debate	   on	   how	   Ed	   values	   correlate	  
with	  transporter	  function.117,133,134	  A	  more	  direct	  method	  to	  measure	  the	  DA	  uptake	  function	  of	  
the	   DA	   transporter	   is	   to	   use	   FSCV,	   which	   records	   the	   release	   and	   uptake	   of	   DA	   following	  
electrical	  stimulation	  in	  brain	  slices	  with	  high	  temporal	  (100	  ms)	  resolution.8,87,	  135	  This	  method	  
has	  been	  used	  to	  show	  that	  DA	  is	  typically	  cleared	  from	  the	  extrasynaptic	  space	  in	  less	  than	  one	  
second	   in	   non-­‐treated	   animals,	   highlighting	   the	   necessity	   of	   a	   higher	   temporal	   resolution	  
technique	  to	  detect	  uptake	  changes.8,87,135	  In	  contrast	  to	  our	  zero	  net	  flux	  results,	  no	  difference	  
in	  DA	  uptake	  rates	  between	  controls	  and	  Mn-­‐treated	  mice	  was	  observed	  by	  FSCV.	  Specifically,	  
our	  analysis	  of	  DA	  Vmax,	  a	  quantification	  of	  the	  rate	  at	  which	  the	  DA	  transporter	  reuptakes	  DA	  
into	   the	   presynaptic	   neuron,	   showed	   no	   difference	   compared	   to	   saline-­‐treated	  mice	   (Figure	  
4.5).	   Previous	   studies	   have	   implicated	   the	   DA	   transporter	   for	   Mn	   transport	   into	   DA	  
neurons.100,101,105,106,136,137	   However,	   there	   is	   uncertainty	   as	   to	   whether	  Mn	   directly	   interacts	  
with	  the	  DA	  transporter	  or,	  once	  inside	  DA	  neurons,	  disrupts	  either	  presynaptic	  proteins	  or	  DA	  
function.99,100,105,136-­‐138	  Our	  FSCV	  results	  argue	  that	  Mn	  does	  not	  directly	  alter	  DA	  uptake,	  as	  no	  
difference	   in	   uptake	   rates	   were	   observed.	   However,	   a	   significant	   concomitant	   reduction	   in	  
stimulated	  DA	  release	  was	  measured	  by	  both	  microdialysis	  and	  voltammetry.	  Taken	  together,	  
these	  results	  suggest	  that	  intracellular	  accumulation	  of	  Mn	  has	  the	  ability	  to	  either	  directly	  or	  
indirectly	   influence	  presynaptic	  DA	   release	  dynamics	   for	   at	   least	   21	  days	   after	   sub-­‐acute	  Mn	  
treatment.	  	  
There	   is	   considerable	   evidence	   suggesting	   that	  Mn	   can	   alter	  DA	  D2	   receptor	   binding	   and	  
protein	  expression,	  but	  the	  lack	  of	  consistent	  findings	  across	  Mn	  treatments	  and	  animal	  models	  





receptors.99,107,108	   Since	   our	   study	   shows	   that	   a	   sub-­‐acute	   Mn	   exposure	   reduces	   DA	   release	  
dynamics	  with	   both	  microdialysis	   and	   voltammetry,	   we	   sought	   to	   determine	   if	   the	   impaired	  
stimulated	  DA	  release	  was	  modulated	  by	  presynaptic	  release-­‐regulating	  DA	  D2	  autoreceptors.	  
An	   advantage	   to	   using	   FSCV	   to	   probe	   DA	   D2	   autoreceptor	   functionality	   is	   that	   brain	   slices	  
exclude	   contributions	   from	   the	   DA	   D2	   impulse-­‐regulating	   receptors	   found	   on	   cell	   bodies,	  
allowing	  for	  a	  selective	  evaluation	  of	  nerve	  terminal	  D2	  autoreceptors	  that	  control	  exocytotic	  
DA	   release.83,139	   The	   results	   from	   the	   present	   study	   show	   no	   difference	   in	   the	   half	  maximal	  
inhibitory	  concentration	   (IC50)	  values	   for	   the	  DA	  D2	  agonist	  quinpirole,	   suggesting	   that	  a	  sub-­‐
acute	  Mn	  exposure	  does	  not	  affect	  DA	  D2	  autoreceptor	  functionality	  in	  the	  CPu.	  Similarly,	  but	  
using	  a	  different	  protocol,	  non-­‐human	  primates	  treated	  with	  Mn	  for	  at	  least	  27	  weeks	  showed	  
no	   alterations	   in	   D2	   autoreceptor	   levels	   in	   the	   caudate	   or	   putamen,	   and	   a	   pre-­‐weaning	  Mn	  
exposure	  (21	  days	  long)	  in	  rats	  also	  showed	  no	  differences	  in	  striatal	  D2	  protein	  levels	  3	  and	  86	  
days	  after	  treatment.59,100140,141	  However,	  there	  are	  other	  studies	  showing	  either	  an	  increase	  or	  
decrease	   in	  DA	  D2	  receptors	  after	  Mn	  treatment,	  and	   it	   is	  postulated	   that	   these	  variations	   in	  
effects	   are	  due	   to	   the	  wide	   range	  of	  Mn	   treatment	  protocols	   and/or	  animal	  models	   that	  are	  
used	   to	   evaluate	   potential	  Mn-­‐DA	   interactions.	   107,108The	   results	   from	   this	   study	  with	   a	   sub-­‐
acute	  Mn	  exposure	  protocol	  suggest	  that	  there	  is	  no	  direct	  effect	  of	  Mn	  on	  DA	  D2	  autoreceptor	  
functionality	   in	   the	   CPu	   and	   furthermore,	   that	   the	   impaired	   DA	   release	   in	   these	  Mn-­‐treated	  
mice	  are	  not	  a	  result	  of	  DA	  D2	  receptor	  dysfunction.	  
Intraneuronal	  Mn	  accumulation	  in	  DA	  neurons	  has	  numerous	  intracellular	  targets	  that	  could	  
disrupt	   presynaptic	   DA	   release.	   For	   example,	   one	   target	   protein	   that	   receives	   considerable	  





Parkinson’s	   disease).142,143	   The	   exact	   role	   of	   α-­‐synuclein	   in	   neurotransmitter	   regulation	   has	  
remained	   elusive,	   but	   there	   is	   increasing	   evidence	   that	   it	   is	   involved	   in	   modulating	  
neurotransmitter	   release.144-­‐146	  Mice	   that	   overexpress	   α-­‐synuclein	   have	   impaired	  DA	   release,	  
which	   does	   not	   appear	   to	   be	   a	   result	   of	   altered	   DA	   synthesis,	   vesicular	   activity,	   or	   DA	  
transporter-­‐mediated	  reuptake.144	   Interestingly,	  these	  DA	  system	  changes	  observed	  by	  Larsen	  
et	   al.	  parallel	   our	   findings	   in	  which	   a	   reduction	   in	  DA	   release	   is	   observed	  with	   no	   change	   in	  
uptake.	   Since	   Parkinson’s	   disease	   and	  manganism	  are	   both	   linked	   to	  DA	   system	  dysfunction,	  
manifested	  as	  a	  loss	  of	  motor	  control,	  it	  is	  plausible	  that	  α-­‐synuclein	  is	  a	  common	  mediator	  in	  
both	   diseases.100,142,143	   However,	   future	   experiments	   would	   need	   to	   be	   performed	   to	   affirm	  
interactions	  between	  Mn	  and	  α-­‐synuclein.	  	  
Although	  it	  is	  enticing	  to	  associate	  Mn	  with	  alterations	  in	  α-­‐synuclein	  expression	  because	  of	  
its	  similarities	  to	  Parkinson’s	  disease,	  it	  is	  possible	  that	  the	  attenuated	  DA	  release	  is	  a	  result	  of	  
dysfunction	   in	   other	   neuromodulators	   that	  would	   be	   susceptible	   to	   excess	  Mn	   accumulation	  
and	  subsequently	  cause	  dysfunctions	  in	  DA	  transmission.	  100,142	  For	  example,	  in	  the	  presence	  of	  
excess	   Mn,	   it	   is	   postulated	   that	   DA	   can	   be	   further	   oxidized,	   leading	   to	   an	   elevation	   in	   the	  
amount	  of	  free	  radicals	  or	  hydrogen	  peroxide	  in	  the	  brain.55,147-­‐150	  Hydrogen	  peroxide	  itself	  is	  a	  
modulator	  of	  synaptic	  DA	  release.151	   If	  excess	  Mn	  causes	  an	  imbalance	  (increase)	   in	  hydrogen	  
peroxide	  levels,	  then	  it	  is	  plausible	  that	  either	  this	  by	  itself	  or	  in	  combination	  with	  α-­‐synuclein	  
could	  lead	  to	  the	  reductions	  we	  observed	  in	  presynaptic	  DA	  transmission.	  	  
4.5	  Conclusion	  
In	   summary,	   this	   work	   used	   several	   neurochemical	   techniques,	   which	   together,	   indicate	  





alterations	   appearing	   7	   days	   after	   treatment.	   This	   is	   the	   first	   time	   that	   DA	   system	   dynamics	  
have	   been	  monitored	   after	  Mn	   exposure	   at	   3	   discrete	   time	   points	   (early,	   intermediate,	   and	  
late)	  in	  mice.	  Specifically,	  our	  results	  suggest	  that	  the	  DA	  system	  appears	  to	  be	  most	  susceptible	  
to	   presynaptic	   alterations	   7	   days	   after	  Mn	   treatment.	   Specifically	   at	   this	   time	   point,	   in	   vivo	  
microdialysis	  revealed	  a	  unique	  concomitant	  attenuation	  in	  striatal	  extracellular	  DA	  (both	  with	  
and	  without	  probe	  correction),	  HVA,	  and	  DOPAC	  levels.	  The	  decreases	  in	  extracellular	  DA	  levels	  
do	   not	   appear	   to	   be	   a	   result	   of	   altered	   DA	   uptake	   or	   DA	   D2	   autoreceptor	   function.	   Most	  
importantly,	   this	   effect	   on	   release	   is	   finite,	   as	   extracellular	   DA	   levels	   appear	   to	   rebound	   to	  
control	   levels	  at	  a	   later	  time	  point	  of	  analysis	  (21	  days).	  Taken	  together,	  these	  results	  suggest	  
that	  Mn	   accumulation	  within	   the	   striatum	   can	   severely	   impair	  DA	   release	   dynamics,	  without	  

















Chapter	  5:	  Behavioral	  Impact	  of	  Striatal	  Mn	  Accumulation	  
5.1	  Introduction	  
	   Chronic	   exposure	   to	  manganese	   (Mn)	   results	   in	  motor	   impairments	   in	   clinical	   patients	   of	  
manganism.58,60,93	  As	  dopamine’s	  role	  in	  reward,	  learning,	  and	  movement	  is	  well	  documented,	  
it	   is	   no	   surprise	   that	   a	   primary	   candidate	   for	   the	   study	   of	   Mn-­‐induced	   neurotoxicity	   is	   the	  
striatal	   dopaminergic	   system.1,4,65,99,104,138	  What	   is	   surprising	   is	   that	   to	   date,	   very	   few	   studies	  
have	   been	   able	   to	   reproduce	   manganism-­‐like	   behavioral	   changes	   in	   lab	   settings.	   Monkeys	  
tested	   on	   learning	   tasks	   before	   and	   after	   dosing	   with	   MnCl2	   via	   inhalation,	   the	   method	   of	  
exposure	  most	  similar	  to	  humans,	  show	  no	  difference	  in	  carrying	  out	  the	  task	  when	  compared	  
to	   controls.101,152	   Similarly,	   rats	   exposed	   to	   manganese	   chloride	   using	   various	   doses	   and	  
paradigms	   reveal	   no	   difference	   in	   open	   field	   locomotor	   activity	   when	   compared	   to	   saline	  
controls.101,153,154	   In	  other	  rodent	  studies,	  when	  a	  baseline	  locomotor	  impairment	  is	  observed,	  
contradictions	   in	   the	   results	   (increase	   versus	   decrease)	   beg	   for	   a	   more	   critical	  
analysis.60,140,155,156	   A	   difference	   in	   locomotor	   activity	   is	   often	   revealed	   when	   comparing	  
previously	  Mn-­‐treated	  mice	  and	  saline-­‐treated	  mice	  after	  the	  administration	  of	  a	  high	  dose	  of	  a	  
psychostimulant	  such	  as	  amphetamine	  or	  cocaine.101,154	  A	  psychostimulant	  challenge	  may	  be	  an	  
effective	  way	  to	  unravel	  subtle	  behavioral	  changes	  in	  animal	  models	  of	  manganism.	  101,154,157	  
	   Locomotor	  activity	   is	  often	  used	  as	  an	   indirect	  measurement	  of	  extracellular	  dopamine	   in	  
the	  striatum.158-­‐160	  As	  our	  previous	  Mn	  studies	  indicated	  a	  time-­‐dependent	  change	  in	  dopamine	  
release	  and	   in	  extracellular	   levels,	  we	  wanted	   to	  evaluate	   if	   the	  same	  correlation	  would	  hold	  
true	   for	   the	  Mn-­‐treated	  dopamine	   system	  of	  C57Bl/6	  mice.	   The	  aim	  of	   this	   study,	   therefore,	  





any	  correlation	  between	  our	  observed	  neurotransmission	  alterations	  (Chapter	  4)	  and	  potential	  
changes	  in	  physical	  function	  due	  to	  the	  established	  subacute	  Mn	  treatment	  protocol.	  
5.2	  Materials	  and	  Methods	  
5.2.1	  Animals	  
All	   experiments	   conducted	   using	   both	   male	   and	   female	   C57Bl/6	   mice	   weighing	   20-­‐30	   g.	  
Mice	  were	  purchased	  from	  Jackson	  Laboratories	  and	  bred-­‐in	  house	  at	  Wayne	  State	  University’s	  
animal	   care	   facilities,	   where	   they	   were	   housed	   3	   -­‐	   4	   mice	   per	   cage.	   Food	   and	   water	   was	  
available	   ad	   libitum.	   All	   protocols	   and	   animal	   care	   followed	   guidelines	   set	   by	   the	   National	  
Institutes	   of	   Health	   Office	   of	   Animal	   Care	   and	   Use	   and	   were	   approved	   by	   the	  Wayne	   State	  
University	  Institutional	  Animal	  Care	  and	  Use	  Committee.	  	  
5.2.2	  Manganese	  Treatment	  
Manganese	  (Mn)	  treatment	  was	  administered	  over	  the	  course	  of	  a	  week,	  every	  third	  day,	  
on	  days	  1,	  4,	  and	  7.	  Mn-­‐treated	  group	  received	  50	  mg/kg	  dose	  subcutaneous	  injections	  of	  0.1	  
mL	   manganese	   (II)	   chloride	   tetrahydrate	   (MnCl2.4H2O),	   made	   up	   in	   saline.	   Saline-­‐treated	  
control	  group	  received	  equivalent	  volume	  injections	  of	  saline	  (0.9%	  sodium	  chloride,	  NaCl).	  This	  
treatment	   was	   adapted	   from	   Dodd	   et	   al.60	   due	   to	   its	   demonstrated	   ability	   to	   result	   in	   Mn	  
accumulation	  in	  the	  basal	  ganglia.	  All	  behavioral	  tests	  were	  conducted	  after	  the	  last	   injection,	  
either	  24	  hours	  later	  (day	  1),	  7	  days	  later,	  or	  21	  days	  later.	  	  
5.2.3	  Locomotor	  Activity	  Testing	  
	   Locomotor	  testing	  was	  done	  over	  the	  course	  of	  2	  hours,	  with	  the	  exception	  of	  tests	  in	  which	  
methamphetamine	   was	   administered,	   which	   were	   conducted	   over	   the	   course	   of	   4	   hours.	  





to	  new	  environment	  stress.	  Animals	  were	  monitored	  in	  three	  categories:	  ambulatory	  distance	  
(cm),	   stereotypic	   count,	   and	   vertical	   count.	   In	   addition	   to	   baseline	   behavior	   data,	   a	  
methamphetamine	  injection	  (3	  mg/kg,	  made	  in	  saline)	  was	  given	  intraperitoneally	  (i.p.)	  and	  the	  
same	   three	   categories	   were	   subsequently	   monitored.	   All	   measurements	   made	   in	   static	  
exposure	   chambers	   using	   16-­‐beam	   infrared	   emitter-­‐detector	   arrays	   (Med	   Associates,	   St.	  
Albans,	   VT)	   that	   measure	   beam	   breaks	   in	   the	   x,	   y,	   and	   z	   direction	   by	   software	   (Open	   Field	  
Activity	  Software	   [SOF-­‐811],	  Med	  Associates,	  St.	  Albans,	  VT).	  Beam	  breaks	  are	   translated	   into	  
total	  distance	  traveled	   in	  the	  x	  and	  y	  direction	  (ambulatory	  distance,	  cm),	   repetitive	  behavior	  
without	   change	   in	   x	   and	   y	   direction	   (stereotypical	   activity,	   counts),	   and	   beam	   breaks	   in	   z	  
direction,	  translated	  to	  rearing	  behavior	  (vertical	  counts).	  All	  activity	  measurements	  were	  made	  
in	  60	  second	  time	  blocks.	  	  
5.2.4	  Beam	  Walk	  Testing	  
To	  perform	  the	  beam-­‐walking	  test,	  mice	  were	  placed	  on	  a	  custom-­‐built	  wooden	  plank	  (7/16	  
in	  x	  36	  in)	  3	  feet	  off	  the	  ground,	  angled	  at	  about	  15°	  towards	  a	  safe	  box.161	  Mice	  were	  trained	  to	  
walk	  across	  beam	  for	  three	  days	  before	  actual	  days	  of	  analysis	  (days	  1,	  7,	  and	  21,	  as	  mentioned	  
above).	   After	   three	  days	   of	   training,	  mice	  were	   video	   recorded	  while	   crossing	   the	   beam	  and	  
time	  to	  traverse	  the	  length	  of	  the	  beam	  was	  recorded.	  Any	  mouse	  that	  did	  not	  cross	  the	  beam,	  
fell	  off,	  or	  took	  more	  than	  30	  seconds	  was	  disqualified	  and	  excluded	  from	  the	  reported	  data	  of	  
group.	  
5.2.5	  Statistical	  Analysis	  
All	   data	   analyzed	   with	   GraphPad	   Prism	   software	   (GraphPad,	   La	   Jolla,	   CA).	   Values	   are	  





statistically	  significant.	  Comparisons	  of	  three	  or	  more	  means	  were	  made	  by	  a	  one-­‐way	  analysis	  
of	   variance	   (ANOVA).	   Two-­‐way	   ANOVA	  with	   Bonferroni	   post-­‐test	   was	   used	  when	   testing	   for	  
interaction	  of	  multiple	  variables.	  Grubbs	  test	  (using	  GraphPad	  Outlier	  calculator	  online)	  used	  to	  
exclude	  outliers	  in	  data	  sets	  with	  an	  alpha	  value	  set	  to	  0.05.	  
5.3	  Results	  
5.3.1	  Baseline	  Ambulatory	  Distance	  
	   To	  evaluate	   the	  effect	  of	  Mn	   treatment	  on	  baseline	   locomotor	  activity,	  mice	  were	  placed	  
inside	  the	  locomotor	  activity	  chamber	  while	  still	  in	  their	  homecages	  and	  movement	  in	  the	  x	  and	  
y	  plane	  was	  recorded	  for	  two	  hours	  with	  no	  external	  stressors.	  The	  resultant	  data,	  summed	  up	  
in	  10-­‐minute	  time	  blocks,	  is	  presented	  in	  Figure	  5.1.	  All	  data	  for	  saline-­‐treated	  controls	  on	  the	  
respective	  days	  of	  analysis	  are	  combined	  to	  form	  one	  control	  group	  (n	  =	  23).	  Compared	  to	  the	  
control	  group,	  Mn-­‐treated	  mice	  on	  day	  1	  had	  significantly	  lower	  locomotor	  activity	  (n	  =	  9,	  two-­‐
way	  ANOVA,	  **p	  <	  0.01	  vs.	  control).	  Baseline	  distance	  traveled	  was	  not	  different	  from	  controls	  









Figure	  5.1:	  Baseline	  Ambulatory	  Distance.	  Distance	  traveled	  is	  plotted	  in	  cm	  on	  the	  y-­‐axis	  and	  
time	  blocks	  of	  10	  minutes	  are	  plotted	  on	  the	  x-­‐axis	  for	  2	  hours	  of	  testing.	  Compared	  to	  saline-­‐
treated	  controls,	  Mn-­‐treated	  mice	  show	  significant	  attenuation	  in	  homecage	  locomotor	  activity	  









5.3.2	  Baseline	  Stereotypy	  
	   Quantifying	   stereotypic	   counts	   during	   testing	   of	   ambulatory	   distance	   assessed	   potential	  
impairment	  in	  repetitive	  movements	  of	  mice	  after	  Mn	  treatment.	  Mn-­‐	  and	  saline-­‐treated	  mice	  
were	  compared	  by	  summing	  up	  total	  stereotypic	  counts	  over	  the	  course	  of	  two	  hours.	  Saline-­‐
treated	  mice	  (n	  =	  26)	  exhibited	  an	  average	  stereotypic	  count	  of	  17767	  ±	  1446.	  Mn-­‐treated	  mice	  
on	  days	  7	  (18111	  ±	  1966,	  n	  =	  13)	  and	  21	  (18548	  ±	  1021,	  n	  =	  8)	  were	  not	  different	  in	  stereotypic	  
activity	   compared	   to	   saline	   control	   group	   (Figure	   5.2).	   Significant	   impairment	   in	   repetitive	  
movement	  was	  observed	  in	  Mn-­‐treated	  mice	  on	  day	  1	  (12280	  ±	  1569,	  n	  =	  16,	  one-­‐way	  ANOVA,	  
*p	  <	  0.05	  vs.	  control).	  	  	  
5.3.3	  Baseline	  Vertical	  Counts	  
	   Vertical	   counts	  were	   quantified	   during	   locomotor	   testing	   to	   assess	   rearing	   behavior	   after	  
Mn	  treatment.	  Mn-­‐treated	  mice	  had	  an	  increase	  in	  vertical	  counts	  progressing	  from	  analysis	  on	  
day	  1	  (450	  ±	  107,	  n	  =	  11),	  7	  (1041	  ±	  159,	  n	  =	  10),	  to	  21	  (2025	  ±	  541,	  n	  =	  8).	  Compared	  to	  saline	  
controls	  (825	  ±	  177,	  n	  =	  21),	  rearing	  behavior	  on	  day	  21	  was	  significantly	  potentiated	  (one-­‐way	  
ANOVA,	  **p	  <	  0.01	  vs.	  control;	  Figure	  5.3).	  
5.3.4	  Ambulatory	  Distance	  –	  Psychostimulant	  Challenge	  
	   Ambulatory	  response	  to	  a	  methamphetamine	  challenge	  was	  monitored	  in	  both	  Mn-­‐treated	  
and	   saline-­‐treated	   mice.	   A	   3	   mg/kg	   i.p.	   dose	   of	   methamphetamine	   caused	   an	   increase	   in	  
locomotor	   activity	   across	   all	   groups	   (Figure	   5.4).	   Analysis	   by	   two-­‐way	   ANOVA	   revealed	   a	  
significant	  effect	  of	  Mn	  treatment	  on	  day	  7	  (n	  =	  10,	  *	  p	  <	  0.05)	  compared	  to	  control	  group	  (n	  =	  
17),	  exhibiting	  a	  blunted	  increase	  (Figure	  5.4C).	  Neither	  day	  1	  (n	  =	  13;	  Figure	  5.4B)	  nor	  day	  21	  (n	  






Figure	  5.2:	  Summation	  of	  Baseline	  Stereotypic	  Counts	  Over	  Two	  Hours.	  Measure	  of	  repetitive	  
movements,	  indicative	  of	  stereotypic	  behavior,	  shows	  impaired	  stereotypy	  in	  mice	  treated	  with	  















Figure	   5.3:	   Baseline	   Vertical	   Counts	   after	   Mn	   Treatment.	   Summation	   of	   baseline	   vertical	  
counts	  over	   two	  hours	   shows	   increased	  vertical	   counts	   in	  mice	   treated	  with	  Mn	  21	  day	  after	  










Figure	  5.4:	  Locomotor	  Activity	  after	  Methamphetamine	  Challenge.	  After	  two	  hours	  of	  baseline	  
collection,	   mice	   were	   challenged	   with	   a	   3	   mg/kg	   i.p.	   injection	   of	   methamphetamine,	   and	  
subsequent	  locomotor	  effects	  were	  monitored	  for	  another	  two	  hours.	  A)	  Ambulatory	  distance	  
traveled	  by	   saline-­‐treated	  mice	   (n	   =	   17).	  B)	   Compared	   to	   saline-­‐treated	   controls,	  Mn-­‐treated	  
mice	  1	  day	  after	   treatment	   (n	  =	  13).	   	  C)	  Methamphetamine	  Mn-­‐treated	  mice	  on	  day	  7	  had	  a	  
blunted	   locomotor	   response	   compared	   to	   the	   saline	   controls	   (Mn-­‐treated:	   n	   =	   10;	   two-­‐way	  
ANOVA,	  *p	  <	  0.05	  vs.	  control).	  D)	  Ambulatory	  distance	  traveled	  by	  mice	  on	  day	  21	  (n	  =	  7)	  was	  







5.3.5	  Stereotypy	  –	  Psychostimulant	  Challenge	  
	   Three	   mg/kg	   i.p.	   injection	   of	   methamphetamine	   was	   used	   to	   elucidate	   effect	   of	   Mn	  
treatment	  on	  repetitive	  behavior	  of	  mice	  in	  response	  to	  a	  psychostimulant	  (Figure	  5.5).	  A	  main	  
effect	  of	  methamphetamine	   treatment	  was	  observed	  by	   two	  way-­‐ANOVA	   (n	  =	  4	   –	  26/group,	  
***p<0.001),	  with	  baseline	  saline	  control	  values	  (17767	  ±	  1446,	  n	  =	  26)	   increasing	  to	  24594	  ±	  
1807	  counts	  (n	  =	  17).	  Mn-­‐treated	  day	  1	  stereotypic	  counts	  increase	  from	  12280	  ±	  1569	  (n	  =	  16)	  
to	  23159	  ±	  1337	  (n	  =	  13),	  day	  7	  counts	  increase	  from	  18111	  ±	  1966	  (n	  =	  13)	  to	  26018	  ±	  4191	  (n	  
=	  10),	  and	  day	  21	  stereotypic	  counts	  increase	  from	  18548	  ±	  1021	  (n	  =	  8)	  to	  28253	  ±	  2702	  (n	  =	  7).	  
This	   data	   means	   that	   the	   expected	   increase	   in	   repetitive	   movements	   in	   response	   to	   the	  
methamphetamine	   injection	   was	   observed	   across	   all	   groups	   of	   animals	   with	   no	   apparent	  
difference	  in	  the	  meth-­‐stimulated	  levels	  of	  stereotypy	  within	  the	  groups	  themselves.	  	  	  
5.3.6	  Vertical	  Counts	  –	  Psychostimulant	  Challenge	  
	   Figure	   5.6	   shows	   measured	   changes	   in	   vertical	   counts	   upon	   methamphetamine	  
administration.	  Average	  vertical	  counts	  of	  saline-­‐treated	  mice	  increased	  from	  1460	  ±	  656.8	  (n	  =	  
22)	  to	  3745	  ±	  1691	  (n	  =	  11).	  Mn-­‐treated	  mice	  tested	  1	  day	  after	  treatment	  increased	  from	  450	  ±	  
107	  (n	  =	  11)	  to	  1723	  ±	  568	  (n	  =	  8).	  Conversely,	  the	  vertical	  counts	  of	  mice	  tested	  on	  day	  7	  after	  
treatment	   decreased	   from	   1041	   ±	   159	   (n	   =	   10)	   to	   420	   ±	   129	   (n	   =	   6).	   The	   same	   trend	   was	  
observed	  in	  the	  group	  analyzed	  on	  day	  21,	  decreasing	  to	  729	  ±	  157	  (n	  =	  7)	  from	  2025	  ±	  541	  (n	  =	  
8).	   This	   divergent	   response	   to	   methamphetamine	   is	   unprecedented	   in	   any	   of	   our	   other	  










Figure	   5.5:	   Summation	   of	   Stereotypic	   Counts	   after	   Psychostimulant	   Challenge.	   Effect	   of	   3	  
mg/kg	   of	  methamphetamine	   on	   stereotypic	   counts	   as	   plotted	   compared	   to	   baseline.	   A	  main	  









Figure	  5.6:	  Summation	  of	  Vertical	  Counts	  after	  Psychostimulant	  Challenge.	  Effect	  of	  3	  mg/kg	  











5.3.7	  Beam	  Walk	  Balance	  Test	  
	   When	  data	  from	  saline-­‐treated	  mice	  from	  all	  three	  time	  points	  were	  collapsed	  to	  form	  one	  
control	  group	  (n	  =	  21),	  the	  time	  to	  cross	  the	  beam	  was	  not	  different	  from	  the	  time	  it	  took	  Mn-­‐
treated	  mice	  to	  complete	  the	  same	  task	  at	  any	  of	  the	  three	  time	  points	  (n	  =	  7,	  n	  =	  7,	  and	  n	  =	  5	  
on	  days	  1,	  7,	  and	  21,	  respectively;	  Figure	  5.7A).	  When	  comparing	  the	  number	  of	  mice	  that	  were	  
disqualified	  from	  each	  group	  because	  they	  did	  not	  successfully	  complete	  the	  task,	  either	  due	  to	  
falling,	  refusal	  to	  walk,	  or	  taking	  more	  than	  30	  seconds,	  Mn-­‐treated	  mice	  on	  day	  1	  were	  almost	  
20%	  more	  likely	  to	  fail	  than	  the	  saline-­‐treated	  controls	  (Figure	  5.7B).	  	  	  
	  
Figure	   5.7:	   Beam	  Walk	   Assessment	   of	  Motor	   Coordination.	   A)	   Time	   required	   to	   traverse	   a	  
narrow	  beam	  compared	  across	  Mn-­‐treated	  groups	  and	  saline	  control.	  One	  way	  ANOVA	  shows	  
no	   difference	   in	   beam	  walk	   time	   between	  Mn-­‐treated	   and	   saline-­‐treated	   controls.	  B)	  When	  
comparing	  how	  many	  mice	  failed	  to	  complete	  the	  task	  in	  each	  group,	  Mn-­‐treated	  mice	  on	  day	  1	  






	   Since	  manganism	  is	  primarily	  characterized	  as	  a	  movement	  disorder,	  the	  aim	  of	  this	  study	  
was	   to	  determine	   if	  our	   intermittent	   sub-­‐acute	  Mn	  treatment	  protocol	   resulted	   in	  behavioral	  
changes	  in	  mice	  treated	  with	  Mn	  over	  the	  course	  of	  a	  week.	  As	  locomotor	  activity	  is	  oftentimes	  
considered	   to	  be	  an	   indirect	  measure	  of	  extracellular	  dopamine	   levels,	  we	  hypothesized	   that	  
the	   attenuation	   in	   extracellular	   and	   stimulated	   dopamine	   observed	   by	  microdialysis	   and	   fast	  
scan	   cyclic	   voltammetry	  would	   result	   in	   hypolocomotive	  mice	   after	  Mn	   treatment.	   Although	  
behavioral	   studies	   have	   been	   conducted	   in	   animals	   treated	   with	   Mn	   in	   the	   past,	   it	   was	  
imperative	   that	  we	  study	   the	  behavior	  of	  our	  mice	  after	   subcutaneous	  Mn	   injections	   for	   two	  
reasons.	  First,	  although	   the	   literature	   reports	  behavioral	  observation	  of	  Mn	  exposed	  animals,	  
the	  results	  obtained	  are	  far	  from	  conclusive.60,101,140,153-­‐156	  While	  some	  report	  decreases	  in	  open	  
field	   locomotor	   behavior,	   others	   are	   unable	   to	   elicit	   any	   phenotypic	   differences	   after	   Mn	  
exposure.	   Furthermore,	   several	   researchers	   report	   hyperlocomotive	   activity	   in	   Mn-­‐treated	  
rodents	   compared	   to	   controls.	   As	   these	   studies	   that	   have	   reported	   hyperlocomotor	   activity	  
vary	  greatly	  in	  their	  mode	  of	  Mn	  exposure	  (e.g.	  intraperitoneal	  or	  subcutaneous	  injections,	  oral	  
administration,	  inhalation),	  duration	  of	  exposure	  (e.g.	  one	  week,	  twenty-­‐one	  days,	  ten	  weeks,	  
five	   months),	   and	   animal	   models	   used	   (e.g.	   mice,	   rats),	   their	   results	   cannot	   be	   directly	  
extrapolated	   to	   predict	   the	   behavioral	   response	   of	   our	   treatment	   protocol	   in	   C57Bl/6	  mice.	  
Second,	  as	  our	  analysis	  timeline	  is	  unique,	  with	  neurochemical	  and	  behavioral	  analyses	  done	  1	  
day,	  7	  days,	  and	  21	  days	  after	  treatment	  cessation,	  our	  interest	  lies	  in	  understanding	  the	  short	  





	   Confirming	   our	   hypothesis,	   baseline	   locomotor	   activity	   data	   shows	   a	   decrease	   in	   X-­‐Y	  
direction	  movement.	  Contrary	  to	  our	  prediction,	   locomotor	  activity	   is	  blunted	  on	  day	  1,	  while	  
lower	  extracellular	  dopamine	  levels	  were	  recorded	  on	  days	  7	  (via	  microdialysis;	  Chapter	  4)	  and	  
day	  21	   (via	   fast	   scan	   cyclic	   voltammetry;	  Chapter	  4).	  Although	  our	   subacute	  Mn	  dose	   is	   high	  
enough	   to	   induce	  behavioral	   changes,	   the	   resultant	   locomotor	   activity	   effects	  may	  not	  be	  as	  
straightforward	   as	   expected.	   Whereas	   in	   human	   patients	   the	   three	   stages	   of	   manganism	  
symptoms	  culminate	  in	  motor	  deficiency	  as	  a	   late	  stage	  phenotype,	  our	  animal	  model	  reveals	  
much	  earlier	  onset	  of	  impairment.	  Additionally,	  as	  opposed	  to	  human	  cases	  of	  manganism,	  this	  
impairment	  does	  not	  appear	   to	  be	  permanent	   in	  murine	  studies,	   showing	  a	   return	   to	  normal	  
activity	  by	  day	  7	  of	  analysis.	  	  
	   Consistent	  with	  the	  decline	  in	  ambulatory	  distance	  on	  day	  1,	  stereotypic	  counts,	  indicative	  
of	  repetitive	  behavior,	  were	  also	  lower	  on	  this	  day.	  This	  attenuation	  in	  stereotypy	  is	  postulated	  
to	  be	  analogous	  to	  the	  rigidity	  observed	  in	  patients	  of	  manganism.	  Although	  no	  overt	  signs	  of	  
rigidity	  were	  observed,	  we	  believe	  the	  inhibition	  of	  characteristic	  functionless	  rodent	  behavior	  
that	  coincides	  with	  the	  time	  point	  of	  reduced	  horizontal	  movement	  signals	  the	  beginning	  of	  a	  
bradykinesic	  state.	  Similar	  to	  ambulatory	  distance	  movements,	  stereotypical	  counts	  returned	  to	  
control	   levels	  when	   tested	  one	  week	   after	   treatment	   cessation.	   This	   compensatory	   rescue	   is	  
seen	  throughout	  our	  studies,	  both	  in	  neurochemical	  measurements	  and	  behavioral	  responses,	  
demonstrating	  the	  ability	  of	  an	  intact	  neurological	  system	  to	  regulate	  homeostatic	  conditions	  in	  
the	  face	  of	  an	  acute	  environmental	  insult	  such	  as	  our	  Mn	  treatment	  protocol.	  	  
	   The	   final	   baseline	   measurements	   made	   sought	   to	   assess	   potential	   changes	   in	   rearing	  





observed.	   Although	   the	   day	   that	   changes	  were	   seen	   in	   rearing	   behavior	   is	   different	   from	   all	  
other	   behavioral	   measurements,	   this	   time	   point	   coincides	   with	   the	   changes	   in	   dopamine	  
release	   as	   measured	   by	   fast	   scan	   cyclic	   voltammetry.	   Unlike	   all	   of	   our	   previous	   behavioral	  
recordings,	  the	  vertical	  counts	  were	  higher	  than	  saline-­‐treated	  controls.	  It	  is	  important	  to	  note	  
that,	  although	  not	  statistically	  significant,	  a	  slight	  decrease	  in	  vertical	  counts	  was	  also	  observed	  
on	  day	   1,	  which	  would	   coincide	  with	   the	   day	   1	   impairments	   seen	   in	   the	   other	   two	  behavior	  
tests.	  
	   All	   three	   aforementioned	   tests	   were	   repeated	   with	   the	   addition	   of	   a	   psychostimulant	  
challenge.	   In	   addition	   to	   blocking	   the	   dopamine	   transporter,	   the	   psychostimulant	  
methamphetamine	   acts	   as	   a	   releaser	   of	   dopamine.1	   As	   previously	   noted,	   an	   increase	   in	  
extracellular	  dopamine	  has	  been	  correlated	  to	  hyperlocomotive	  activity;	   therefore,	  a	  3	  mg/kg	  
i.p.	   challenge	   of	   methamphetamine	   is	   expected	   to	   access	   higher	   levels	   of	   intraneuronal	  
dopamine	  stores.	  We	  hypothesized	  that	  due	  to	  the	  lower	  levels	  of	  stimulated	  and	  extracellular	  
dopamine	  measured	   in	   previous	   experiments,	   this	  would	   not	   be	  possible	   for	   the	  Mn-­‐treated	  
mice	   at	   certain	   time	   points.	   The	   expected	   outcome	   was	   that	   although	   methamphetamine	  
would	   significantly	   increase	   movement	   in	   saline-­‐treated	   control	   mice,	   no	   potentiation	   of	  
locomotor	   activity	   would	   be	   observed	   in	   Mn-­‐treated	   animals.	   The	   acute	   challenge	   of	  
methamphetamine	  resulted	  in	  a	  potentiation	  of	  ambulatory	  distance	  traveled	  in	  saline-­‐treated	  
mice	  and	  Mn-­‐treated	  mice	  on	  days	  1	  and	  21.	  As	  predicted,	  testing	  on	  day	  7	  after	  Mn	  treatment	  
completion	   revealed	   blunted	   stimulation	   of	   movement.	   This	   blunted	   methamphetamine-­‐
induced	   activity	   coincides	   with	   the	   time	   point	   of	   lowest	   levels	   of	   extracellular	   dopamine,	  





dopamine	   by	  methamphetamine.	   The	  most	   inexplicable	   trend	   in	   psychostimulant	   challenged	  
behavioral	  response	  was	  seen	  in	  rearing	  behavior:	  both	  saline-­‐treated	  and	  Mn-­‐treated	  mice	  on	  
day	  1	  showed	  an	   increase	   in	  vertical	  counts	  after	  methamphetamine	  stimulation,	  while	  day	  7	  
and	   day	   21	   analysis	   revealed	   a	   decrease.	   The	   lower	   vertical	   counts	   despite	   a	   high	   dose	   of	  
stimulant	   could	   simply	   be	   due	   to	   the	   increase	   seen	   in	   stereotypy;	   as	   there	   is	   a	   surge	   in	  
repetitive	  behavior	  at	  those	  time	  points,	  there	  may	  be	  less	  interest	  in	  rearing.	  
	   Aside	   from	   activity	   chamber	   testing,	   the	   beam-­‐walking	   test	   was	   used	   to	   characterize	  
balance	  and	  coordination	  of	  Mn-­‐treated	  mice,	  as	  well	  as	  an	   indicator	  of	  nigrostriatal	  damage.	  
Thus,	  the	  beam-­‐walking	  test	  has	  been	  used	  to	  assess	  the	  impact	  of	  Mn	  treatment	  on	  the	  basal	  
ganglia.162,163	   There	   was	   no	   difference	   in	   coordination	   between	   Mn-­‐	   and	   saline-­‐treatment	  
groups	  as	  the	  time	  required	  to	  traverse	  the	  beam	  was	  the	  same	  in	  both	  groups.	  These	  beam-­‐
walking	   data	   confirm	   that	   the	   subacute	   treatment	   protocol	   used	   for	   our	   work	   does	   not	  
significantly	   damage	   the	   nigrostriatal	   pathway,	   which	   further	   substantiates	   our	   previous	  
findings	  that	  recovery	  was	  demonstrated	  after	  impaired	  motor	  behavior.	  Interestingly,	  although	  
no	   change	   is	   seen	  between	  groups	  overall,	   20%	  more	  mice	  were	  observed	   to	   fail	   at	   the	   task	  
(due	  to	  falling	  or	  noncompliance)	  than	  any	  other	  group	  on	  day	  1.	  Supplementing	  the	  impaired	  
locomotor	   and	   stereotypy	   data	   at	   the	   same	   time	   point	   of	   analysis,	   this	   would	   suggest	   the	  
beginning	  of	  a	  bradykinesic	  state	  in	  Mn-­‐treated	  mice	  on	  day	  1.	  	  
Others	   have	   also	   reported	   similar	   locomotor	   impairment	   on	   day	   1	   in	   spite	   of	   a	   lack	   of	  
parallel	  changes	  in	  dopamine	  levels.156	  In	  their	  work,	  however,	  GAD67-­‐GFP	  knock-­‐in	  mice	  were	  
used,	   which	   have	   γ-­‐aminobutyric	   acid	   (GABA)	   neurons	   specifically	   labeled	   with	   green	  





observe	   that	   although	   the	   dopamine	   system	   was	   not	   altered	   within	   twenty-­‐four	   hours	   of	  
manganese	  treatment,	  there	  was	  activation	  of	  GABA	  neurons.	  We	  believe	  that	  this	  could	  be	  the	  
reason	   why	   our	   dopamine-­‐focused	   characterization	   of	   manganese	   treated	   mice	   did	   not	  
produce	   behavioral	   changes	   that	   agreed	   with	   the	   time	   points	   of	   neurochemical	   alterations.	  
Future	   behavioral	   studies	   aim	   to	   monitor	   the	   GABA	   system	   as	   well	   to	   uncover	   potential	  
connections	  between	  the	  two.	  
5.5	  Conclusion	  
	   Overall,	  these	  locomotor	  and	  behavioral	  characterizations	  enabled	  us	  to	  better	  understand	  
fine	  motor	  changes	  in	  C57	  mice	  after	  an	  intermittent	  administration	  of	  MnCl2.	  These	  behavior	  
studies	   primarily	   revealed	   movement	   deficits	   within	   24	   hours	   after	   Mn	   treatment	   was	  
completed.	  Although	  levels	  of	  movement	  were	  significantly	  decreased,	  typically	  within	  the	  first	  
24	  hours,	  all	  attenuated	  values	  returned	  to	  control	  levels	  within	  the	  time	  course	  of	  this	  study.	  
From	  this	  pattern,	  we	  can	  draw	  the	  conclusion	  that	  Mn	  exposure	  does	  impair	  motor	  behavior.	  
However,	  at	   the	  Mn-­‐levels	  administered	   in	  our	   study,	   the	   impact	   is	   reversible,	  as	  a	   return	   to	  
control	  levels	  is	  observed	  within	  7	  days	  of	  the	  last	  treatment	  dose.	  To	  further	  probe	  and	  push	  
the	   dopaminergic	   striatal	   system,	   mice	   were	   challenged	   with	   methamphetamine,	   which	  
blunted	   stimulated	  ambulatory	  distance	   traveled	  on	  day	  7,	   elucidating	  what	  we	  believe	   is	   an	  
inability	  of	  the	  system	  to	  access	  additional	  intraneuronal	  dopamine	  pools.	  The	  hypothesis	  that	  
dopamine	  reserve	  pools	  are	  altered	  after	  Mn	  treatment	  was	  then	  meticulously	  tested	  using	  fast	  







Chapter	  6:	  Investigation	  of	  Dopamine	  Reserve	  Pool	  after	  Manganese	  Treatment	  
6.1	  Introduction	  
Thus	  far,	  our	  results	  have	  demonstrated	  that	  a	  sub-­‐acute	  Mn	  treatment	  protocol	  results	  in	  
lower	   dopamine	   extracellular	   levels	   and	   lower	   striatal	   dopamine	   release,	   without	   any	  
compensatory	   changes	   in	   dopamine	   uptake	   or	   autoreceptor	   functionality.	   High	   potassium	  
stimulation	  via	  microdialysis	  also	  revealed	  a	  blunted	   increase	   in	  dopamine	  extracellular	   levels	  
as	   compared	   to	   the	   control	   group.	   Furthermore,	   there	   was	   an	   ineffectiveness	   in	  
methamphetamine’s	  ability	   to	   stimulate	  hyperlocomotor	  behavior	   in	  Mn-­‐treated	  mice	  7	  days	  
after	   treatment,	   an	   indication	   that	  methamphetamine	  may	   not	   be	   able	   to	   access	   additional	  
stores	   of	   dopamine	   that	   are	   required	   to	   stimulate	   locomotor	   behavior.	   Together,	   these	   data	  
suggest	   that	   the	   result	  of	  Mn	  accumulation	   in	   the	  striatum	  may	  be	  an	   intracellular	  change	   in	  
dopamine	  regulation.	  	  
6.2	  Vesicles:	  Key	  to	  Intraneuronal	  Regulation	  of	  Dopamine	  Release	  
6.2.1	  Exocytosis	  
Once	  synthesized	  in	  the	  cell	  body,	  dopamine	  is	  packaged	  into	  secretory	  vesicles	  and	  stored	  
in	   the	  nerve	   terminal.1	  Exocytotic	   release	  of	  neurotransmitters	   from	  these	  vesicles	   is	  a	  highly	  
regulated	  and	  rapid	  five-­‐step	  process.1	  In	  order	  for	  vesicles	  to	  release	  dopamine	  quickly	  at	  the	  
signal	   of	   an	   action	   potential,	   they	   are	   first	   docked	   at	   the	   active	   zone	   of	   the	   nerve	   terminal.	  
Second,	   vesicles	   are	   primed	  with	   adenosine	   triphosphate	   hydrolysis,	   which	   enables	   them	   to	  
respond	  to	  calcium	  influx	  at	  the	  millisecond	  timescale.	  In	  the	  third	  step,	  upon	  influx	  of	  calcium,	  
vesicles	   fuse	   to	   the	   plasma	   membrane	   and	   release	   their	   contents	   into	   the	   synaptic	   space.	  





endocytosis.	  Finally,	  vesicles	  are	  recycled	  and	  re-­‐loaded	  with	  neurotransmitters	  by	  the	  vesicular	  
monoamine	   transporter	   (VMAT).	   There	   is	   considerable	   debate	   about	   the	  mechanism	   of	   this	  
final	  step.	  In	  a	  recent	  review,	  Denker	  et	  al.	  report	  evidence	  for	  four	  different	  models	  of	  vesicle	  
recycling.164	   In	   support	   of	   the	   “kiss-­‐and-­‐run”	   model,	   it	   has	   been	   shown	   that	   in	   some	   cases,	  
synaptic	  vesicles	  only	  partially	  fuse	  to	  the	  membrane,	  after	  which	  the	  same	  individual	  vesicles	  
are	   refilled	   for	   multiple	   rounds	   of	   exocytosis.165-­‐168	   	   A	   second	   and	   more	   prominent	   theory	  
argues	   in	   favor	   of	   full	   fusion	   of	   vesicles	   into	   the	   plasma	  membrane,	   after	  which	   vesicles	   are	  
recycled	   in	   a	  method	  mediated	  by	   the	  protein	   clathrin.169-­‐171	   The	   third	  model	  proposed,	  bulk	  
endocytosis,	  suggests	  that	  after	  releasing	  dopamine,	  vesicles	  fused	  to	  the	  membrane	  generate	  
new	  vesicles	  for	  recycling.172-­‐174	  The	  fourth	  model	  called	  the	  endosomal	  sorting	  model	  suggests	  
that	   the	   vesicles	   fused	   to	   the	   plasma	   membrane	   then	   fuse	   to	   a	   sorting	   endosome	   that	  
generates	  new	  vesicles	  to	  store	  and	  release	  dopamine.175-­‐177	  Although	  the	  fusion	  and	  recycling	  
components	   of	   exocytotic	   release	   are	   important	   areas	   of	   dopamine	   regulation,	   don’t	   believe	  
that	  manganese	  treatment	  is	  disrupting	  this	  process.	  If	  that	  had	  been	  the	  case,	  we	  hypothesize	  
that	  over	  time,	  we	  would	  stop	  seeing	  dopamine	  release	  altogether.	  On	  the	  contrary,	  our	  goal	  in	  
examining	   dopamine	   vesicles	   of	  Mn-­‐treated	  mice	   is	   to	   elucidate	   potential	   changes	   in	   vesicle	  
storage	   and	   trafficking.	   As	   it	   has	   been	   shown	  by	   Stanwood	  et	   al.	   that	  manganese	   treatment	  
leads	  to	  a	  75%	  decrease	  in	  synapsin	  staining,	  a	  key	  protein	  in	  vesicle	  trafficking,	  we	  believe	  our	  
impaired	   release	   results	   combined	   with	   the	   absence	   of	   change	   in	   intraneuronal	   levels	   of	  







6.2.2	  Dopamine	  Vesicle	  Pools	  
While	  in	  the	  axon	  terminal,	  dopamine	  vesicles	  have	  been	  shown	  to	  exist	  in	  three	  different	  
pools:	  readily	  releasable,	  recycling,	  and	  reserve.179	  The	  readily	  releasable	  pool	  accounts	  for	  ~	  1	  
–	   2%	   of	   the	   total	   vesicles	   which	   are	   docked	   at	   the	   “active	   site”	   of	   the	   neuron	   and	   release	  
dopamine	   upon	   mild	   stimulation.	   The	   recycling	   pool,	   which	   replaces	   readily	   releasable	   pool	  
vesicles	  as	  they	  are	  depleted,	  makes	  up	  10	  –	  20%	  of	  the	  total	  vesicles.	  The	  reserve	  pool	  makes	  
up	   the	  majority,	  accounting	   for	  ~	  80	   -­‐	  90%	  of	   total	   vesicles,	  and	   is	  mobilized	  only	   if	   all	  other	  
pools	  are	  depleted	  or	  upon	  prolonged	  stimulation.	  	  
A	   point	   of	   contention	   regarding	   the	   secretory	   vesicles	   is	   in	   understanding	   how	   these	  
vesicles	   exchange	   between	   the	   three	   different	   pools,	   if	   at	   all.	   Additionally,	   it	   is	   unclear	   how	  
“mobile”	  each	  of	  these	  pools	  are	  and	  therefore	  how	  they	  are	  recruited	  to	  the	  active	  zone	  for	  
release.	  It	  has	  been	  well	  established	  that	  the	  family	  of	  proteins	  known	  as	  synapsins	  are	  in	  large	  
part	  responsible	  for	  segregating	  the	  different	  pools	  of	  vesicles.	  It	  is	  hypothesized	  that	  regulating	  
movement	  of	  vesicles	  from	  one	  area	  to	  another	  is	  also	  accomplished	  by	  synapsins.1	  A	  number	  
of	   studies	   have	   been	   conducted	   to	   better	   understand	  patterns	   in	  mobility	   and	   immobility	   of	  
vesicles,	  but	  with	  varying	  results.	  When	  studied	  by	  stimulated	  emission	  depletion	  microscopy,	  
apparent	  vesicle	  movement	   is	  mostly	   random,	  but	   shows	  certain	  areas	  of	   immobility.180,181	   In	  
mouse	  neuromuscular	   junctions,	  Gaffield	  and	  Betz	   report	   that	   vesicles	  are	   immobile	  at	   room	  
temperature,	   but	   become	   mobile	   at	   physiological	   temperature.182	   Neuromuscular	   junction	  
analysis	  reveals	  a	  pool	  of	  recycling	  vesicles	  that	  are	  mobile	  even	  at	  rest,	  while	  the	  reserve	  pool	  





observed	  to	   lose	  their	  mobility	  over	  time,	  regardless	  of	  which	  pool	   they	  were	  classified	  to	  be	  
in.184	  
Together,	  these	  studies	  on	  the	  mobility	  of	  vesicles	  lend	  evidence	  to	  a	  high	  intermixing	  rate	  
amongst	  vesicles	  proposed	  by	  Denker	  and	  Rizzoli.164	  They	  also	  suggest	  that	  the	  reserve	  pool	  is	  
the	   compilation	  of	   “mature”	   vesicles,	  which	  are	   created	  after	  multiply	   endocytosed	   recycling	  
vesicles	   lose	   their	   mobility.	   However,	   it	   is	   important	   to	   note	   that	   limited	   mobility	   does	   not	  
mean	  these	  vesicles	  no	  longer	  release	  neurotransmitters.	  In	  fact,	  reserve	  pool	  vesicles	  are	  still	  
capable	  of	  efficient	  exocytosis.	  185,186	  	  
6.3	  FSCV	  Study	  of	  Dopamine’s	  Vesicular	  Stores	  
We	   hypothesize	   that	   dysfunction	   in	   intracellular	   dopamine	   regulation	   after	   exposure	   to	  
manganese	  stems	  from	  improper	  vesicle	  segregation	  and	  trafficking.	  Specifically,	  if	  the	  vesicles	  
were	  unable	   to	   carry	  out	   their	   recycling	  and	  mobilization	   function	  due	   to	   striatal	  manganese	  
accumulation,	   a	   change	   in	   normal	   rate	   of	   release	   of	   dopamine	  would	   be	   observed.	   External	  
stimulation	  is	  used	  to	  study	  dopamine	  vesicular	  release,	  as	  such	  stimulation	  causes	  the	  neuron	  
to	  release	  the	  contents	  of	  the	  vesicles	  docked	  at	  the	  terminal.	  In	  vivo,	  this	  dopamine	  would	  be	  
released	   in	   response	   to	  a	   sufficient	  action	  potential	   and	   subsequent	   calcium	   influx.	  Changing	  
the	  stimulation	   intensities	  can	  be	  used	   to	   tease	  apart	   the	  various	  subcategories	  of	  dopamine	  
vesicles.	  In	  addition	  to	  external	  stimulation,	  the	  reserve	  pool	  has	  also	  been	  shown	  to	  mobilize	  
by	   the	   administration	   of	   cocaine,	   a	   drug	   heretofore	   thought	   to	   act	   only	   as	   a	   dopamine	  
transporter	  inhibitor.187	  
Slice	  fast	  scan	  cyclic	  voltammetry	  (FSCV)	  can	  be	  used	  to	  probe	  the	  model	  of	  distinct	  vesicle	  





(TBZ),	   an	   inhibitor	   of	   the	   VMAT,	   alpha-­‐methyl-­‐p-­‐tyrosine	   (α-­‐MPT),	   a	   tyrosine	   hydroxylase	  
inhibitor	   (inhibiting	   dopamine	   synthesis),	   amphetamine,	   a	   competitive	   dopamine	   transporter	  
inhibitor	   that	   releases	  dopamine	   from	  vesicles,	   and	   cocaine,	   differences	   in	  dopamine	   release	  
can	   be	   evaluated.	   The	   combination	   of	   synthesis	   and	   VMAT	   inhibitors	   allows	   for	   the	  
differentiation	  of	  readily	  releasable	  versus	  reserve	  pool	  vesicles,	  as	  well	  as	  for	  the	  assessment	  
of	   whether	   the	   attenuation	   of	   release	   is	   due	   to	   impaired	   loading	   of	   vesicles	   or	   in	   the	  
mobilization	   of	   those	   vesicles	   to	   the	   neuron’s	   docking	   site.	   Impaired	   release	   upon	   external	  
stimulation	  suggests	  that	  Mn’s	  mechanism	  of	  action	  may	  be	  caused	  by	  the	  hindrance	  of	  vesicle	  
mobilization,	  or	   in	   the	  amount	  of	  dopamine	  available	   in	   reserve	  pool	   vesicles.	  An	   inability	   to	  
retrieve	   dopamine	   from	   the	   reserve	   pool	   would	   explain	   the	   more	   extensive,	   long-­‐term	  
attenuation	  in	  release	  observed	  when	  stimulated	  with	  120	  mM	  of	  KCl	  for	  20	  minutes,	  which	  is	  
considered	  to	  be	  a	  very	  strong	  stimulation.	  In	  this	  study,	  dopamine	  levels	  after	  depletion	  of	  the	  
readily	  releasable	  and	  recycling	  pools	  in	  both	  saline-­‐	  and	  Mn-­‐treated	  mice	  were	  compared	  so	  as	  
to	  evaluate	  the	  condition	  of	  the	  reserve	  pool	  and	  its	  ability	  to	  replace	  the	  depleted	  pools	  after	  
significant	  Mn	  accumulation.	  
6.4	  Materials	  and	  Methods	  
6.4.1	  Animals	  
Male	   and	   female	   C57Bl/6	   mice,	   either	   purchased	   from	   Jackson	   Laboratories	   or	   bred	   in	  
house,	   were	   used	   for	   all	   experiments.	   Until	   ready	   for	   use,	  mice	   were	   housed	   (3-­‐4	  mice	   per	  
cage)	  at	  the	  animal	  care	  facilities	  of	  Wayne	  State	  University.	  Food	  and	  water	  was	  available	  ad	  





Health	   Office	   of	   Animal	   Care	   and	   Use	   and	   were	   approved	   by	   the	   Wayne	   State	   University	  
Institutional	  Animal	  Care	  and	  Use	  Committee.	  	  
6.4.2	  Chemicals	  
	   Components	  of	  artificial	  cerebrospinal	   fluid,	  MnCl2.4H2O,	   tetrabenazine	   (TBZ),	  α-­‐methyl-­‐p-­‐
tyrosine	  (αMPT),	  amphetamine,	  and	  cocaine	  were	  obtained	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO)	  
and	  Fisher	  Scientific	  (Pittsburgh,	  PA)	  and	  were	  of	  the	  highest	  quality	  available.	  	  
6.4.3	  Manganese	  Treatment	  
All	  animals	  were	  divided	  into	  two	  groups:	  saline-­‐treated	  controls	  and	  Mn-­‐treated.	  The	  Mn	  
group	   was	   given	   0.1	   mL	   subcutaneous	   injections	   of	   50	   mg/kg	   dose	   manganese	   (II)	   chloride	  
tetrahydrate	   (MnCl2.4H2O)	  made	   up	   in	   sterile	   saline	   (0.9%	   sodium	   chloride,	   NaCl).	   Injections	  
were	  given	  three	  times	  over	   the	  course	  of	  a	  week,	  on	  days	  1,	  4,	  and	  7.	  Equivalent	  volume	  of	  
saline	   was	   administered	   to	   control	   group	   on	   the	   same	   days.	   After	   treatment	   completion,	  
experiments	   for	   neurochemical	   analysis	   were	   conducted	   1,	   7,	   and	   21	   days	   after	   final	   Mn	  
injection.	  	  
6.4.4	  Fast	  Scan	  Cyclic	  Voltammetry	  
The	  method	  of	  fast	  scan	  cyclic	  voltammetry	  is	  explained	  in	  detail	  in	  Chapters	  3	  and	  4.	  A	  brief	  
summary	   of	   the	   experimental	   details	   is	   included	   here	   as	   it	   was	   applied	   to	   the	   experiments	  
conducted	   in	   this	   study.	   Acquisition	   of	   the	   brain	   slices	   containing	   the	   caudate-­‐putamen,	  
electrode	  placement,	  and	  collection	  of	  electrochemical	  data	  is	  as	  previously	  described.	  	  
Dopamine	   release	   and	   uptake	   measurements	   were	   made	   until	   at	   least	   three	   stable,	  
consecutive	   baseline	   values	   were	   obtained.	   For	   the	   first	   set	   of	   experiments,	   once	   a	   stable	  





perfused	  with	  10	  µM	  TBZ,	   a	  VMAT	   inhibitor,	  while	  applying	   single	  pulse	   stimulations	  every	  5	  
minutes	  to	  deplete	  the	  readily	  releasable	  pool.	  Successful	  dopamine	  depletion	  was	  observed	  by	  
the	  complete	  loss	  of	  the	  dopamine	  signal.	  At	  that	  point,	  a	  combination	  of	  10	  µM	  TBZ	  and	  20	  µM	  
amphetamine	  were	  perfused	  over	  the	  brain	  slice	  for	  25	  minutes.	  The	  purpose	  of	  the	  co-­‐infusion	  
of	  amphetamine	  is	  that	  it	  is	  capable	  of	  releasing	  cytosolic	  dopamine	  into	  the	  extracellular	  space	  
by	  reverse	  transport.139,189	  Thus,	  with	  amphetamine	  on	  board,	  it	  is	  believed	  that	  the	  transporter	  
is	   working	   in	   the	   opposite	   direction	   by	   transporting	   dopamine	   from	   the	   reserve	   pool	   of	  
dopamine	   vesicles	   out	   into	   the	   extracellular	   space.	   A	   continuous	   12.5-­‐minute	   file	   was	   then	  
collected	   without	   stimulation.	   The	   amplitude	   of	   the	   resultant	   peak	   was	   compared	   between	  
saline-­‐treated	  and	  Mn-­‐treated	  mice	  at	  the	  three	  time	  points	  of	  analysis	  (day	  1,	  7,	  and	  21	  after	  
treatment)	  to	  assess	  the	  intracellular	  levels	  of	  dopamine	  in	  the	  reserve	  pool.	  	  
For	   a	   more	   selective	   analysis	   of	   the	   reserve	   pool	   by	   using	   a	   drug	   that	   blocks	   dopamine	  
synthesis,	  50	  µM	  α-­‐MPT,	  a	  tyrosine	  hydroxylase	  inhibitor,	  was	  perfused	  onto	  the	  slices	  as	  single	  
stimulations	  were	  applied	  to	  selectively	  deplete	  cytosolic	  and	  readily	  releasable	  pool	  dopamine.	  
The	  reserve	  pool	  dopamine	  was	  again	  pharmacologically	  released	  using	  20	  µM	  amphetamine.	  
After	  collecting	  a	  continuous	  file	  during	  perfusion	  without	  any	  electrical	  stimulation,	  maximum	  
peak	  heights	  were	  compared	  to	  evaluate	  dopamine	  reserve	  pool	  content	  between	  saline-­‐	  and	  
Mn-­‐treated	  mice.	  
In	   a	   third	   experiment,	   α-­‐MPT	   and	   cocaine	  were	   used	   to	   determine	   if	  mobilization	   of	   the	  
reserve	  pool	  was	  different	  between	  saline-­‐treated	  and	  Mn-­‐treated	  mice	  1,	  7,	  and	  21	  days	  after	  
treatment	   cessation.	  By	  perfusion	  of	   the	  pharmacological	   agent	  α-­‐MPT	   (50	  µM),	   synthesis	  of	  





Once	   the	   dopamine	   signal	   was	   completely	   diminished,	   a	   20	   µM	   cocaine	   solution	   was	   co-­‐
perfused	   onto	   the	   slice	   (in	   addition	   to	   the	   50	   µM	   α-­‐MPT)	   while	   electrical	   stimulations	   are	  
continued	  every	  5	  minutes	  to	  mobilize	  the	  reserve	  pool	  vesicles.	  Saline-­‐	  and	  Mn-­‐treated	  mice	  
were	   compared	   based	   on	   how	   long	   it	   took	   the	   stimulations	   to	   deplete	   this	   new,	   cocaine-­‐
induced	  signal	  of	  dopamine,	  as	  well	  as	  on	  the	  amplitude	  of	  the	  signal.	  	  
6.4.5	  Statistical	  Analysis	  
All	   data	   analyzed	   with	   GraphPad	   Prism	   software	   (GraphPad,	   La	   Jolla,	   CA).	   Values	   are	  
expressed	  as	  means	  ±	  standard	  error	  of	  means	  (SEMs)	  with	  a	  difference	  of	  P	  <	  0.05	  considered	  
statistically	   significant.	   Comparisons	   of	  means	  were	  made	   by	   a	   one-­‐way	   analysis	   of	   variance	  
(ANOVA)	  with	  Dunnett’s	  post-­‐test	  to	  compare	   individual	  analysis	  time	  points	  to	  saline	  control	  
group.	  Grubbs	  test	  (by	  GraphPad	  Outlier	  calculator	  online)	  was	  used	  to	  exclude	  outliers	  in	  data	  
sets	  with	  an	  alpha	  value	  set	  to	  0.05.	  
6.5	  Results	  
6.5.1	  Tetrabenazine/Amphetamine	  –	  Efflux	  after	  VMAT	  Inhibition	  	  
	   After	  depletion	  of	  the	  other	  two	  pools,	  as	  apparent	  by	  the	  diminished	  current	  versus	  time	  
traces	  observed	  with	  FSCV	  (Figure	  6.1C),	  amphetamine	  evoked	  efflux	  of	  reserve	  pool	  dopamine	  
was	  quantified	  by	  measuring	  the	  amplitude	  of	   the	  resultant	  current	   (Figure	  6.1).	  The	  average	  
concentration	  of	  amphetamine-­‐induced	  dopamine	  released	  in	  the	  saline-­‐treated	  control	  group	  
was	   886	   ±	   202	   nM	   (n	   =	   8).	   After	   Mn	   treatment,	   analysis	   on	   day	   1	   revealed	   a	   dopamine	  
concentration	  of	  1207	  ±	  314	  nM	  (n	  =	  5)	  dopamine	  in	  the	  reserve	  pool.	  Neither	  this	  time	  point,	  
nor	  results	  from	  day	  7	  (1425	  ±	  261	  nM,	  n	  =	  4)	  or	  day	  21	  (1325	  ±	  498	  nM,	  n	  =	  6)	  were	  different	  







Figure	   6.1:	   Representative	   FSCV	   data	   after	   TBZ	   and	   amphetamine	   perfusion.	   A)	   False	   color	  
plot	  indicating	  pre-­‐drug	  dopamine	  oxidation	  and	  reduction	  peaks.	  B)	  Representative	  color	  plot	  
of	  Mn-­‐treated	  mouse	   from	  day	   1	   analysis	   group.	  Note	   extended	   release	   and	   uptake	   profiles	  
after	   perfusion	   of	   20	   µM	   amphetamine.	   C)	   Representative	   concentration	   versus	   time	   traces	  
throughout	  tetrabenazine	  perfusion	  demonstrating	  diminishing	  dopamine	  signal	  as	  a	  result	  of	  
blocking	   the	   vesicular	   monoamine	   transporter.	   The	   final	   panel	   illustrates	   how	   amplitude	   of	  







Figure	  6.2:	  Maximum	  reserve	  pool	  dopamine	  released	  after	  TBZ	  and	  amphetamine	  perfusion.	  
No	  change	   in	  quantity	  of	   dopamine	   released	   from	   reserve	  pool	   after	   readily	   releasable	  pool,	  











6.5.2	  α-­‐methyl-­‐p-­‐tyrosine/Amphetamine	  –	  Efflux	  after	  Synthesis	  Inhibition	  
	   The	   concentration	   of	   dopamine	   in	   reserve	   pools	   was	   also	   evaluated	   using	   α-­‐methyl-­‐p-­‐
tyrosine	  (αMPT),	  a	  dopamine	  synthesis	  blocker.	  The	  amplitude	  of	  measured	  dopamine	  from	  the	  
reserve	  pool	  was	  correlated	  to	  a	  concentration	  of	  3469	  ±	  837	  nM	  (n	  =	  7).	  Brain	  slices	  from	  Mn-­‐
treated	  group	  revealed	  similar	  concentrations	  on	  day	  1	  (1696	  ±	  598	  nM,	  n	  =	  6),	  day	  7	  (1291	  ±	  
493	  nM,	  n	  =	  4),	  and	  day	  21	  (3034	  ±	  931	  nM,	  n	  =	  6)	  of	  analysis	  (Figure	  6.3).	  In	  agreement	  with	  
the	  first	  analysis	  of	  reserve	  pool	  quantitation,	  none	  of	  the	  Mn-­‐treated	  groups’	  time	  points	  were	  
different	  from	  the	  saline-­‐treated	  group	  (one-­‐way	  ANOVA,	  Dunnett’s	  post-­‐test).	  
	  
Figure	   6.3:	   Reserve	  pool	   dopamine	   concentration	   after	  αMPT	  and	   amphetamine	  perfusion.	  
No	  difference	  in	  quantity	  of	  dopamine	  released	  from	  reserve	  pool	  after	  readily	  releasable	  pool,	  
recycling	  pool,	  and	  cytosolic	  dopamine	  depleted	  by	  synthesis	  blocker	  (α-­‐methyl-­‐p-­‐tyrosine;	  n	  =	  






6.5.3	  α-­‐methyl-­‐p-­‐tyrosine/Cocaine	  –	  Mobilization	  after	  Synthesis	  Inhibition	  
	   Cocaine	  acts	  on	  the	  reserve	  pool	  vesicles	  to	  mobilize	  them	  to	  the	  axon	  terminal	  for	  release,	  
therefore	   this	   experiment	   was	   conducted	   to	   root	   out	   any	   potential	   impairment	   in	   the	  
mobilization	  mechanism	   of	   vesicles	   as	   a	   result	   of	  Mn	   treatment.	   The	   amplitude	   of	   released	  
dopamine	  was	  quantified,	  as	  well	  as	  the	  amount	  of	  time	  required	  to	  empty	  out	  the	  reserve	  pool	  
(Figure	   6.4),	   and	   compared	   across	   groups.	   Mn-­‐treated	   mice	   on	   day	   1	   revealed	   a	   cocaine-­‐
mobilized	  dopamine	  reserve	  pool	  concentration	  of	  385	  ±	  58	  nM	  (n	  =	  4).	  On	  day	  7,	  an	  amplitude	  
of	  460	  ±	  82	  nM	  (n	  =	  5)	  was	  recorded	  and	  on	  day	  21,	  388	  ±	  53	  nM	  (n	  =	  5).	  All	  three	  values,	  while	  
slightly	  lower,	  were	  not	  different	  from	  the	  concentration	  of	  dopamine	  in	  the	  control	  group	  (586	  
±	  109	  nM,	  n	  =	  7,	  one-­‐way	  ANOVA,	  Dunnett’s	  post-­‐test,	  Figure	  6.5).	  On	  average,	  the	  reserve	  pool	  
of	  saline-­‐treated	  mice	  was	  depleted	  in	  38.6	  ±	  8.8	  min.	  In	  comparison,	  the	  Mn-­‐treated	  mice	  lost	  
cocaine-­‐induced	  dopamine	  signal	  in	  23.8	  ±	  3.8	  min	  (Mn	  day	  1),	  32.0	  ±	  7.7	  min	  (Mn	  day	  7),	  and	  
34.0	  ±	  4.3	  min	   (Mn	  day	  21).	  As	   illustrated	   in	   Figure	  6.6,	   none	  of	   these	  depletion	   times	  were	  






Figure	  6.4:	  Time	  course	  of	  dopamine	  release	  changes	  upon	  cocaine	  perfusion.	  Concentration	  
versus	  time	  traces	  during	  cocaine	  perfusion	  demonstrating	  time	  course	  of	  changes	  in	  dopamine	  
signal.	   The	   arrow	   indicates	   how	  maximum	   amplitude	   is	   quantified,	   as	   well	   as	   total	   time	   for	  






Figure	   6.5:	   Reserve	   pool	   dopamine	   concentration	   after	   cocaine	   perfusion.	  No	   difference	   in	  
quantity	   of	   cocaine-­‐mobilized	   dopamine	   released	   from	   reserve	   pool	   after	   readily	   releasable	  
pool,	   recycling	   pool,	   and	   cytosolic	   dopamine	   depleted	   by	   synthesis	   blocker	   (α-­‐methyl-­‐p-­‐








Figure	   6.6:	   Maximum	   time	   required	   to	   deplete	   cocaine-­‐mobilized	   dopamine	   reserve	   pool.	  
Time	  to	  deplete	   reserve	  pool	  by	  cocaine	  mobilization	  not	  different	  between	  saline-­‐treated	  or	  











	   The	  mechanism	   of	   how	  manganese	   enters	   the	   neuron	   is	   not	   well	   understood.	   However,	  
there	  is	  evidence	  to	  show	  preferential	  accumulation	  of	  manganese	  at	  subcellular	  organelles	  like	  
the	  mitochondria	   and	   the	  Golgi	   apparatus.190,191	  As	  our	  data	   shows	   functional	   impairment	  of	  
dopamine	  neurons	  without	  change	  in	  overall	  levels	  of	  dopamine	  content,	  our	  goal	  in	  this	  work	  
was	  to	  probe	  intraneuronal	  aspects	  of	  dopamine	  regulation	  to	  uncover	  potential	  interactions	  of	  
manganese	   with	   dopamine	   inside	   dopaminergic	   neurons.	   As	   quantal	   dopamine	   release	   is	  
regulated	   by	   the	   exocytosis	   process,	   the	   results	   from	   our	   initial	   studies	   and	   evidence	   in	   the	  
literature	  of	  synapsin	  loss	  after	  manganese	  treatment	  suggested	  that	  there	  may	  be	  dysfunction	  
in	  the	  synaptic	  vesicles	  of	  our	  Mn-­‐treated	  mice.	  Prior	  to	  inspection	  of	  the	  intraneuronal	  stores	  
of	   dopamine,	   we	   hypothesized	   that	   the	   impaired	   dopamine	   release	   data	   were	   the	   result	   of	  
either	  an	   inability	  of	  reserve	  pool	  vesicles	  to	  mobilize	  after	  Mn	  accumulation	  or	  a	  disparity	   in	  
the	   number	   of	   vesicles	   available	   in	   the	   reserve	   pool	   as	   compared	   to	   the	   number	   of	   vesicles	  
available	   for	   release	   in	   the	  reserve	  pool.	  The	   technique	  of	  FSCV	  provided	  a	  novel	  method	   for	  
extracting	  both	  quantitative	  and	  dynamic	   information	   regarding	  vesicular	   stores	  which	  would	  
not	  have	  been	  possible	  in	  the	  past	  using	  imaging	  or	  tissue	  analysis	  methods.	  
	   To	  elucidate	  the	  concentration	  of	  dopamine	  available	  in	  the	  reserve	  pool,	  reloading	  of	  new	  
vesicles	   was	   blocked	   by	   inhibiting	   the	   VMAT.	   The	   average	   concentrations	   of	   dopamine	   in	  
reserve	  pool	  vesicles	  after	  Mn-­‐treatment	  were	  not	  found	  to	  be	  different.	  This	  measurement	  of	  
dopamine	   available	   in	   the	   reserve	   pool	   is	   in	   agreement	   with	   our	   previous	   tissue	   content	  
studies,	   where	   there	   were	   no	   differences	   in	   dopamine	   tissue	   content	   levels	   across	   Mn-­‐





pool	   vesicles,	   the	   lower	   release	   after	  Mn-­‐treatment	  with	  no	   tissue	   content	   change	   in	  overall	  
intracellular/extracellular	   levels	   could	   have	   been	   attributed	   to	   a	   greater	   amount	   of	   vesicles	  
“maturing”	   into	   the	   reluctantly	   releasable	   reserve	   pool	   of	   vesicles.164	   The	   pitfall	   of	   using	   a	  
VMAT	  blocker	  is	  that	  dopamine,	  serotonin,	  and	  norepinephrine	  all	  share	  the	  same	  transporter.1	  
To	   target	   dopamine	   more	   selectively,	   a	   second	   study	   was	   conducted.	   This	   time,	   dopamine	  
synthesis	   was	   directly	   blocked	   to	   eliminate	   contributions	   from	   the	   readily	   releasable	   and	  
recycling	   pools	   so	   that	   the	   only	   dopamine	   present	   in	   the	   axon	   terminal	   would	   be	   from	   the	  
reserve	  pool.	  In	  agreement	  with	  the	  first	  study,	  reserve	  pool	  concentrations	  were	  again	  found	  
to	   be	   not	   different	   when	   comparing	   saline-­‐treated	   and	   Mn-­‐treated	   mice.	   As	   both	   these	  
experiments	   proved	   our	   first	   hypothesis	   to	   be	   incorrect,	  we	   devised	   a	   study	   to	   examine	   the	  
function	  of	  the	  vesicular	  system	  by	  assessing	  the	  synapsin-­‐mediated	  mobilization	  of	  the	  reserve	  
pool.	   However	   using	   FSCV,	   we	   were	   unable	   to	   detect	   any	   functional	   impairment	   in	   the	  
mobilization	  of	  the	  reserve	  pool.	  	  	  
	   Together,	   the	   evidence	   presented	   in	   this	   chapter	   discredits	   the	   postulation	   that	   lower	  
vesicular	  release	  of	  dopamine,	  as	  well	  as	  lower	  extracellular	  levels,	  are	  the	  result	  of	  abnormal	  
reserve	  pool	  content	  or	  mobilization.	  To	  our	  knowledge,	  this	  is	  the	  first	  time	  that	  FSCV	  has	  been	  
used	   to	   probe	   dopamine	   vesicular	   levels	   and	   mobilization	   after	   striatal	   manganese	  
accumulation.	   Although	   this	   study	   suggests	   no	   dopamine	   impairments	   with	   recruitment	   and	  
dopamine	  storage,	   it	  does	  not	  change	  the	  fact	  that	  the	  combination	  of	  our	  work	  firmly	   in	  the	  
direction	   of	   presynaptic	   dopamine	   impairment.	   As	   such,	   there	   are	   several	   other	   hypotheses	  
that	   have	   been	   proposed	   to	   link	   high	   levels	   of	   metals	   in	   the	   brain	   to	   aberrant	   presynaptic	  





and	  postsynaptic	  effects	  of	  metal	   toxicity	  at	   the	  synapse,	  citing	  studies	  of	  aluminum,	  arsenic,	  
cadmium,	  lead,	  and	  manganese,	  to	  name	  a	  few.192	  Other	  metals,	  such	  as	  aluminum,	  cadmium,	  
and	   lead	   affect	   voltage	   gated	   calcium	   channels	   via	   inhibition	   or	   downregulation.193-­‐199	   It	   has	  
been	  suggested	  that	  Mn’s	  presynaptic	  actions	  also	  occur	  at	  sodium	  or	  potassium	  voltage	  gated	  
channels.	   In	   voltage	   clamp	   experiments,	   Mn	   blocked	   tetrodotoxin	   sensitive	   and	   insensitive	  
sodium	  channels.200	  The	  effect	  of	  Mn	  on	  potassium	  channels	  was	  shown	  to	  be	  divergent,	  with	  
high	  concentrations	   (i.e.	  10	  mM)	  reducing	  channel	  currents	  while	   lower	  concentrations	   (i.e.	  1	  
mM)	   increase	   their	   amplitudes.201	   These	   potassium	   and	   sodium	   channels	   act	   in	   a	   regulated	  
manner	   to	   propagate	   action	   potentials,	   which	   in	   turn	   determine	   whether	   or	   not	   exocytotic	  
release	  will	   occur.	   Thus,	   it	   is	   plausible	   to	   surmise	   that	   the	  Mn	   induced	   changes	   in	  dopamine	  
release	  we	  have	  observed	  stem	  from	  the	  aforementioned	  irregular	  functioning	  of	  voltage-­‐gated	  
ion	  channels.	  Although	  purely	  conjecture	  at	  this	  stage,	  future	  experiments	  can	  be	  designed	  to	  














Chapter	  7:	  Summary	  and	  Conclusions	  
Research	   in	   the	   manganism	   field	   has	   made	   great	   strides	   in	   characterizing	   its	  
symptomatology	  and	  understanding	  the	  risks	  associated	  with	  overexposure	  to	  the	  biologically	  
essential	   trace	  element	  manganese.	  As	  a	  disorder	  of	   the	  brain,	  undoubtedly	  one	  of	   the	  most	  
complex	  networks	  of	  communication	  in	  the	  human	  body,	  it	  is	  expected	  that	  manganism	  would	  
be	   the	   result	   of	   dysfunction	   in	   many	   different	   neurotransmitter	   systems.	   Of	   those,	   a	   link	  
between	  the	  dopaminergic	  system	  and	  manganism	  has	  been	  repeatedly	  established	  based	  on	  
symptoms,	  the	  brain	  regions	  in	  which	  manganese	  accumulates,	  imaging	  studies,	  tissue	  studies,	  
and	   other	   neurochemical	   measurements.	   Surprisingly	   little	   work	   has	   been	   done	   to	   assess	  
dopamine	  functionality	  after	  high	  levels	  of	  manganese	  exposure.	  Furthermore,	  due	  to	  the	  wide	  
range	  of	  exposure	  protocols	  and	  animal	  models	  used	  for	  the	  studies	  that	  are	  conducted,	  there	  
is	  great	  disparity	  in	  the	  results	  obtained.	  Due	  to	  the	  analytical	  advantage	  granted	  by	  techniques	  
such	  as	  fast	  scan	  cyclic	  voltammetry	  (FSCV)	  and	  microdialysis	  that	  allows	  for	  functional	  analysis	  
of	   the	   brain	   in	   specific	   and	   discrete	   brain	   regions,	   it	   is	   now	   possible	   to	   take	   a	  multi-­‐faceted	  
approach	  to	  studying	  neurological	  disorders	  such	  as	  manganism.	  
The	  overarching	  goal	  of	  this	  work	  was	  to	  expose	  mice	  to	  manganese	  over	  the	  course	  of	  a	  
short	   time	  period	  and	   then	   study	   its	   impact	  on	   the	  dopamine	  and	  behavioral	   system	  using	  a	  
variety	   of	   complementary	   analytical	   techniques.	   A	   time	   dependent	   analysis	   regime	   was	  
established	  to	  allow	  for	  short	  and	  long	  term	  study	  of	  the	  treated	  animals.	  
7.1	  Neurochemical	  Characterization	  upon	  Sub-­‐acute	  Manganese	  Treatment	  
The	  goal	  of	  our	   initial	  studies	  following	  the	  week-­‐long	  intermittent	  dosing	  protocol	  was	  to	  





revealed	   significant	   accumulation	   of	   manganese	   for	   up	   to	   three	   weeks	   after	   treatment	   was	  
completed.	   The	   results	   of	   these	   experiments	   are	   summarized	   below	   in	   Table	   7.1.	   Parallel	  
analysis	  of	  striatal	  tissue	  did	  not	  show	  any	  difference	  in	  the	  combined	  intra-­‐	  and	  extraneuronal	  
levels	   of	   dopamine.	   Even	   so,	   we	   hypothesized	   that	   some	   type	   of	   impairment	   on	   the	  
dopaminergic	   system	   was	   bound	   to	   exist	   due	   to	   the	   significantly	   large	   increase	   in	   striatal	  
manganese	  concentrations	  after	  treatment.	  When	  sampling	  the	  extracellular	  space	  using	  in	  vivo	  
microdialysis,	  subtle	  differences	   in	  uncorrected	  baseline	   levels	  of	  dopamine	  were	  seen	  7	  days	  
after	   treatment.	   Furthermore,	   when	   corrected	   for	   probe	   recovery	   using	   the	   microdialysis	  
method	  of	  no	  net	   flux,	   the	  same	  time	  point	  was	  confirmed	  to	  have	   lower	   levels	  of	  dopamine	  
compared	   to	   saline-­‐treated	   controls.	   Furthermore,	   lower	   levels	   of	   dopamine’s	   metabolites	  
were	  observed	  7	  days	  after	  treatment,	  which	  continued	  to	  be	  low	  until	  the	  day	  21	  analysis.	  As	  
there	  was	  a	  discrepancy	  between	  what	  dopamine	  tissue	  studies	  showed	  and	  what	  was	  revealed	  
by	   the	  microdialysis	   results,	  we	  hypothesized	  that	   the	  change	  might	  be	  due	  to	   the	  release	  of	  
dopamine	   from	   inside	   the	   neuron.	   To	   test	   this,	  we	  modified	   the	   aCSF	   solution	   to	   chemically	  
stimulate	  treated	  animals	  with	  high	  concentrations	  of	  potassium	  using	  reverse	  infusion	  through	  
the	   microdialysis	   probe.	   Indeed,	   impairment	   in	   how	   much	   dopamine	   could	   be	   released	   in	  
response	  to	  the	  strong	  stimulation	  was	  observed	   in	  Mn-­‐treated	  mice	  compared	  to	  the	  saline-­‐
treated	  group;	  in	  this	  case,	  attenuation	  of	  release	  was	  seen	  as	  early	  as	  24	  hours	  after	  treatment	  
cessation	  and	  persisted	  until	  21	  days	  later.	  
Extracellular	  dopamine	   levels	  are	  not	  only	  affected	  by	  release	  of	  dopamine	  but	  also	  by	   its	  
reuptake	  by	  the	  dopamine	  transporter.	  In	  order	  to	  assess	  the	  kinetics	  of	  transporter	  activity,	  as	  





these	   dopamine	   dynamics	   on	   the	   sub-­‐second	   time	   scale.	  With	   a	  much	   lighter	   stimulation	   as	  
compared	  to	  the	  high	  potassium	  study	  (both	  in	  terms	  of	  duration	  and	  intensity),	  we	  were	  able	  
to	   elucidate	   release	   impairment	   only	   on	   day	   21.	   However,	   no	   compensatory	   changes	   in	  
dopamine	  uptake	  rates	  were	  observed	  due	  to	  Mn-­‐treatment.	  A	  final	  attempt	  at	  uncovering	  the	  
mechanism	   of	   extracellular	   regulation	   of	   dopamine	   levels	   was	   made	   by	   assessing	   the	  
functionality	   of	   the	   presynaptic	   dopamine	   D2	   autoreceptors.	   There	   was	   no	   difference	   in	  
dopamine	   receptor	   functionality	   between	   the	  Mn-­‐treatment	   groups	   and	   the	   saline	   controls,	  
confirming	   that	   the	   alteration	   to	   dopamine	   neurotransmission	   was	   solely	   at	   the	   release	  
mechanism	  of	  the	  neuron.	  
	  
	  
(vs.	  control)	   Day	  1	   Day	  7	   Day	  21	  
Intracellular	  DA	   -­‐	   -­‐	   -­‐	  
Microdialysis	  DA	  
Baseline	   -­‐	  
ê -­‐	  
DA	  Metabolites	   -­‐	   ê ê 
K+	  Stimulated	  DA	  
Release	  
ê ê ê 
FSCV	  DA	  Release	   -­‐	   -­‐	   ê 
FSCV	  DA	  Uptake	   -­‐	   -­‐	   -­‐	  
DA	  Autoreceptor	  





Table	  7.1:	  Summary	  of	  dopamine	  neurochemical	  analysis	  by	  microdialysis	  and	  FSCV.	  	  










7.2	  Study	  of	  the	  Behavioral	  Impact	  of	  Manganese	  Exposure	  
Like	   Parkinson’s	   disease,	   the	  movement	   impairment	   of	  manganism	   patients	   is	   one	   of	   its	  
most	  characteristic	  symptoms.	  Furthermore,	  changes	  in	  striatal	  dopamine	  levels	  are	  oftentimes	  
associated	  with	  changes	  in	  locomotor	  activity.	  The	  results	  from	  our	  initial	  experiments	  led	  us	  to	  
hypothesize	   that	   the	   dopamine	   changes	   from	   our	   manganese	   protocol	   should	   manifest	   in	  
changes	  in	  locomotor	  activity	  and	  coordination	  of	  treated	  mice	  as	  compared	  to	  controls	  (Table	  
7.2).	  When	  recording	  baseline	  locomotor	  activity,	  impaired	  movement	  in	  the	  X	  and	  Y	  direction	  
was	  observed	  on	  day	  1	  after	  treatment.	  No	  differences	  in	  locomotor	  activity	  were	  seen	  at	  any	  
of	   the	   time	  points	  at	  which	  dopamine	  was	   impaired.	   Furthermore,	  both	   stereotypic	  behavior	  
and	   beam	   walk	   analysis	   supported	   the	   data	   from	   locomotor	   testing,	   suggesting	   behavioral	  
impairments	  before	  any	  change	  in	  striatal	  dopamine	  release	  or	  extracellular	  levels.	  
Interestingly,	  Yang	  et	  al.	  have	  reported	  similar	  patterns	  of	   locomotor	  activity	  changes	  that	  
do	  not	  match	  up	  with	  any	  correlated	  alterations	   in	  dopamine	  neuron	  activation.	   In	   fact,	   they	  
observed	  behavioral	  changes	  at	   the	  same	  time	  point	  as	  our	  study,	  24	  hours	  after	  manganese	  
chloride	   exposure.	   Furthermore,	   they	   did	   observe	   changes	   in	   neurons	   of	   a	   different	  
neurotransmitter,	   γ-­‐aminobutyric	   acid	   (GABA).	   Others	   have	   also	   reported	   GABA	   changes	   in	  
response	   to	   manganese	   treatment	   protocols,	   which	   supports	   our	   expectation	   stated	   in	   the	  
introduction	   that	   multiple	   neuronal	   systems	   should	   be	   affected	   to	   result	   in	   a	   neurological	  
disorder	  as	  complex	  as	  manganism.	  The	  possibility	  of	  GABA	  dysregulation	  affecting	  locomotor	  
behavior	   would	   also	   explain	   why	   our	   locomotor	   changes	   did	   not	   directly	   correlate	   to	  
neurochemical	  dopamine	  changes	  recorded	  by	  FSCV	  and	  microdialysis,	  as	  our	  focus	  has	  been	  to	  





Another	   observation	   from	   the	   behavioral	   experiments	   was	   the	   inability	   of	  
methamphetamine	  to	  stimulate	  behavior	  to	  the	  extent	  that	  would	  be	  expected	  (and	  is	  seen)	  in	  
control	  animals.	  Methamphetamine’s	  mechanism	  of	  action	  on	  dopamine	  neurons	   is	  to	  recruit	  
additional	  dopamine	  from	  inside	  the	  neuron	  via	  the	  dopamine	  transporter,	  thereby	  creating	  a	  
hyperlocomotive	   state.	   The	   inability	   of	   methamphetamine	   to	   induce	   hyperactivity	   would	  
suggest	   unavailability	   of	   dopamine	   vesicles	   for	   release,	   which	   would	   explain	   why	   our	  
intraneuronal	   tissue	   results	   did	   not	   reveal	   any	   difference	   in	   overall	   dopamine	   levels	   even	  
though	   released	   and	   extracellular	   dopamine	   concentrations	  were	   attenuated.	   Since	   stronger	  
stimulation	   resulted	   in	   greater	   impairment	   in	   release,	   this	   would	   suggest	   that	   access	   to	   the	  
reserve	   pool	   is	   somehow	   affected	   by	   manganese	   accumulation.	   Therefore,	   the	   next	   step	   in	  
understanding	  the	  mechanism	  between	  dopamine	  and	  Mn	  sought	  to	  take	  a	  deeper	  look	  at	  the	  
vesicle	  pools	  of	  dopamine	  using	  FSCV.	  
	  
	  
(vs.	  control)	   Day	  1	   Day	  7	   Day	  21	  
Ambulatory	  Distance	   ê -­‐	   -­‐	  
Stereotypy	   ê -­‐	   -­‐	  
Vertical	  Count	   -­‐	   -­‐	   é 
Ambulatory	  -­‐	  Meth	   -­‐	   ê -­‐	  
Stereotypy	  -­‐	  Meth	   -­‐	   -­‐	   -­‐	  
Vertical	  -­‐	  Meth	   é ê ê 
Beam	  Walk	  Time	   -­‐	   -­‐	   -­‐	  
Beam	  Walk	  Failure	  




Table	   7.2:	   Summary	   of	   behavior	   studies	   performed	   after	   sub-­‐acute	  manganese	   treatment.	  







7.3	  Reserve	  Pool	  Analysis	  
	  To	  better	  understand	  the	  state	  of	  the	  dopamine	  reserve	  pool,	  pharmacological	  agents	  were	  
used	  that	  would	  prevent	  more	  vesicles	  from	  being	  added	  to	  the	  reserve	  pool.	  Once	  the	  readily	  
releasable	   pool	   and	   the	   recycling	   pool	   of	   dopamine	   vesicles	   were	   depleted,	   first	   by	   using	   a	  
vesicular	  monoamine	   transport	   blocker	   (to	   prevent	   loading	   of	   new	   vesicles),	   then	  by	   using	   a	  
dopamine	  synthesis	  blocker,	  we	  strategically	   forced	   the	   reserve	  pool	   contents	   to	  be	   released	  
into	   the	   synaptic	   space	   by	   amphetamine	   efflux.	   Unfortunately,	   neither	   method	   revealed	   a	  
change	  in	  the	  concentration	  of	  dopamine	  in	  the	  reserve	  pool	  of	  Mn-­‐treated	  mice	  as	  compared	  
to	   the	   saline-­‐treated	   ones.	   Furthermore,	   our	   third	   study	   analyzing	   the	   mobilization	   of	   the	  
reserve	  pool	  to	  the	  terminal	  for	  release	  using	  cocaine	  also	  did	  not	  reveal	  any	  impairment	  due	  to	  
manganese	  exposure.	  This	  set	  of	  experiments,	  although	  disproving	  our	  hypothesis,	  did	  have	  the	  
advantage	  of	  ruling	  out	  one	  theory	  of	  how	  manganese	  may	  be	  acting	  on	  the	  dopamine	  system.	  
Without	  the	  spatial	  and	  temporal	  resolution	  of	  a	  technique	  like	  FSCV,	  such	  an	  intricate	  study	  of	  
intraneuronal	  stores	  would	  not	  have	  been	  possible	  in	  the	  past.	  
7.4	  Overall	  Conclusion	  and	  Future	  Directions	  
Overall,	   this	  work	  made	  great	  strides	   in	  characterizing	  the	  functional	  changes	  Mn	  induced	  
upon	  the	  striatal	  dopamine	  system	  using	  a	  variety	  of	  neuroanalytical	  techniques.	  Furthermore,	  
the	   time-­‐dependent	   analysis	   of	   behavior	   allowed	   us	   to	   uncover	   data	   in	   support	   of	   the	  
involvement	   of	   other	   neurotransmitters	   in	   locomotor	   impairment	   since	   changes	   in	   behavior	  
were	   disparate	   from	   the	   changes	   we	   found	   in	   the	   dopamine	   system.	   Future	   experiments	  
evaluating	   manganese’s	   affect	   on	   the	   brain	   should	   evaluate	   GABA	   levels	   after	   manganese	  





such	   as	   the	   generation	   of	   reactive	   oxidation	   species	   like	   hydrogen	   peroxide	   that	   have	   been	  
shown	  to	  regulate	  dopamine	  release,	  should	  also	  be	  tested	  in	  future	  experiments	  to	  confirm	  or	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Although	  manganese	  (Mn)	  is	  fundamental	  for	  many	  biological	  processes,	  exposure	  to	  excess	  
amounts	  leads	  to	  a	  neurological	  disorder	  termed	  manganism.	  Due	  to	  its	  symptomatic	  similarity	  
to	   Parkinson’s	   disease,	   as	   well	   its	   preferential	   accumulation	   in	   dopamine	   rich	   brain	   regions,	  
alterations	  in	  the	  dopamine	  system	  are	  implicated	  in	  the	  onset	  of	  manganism.	  In	  my	  research,	  
Mn	   overexposure	   is	   mimicked	   via	   subcutaneous	   administration	   of	   manganese	   chloride	   to	  
C57BL/6	  mice	  over	  the	  course	  of	  seven	  days	  using	  a	  protocol	  that	  has	  been	  shown	  to	  result	  in	  
accumulation	  of	  Mn	   in	   the	  basal	   ganglia.	   The	   subsequent	   short	   and	   long	   term	  effects	  of	   this	  
treatment	   on	   striatal	   dopamine	   function	   were	   evaluated	   1,	   7,	   and	   21	   days	   after	   treatment	  
cessation.	  This	  work	  used	  a	  variety	  of	  complementary	  analytical	  methods	  to	  take	  a	  multifaceted	  
approach	  in	  studying	  the	  Mn-­‐treated	  animals.	  The	  first	  study	  used	  fast	  scan	  cyclic	  voltammetry,	  
microdialysis,	  and	   tissue	  content	  analysis	   to	  characterize	   the	  dopamine	  system	  after	   the	  sub-­‐
acute	  treatment	  protocol.	  Behavioral	  tests	  were	  subsequently	  used	  to	  elucidate	  any	  phenotypic	  





conducted	  to	  test	  the	  hypothesis	  of	  intraneuronal	  dysfunction	  to	  explain	  the	  changes	  observed	  
in	  the	  first	  study.	  	  
Overall,	   these	   findings	   revealed	   that	   the	   dopamine	   system	   in	   the	   striatum	   has	   lower	  
extracellular	  levels	  of	  dopamine	  after	  Mn	  accumulation	  due	  to	  a	  functional	  defect	  in	  the	  release	  
mechanism	  that	  is	  apparent	  within	  a	  week	  of	  treatment.	  Interestingly,	  most	  behavioral	  changes	  
appear	   to	   manifest	   within	   24	   hours	   of	   treatment,	   when	   no	   dopamine	   change	   is	   observed,	  
indicating	   the	   involvement	   of	   other	   neurotransmitter	   systems	   in	   the	   onset	   of	  motor	   deficits	  
following	  Mn	   exposure.	   Finally,	   by	  methodically	   evaluating	   the	   quantity	   and	   functionality	   of	  
dopamine	  vesicles	  at	  the	  axon	  terminal,	  we	  were	  able	  to	  provide	  evidence	  against	  the	  theory	  
that	  dopamine	  release	  following	  Mn	  accumulation	  is	  due	  to	  an	  inability	  of	  the	  reserve	  pool	  of	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